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[571 ABSTRACT 
The present invention relates to nucleic acid enzymes or 
enzymatic RNA molecules that are capable of cleaving a 
variety of bonds, including phosphodiester bonds and amide 
bonds, in a variety of substrates. Thus, the disclosed enzy- 
matic RNA molecules are capable of functioning as 
nucleases and/or peptidases. The present invention also 
relates to compositions containing the disclosed enzymatic 
RNA molecule and to methods of making, selecting, and 
using such enzymes and compositions. 
1989, pp. 361-371. 
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2: THERMOPHZLA GROUP I INTRONS THAT 
CLEAVE AMIDE BONDS 
This invention was made with government support under 
NASA Grant No. NAGW-2881. The government has certain 
rights in the invention. 
CROSS REFERENCE TO RELATED 
APPLICATION 
The present application is a continuation-in-part of 
copending U.S. application Ser. No. 08/242,402, filed May 
13, 1994. 
TJXHNICAL F E L D  
The present invention relates to nucleic acid enzymes or 
enzymatic RNA molecules that are capable of cleaving a 
variety of bonds, including phosphodiester bonds and amide 
bonds, in a variety of substrates. Thus, the disclosed enzy- 
matic RNA molecules are capable of functioning as 
nucleases or peptidases. The present invention also relates to 
compositions containing the disclosed enzymatic RNA mol- 
ecules and to methods of making and using such enzymes 
and compositions. 
BACKGROUND 
The need for catalysts that operate outside of their native 
context or which catalyze reactions that are not represented 
in nature has resulted in the development of “enzyme 
engineering” technology. The usual route taken in enzyme 
engineering has been a “rational design” approach, relying 
upon the understanding of natural enzymes to aid in the 
construction of new enzymes. Unfortunately, the state of 
proficiency in the areas of protein structure and chemistry is 
insufficient to make the generation of novel biological 
catalysts routine. 
Recently, a different approach for developing novel cata- 
lysts has been applied. This method involves the construc- 
tion of a heterogeneous pool of macromolecules and the 
application of an in vitro selection procedure to isolate 
molecules from the pool that catalyze the desired reaction. 
Selecting catalysts from a pool of macromolecules is not 
dependent on a comprehensive understanding of their struc- 
tural and chemical properties. Accordingly, this process has 
been dubbed “irrational design” (Brenner and Lemer, PNAS 
The process of Darwinian evolution, by which enzymes 
arise in nature, does not operate by generating a diverse 
population of variants and harvesting the most advantageous 
individuals. In biological systems, diversity is maintained by 
ongoing mutations, and the population is shaped by selec- 
tion. Novel mutations augment existing variation, so that the 
evolutionary search is biased, in an appropriate fashion, by 
selection events that have already occurred (Eigen, et al., J. 
Phyx Chem. 92: 6881 (1988)). The more advantageous 
mutants, which are relatively abundant in the population, 
give rise to larger numbers of novel variants when compared 
to the less advantageous mutants. 
Most efforts to date involving the rational design of 
enzymatic RNA molecules or ribozymes have not led to 
molecules with fundamentally new or improved catalytic 
function. However, the application of irrational design meth- 
ods via a process we have described as “directed molecular 
evolution” or “in vitro evolution”, which is patterned after 
Darwinian evolution of organisms in nature, has the poten- 
USA 89: 5381-5383 (1992)). 
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2 
tial to lead to the production of RNA molecules that have 
desirable functional characteristics. 
This technique has been applied with varying degrees of 
success to RNA molecules in solution (see, e.g., Mills, et al., 
PNAS USA 58: 217 (1967); Green, et al., Nature 347: 406 
(1990); Chowrira, et al., Nature 354: 320 (1991); Joyce, 
Gene 82: 83 (1989); Beaudry and Joyce, Science 257: 
635-641 (1992); Robertson and Joyce, Nature 344: 467 
(1990)), as well as lo RNAs bound to a ligand that is 
attached to a solid support (Tuerk, et al., Science 249: 505 
(1990); Ellington, et al., Nature 346: 818 (1990)). It has also 
been applied to peptides attached directly to a solid support 
(Lam, et al., Nature 354: 82 (1991)); and to peptide epitopes 
expressed within a viral coat protein (Scott, et al., Science 
249: 386 (1990); Devlin, et al., Science 249: 249 (1990); 
Cwirla, et al., PNAS USA 87: 6378 (1990)). 
Therefore, in this context, the discoveries and inventions 
disclosed herein-are particularly significant, in that they 
highlight the potential of in vitro evolution as a means of 
designing increasingly more efficient catalytic molecules. 
BRIEF SUMMARY OF THE INVENTION 
We have achieved a considerable degree of success in 
engineering new enzymatically active oligonucleotide mol- 
ecules. Not only are the within-disclosed techniques useful 
in the design, identification and use of enzymatically active 
RNA molecules with improved specificities, reaction rates, 
and substrate binding capabilities, to name a few examples, 
success has now been achieved in designing oligonucleotide 
molecules that cleave bonds other than, or in addition to, 
phosphodiester bonds generally linking adjacent nucleotides 
in oligonucleotide molecules. 
In particular, the present invention discloses enzymatic 
RNA molecules having peptidase activity. Enzymatic RNA 
molecules of the present invention are thus capable of 
functioning as nucleophiles, cleaving phosphodiester bonds, 
amide bonds, or both. 
Therefore, the present invention contemplates enzymatic 
RNA molecules capable of specifically cleaving amide 
bonds, wherein the enzymatic RNA molecules include one 
or more point mutations which improve the enzymatic 
performance of the enzymatic RNA molecules. In various 
embodiments, the enzymatic RNA molecule further includes 
one or more point mutations which affect the substrate 
specificity of the enzymatic RNA molecule. In one variation, 
the enzymatic performance comprises catalytic efficiency. It 
is also contemplated that enzymatic performance may com- 
prise substrate binding aftinity. In various embodiments, the 
substrate may comprise a polypeptide or protein. 
Still other embodiments contemplate enzymatic RNA 
molecules wherein enzymatic performance comprises sub- 
strate specificity. In various embodiments, that specificity is 
changed via altering the recognition sequence. As noted 
above, substrates may comprise a polypeptide or protein. 
The present invention contemplates enzymatic RNA mol- 
ecules that cleave amide bonds. In one embodiment, the 
enzymatic RNA molecule is derived from a group I, 11,111, 
or IV intron. In one variation, the group I intron is derived 
from a group I intron; in another variation, the group I intron 
is derived from the group I intron of Tetrahymena thermo- 
phila precursor rRNA. In another embodiment, an enzy- 
matic RNA molecule of the present invention is derived 
from the molecule identified herein as SEQ ID NO 1. 
In another variation, an enzymatic RNA molecule con- 
templated herein comprises the portions of a group I, 11,111 
5,595,873 
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or IV intron having catalytic activity. In an alternative The present invention further contemplates a ribozyme 
embodiment, an enzymatic RNA molecule comprises the amidase intermediate comprising a ribonucleotide polymer 
portions of a Tetrahymena group I intron having catalytic including a 5’ terminal nucleotide with a ribose sugar having 
activity. In yet-another embodiment, an enzymatic RNA a 2’ hydroxyl, and a peptide having one or more amino acid 
molecule of the present invention is derived from an L-I9 or residues including a carboxy terminal amino acid residue, 
L-21 RNA molecule and includes the portions of the L-19 or the carboxy terminal amino acid residue being covalently 
L-21 RNA molecule having catalytic activity. linked by an ester bond to the 2’ hydroxyl of the ribonucle- 
The present invention further contemplates enzymatic otide polymer. In one alternative embodiment, the ester bond 
RNA molecu1es including one or moIe mutations. various is chemically unstable under physiological conditions. In 
embodiments of the disclosed invention contemplate that an 1o another, the ester bond is acid labile. The invention further 
enzymatic RNA molecule of the present invention includes ContemPlateS m~bodiments whereby the r i b o ~ ~ c k ~ t i d e  
one or more mutations not typically found in wild type Polymer has a Catalytic activity for hydrolyzing the ester 
enzymatic RNA molecules or ribozymes. bond. 
In various embodiments, enzymatic RNA molecules of In yet another variation, the present invention contem- 
the present invention include one or more of the following 15 Plates a ribozYme amidase intm-r~ediate Comprising a 
mutations: ~ : G + A ;  51/52:insert AGAA; 87:A+deleted; nucleotide polymer; a cofactor including a guanine nucle- 
9 4 : ~ + u ;  9 4 : ~ + ~ ;  ] 1 5 : ~ + ~ ;  1 1 6 : ~ + ~ ;  1 3 8 : ~ + , ~ ;  otide having a ribose sugar with a 2’ hydroxyl; and a peptide 
1 6 6 : ~ + ~ ;  1 6 7 : ~ 4 3 ;  1 7 0 c + u ;  1 8 8 : ~ + ~ ;  1 9 0 : ~ - - > ~ ;  having one or more amino acid residues including a carboxy 
1 9 1 : ~ + u ;  205:u+c; 2 1 5 : ~ + , ~ ;  ~J~:u+A; 258:u+c; terminal amino acid residue, the carboxyl terminal amino 
312:G+A; 313:G+U; 3 1 3 : ~ + c ;  3 1 4 : ~ + ~ ;  3 1 7 : ~ + ~ ;  acid residue being covalently linked by an ester bond to the 
317:U-K 317:UjA; 333:U+C; 350:C+U; and 364:C+ 2o 2‘ hydroxyl of the guanine mcleotide. 
U. In various alternative embodiments, an enzymatic RNA The invention also discloses an enzymatic RNA molecule 
molecule of the present invention has 1-4 point mutations, comprising a ribonucleotide polymer having a catalytic 
5-8 point mutations, 9-12 point mutations, or 13 or more activity for hydrolyzing an amide substrate to produce an 
point mutations. amino cleavage product and a ribozyme amidase interme- 
Other examples of combinations of mutations which may 25 diate. In one variation, the ribonucleotide polymer has a 5’ 
be present in emymatic RNA molecules of the present terminal nucleotide with a ribose Sugar having a nucleo- 
invention include the following: (a) 98:C+U and philic 2‘ hydroxyl, and the ribozyme amidase intermediate 
3 1 3 - 3 1 4 : ~ ~ + ~ ~ ;  0) 98:c+u, 205:u+c, and 3 1 7 : ~  + includes an ester linkage between the nucleophilic 2’ 
R; (c) 94:A+Y and 215:G+A; (d) 94; :A+Y, 205:U+C, 3o hydroxyl and a CarbOXY group of the amide substrate. In 
and 3 1 3 - 3 1 4 ~ ~ + ~ ~ ;  (e) 9 4 : ~ + y ,  9 8 : ~  +u, and another variation, the 5’ terminal nucleotide includes a 
333:U-C; ( f )  44:C+A, 94:A+U, 115:A+U, 116:G+A, 
138:C+A, 188:G+A, 190:U+A, 191:G+U, 205:U+C, The present invention also discloses enzymatic RNA 
215:G+A, 312G+A, and 317:U+G; (g) 44:G+A, molecules wherein the amide substrate includes a peptide 
94:A+U, 115:A+U, 116G+A, 138:C+A, 167:U+G, 35 having one or more amino acid residues including a carboxy 
188:G+A, 190:U+A, 191:G+U, 205:U+C, 215:G+A, terminal amino acid residue bearing the carboxy group of 
239:U+A, and 312G+A; (h) 44:G+A, 51/52:insert the amide substrate, the carboxy terminal amino acid residue 
AGAA, 87:A+del, 94A+U, 115:A+U, 116:G+A, being covalently linked by the ester linkage to the 2’ 
166:C+A, 170:C+U, 188:G+A, 190:U+A, 191 :G+U, hydroxyl of the ribonucleotide polymer. In an alternative 
205:U+C, 215:G+A, 239:U+A, 312:G+A, 35O:C+U, 4o embodiment, the ribonucleotide polymer has an effective 
and 364:C+U; or (i) 44:G+A, 51/52:insertAGAA, 87:A+ binding aflinity for the amide substrate and lacks an effective 
del, 94:A+U, 115:A+U, 116:G+A, 166:C+A, 170:C+ binding aBinity for the amino cleavage product. In another 
U, 188:G+A, 190:U+A, 191:G+U, 205:U+C, 215:G+ variation, the catalytic activity of the ribonucleotide polymer 
A, 313:G+C, and 314A+G. is dependent upon the presence of divalent ions. An alter- 
The present invention further contemplates an enzymatic 45 native embodiment contemplates that an enzymatic RNA 
RNA molecule capable of specificdly cleaving amide molecule as disclosed herein further comprises a cofactor 
bonds, wherein the enzymatic RNA molecule includes one bound to the ribonucleotide polymer, the cofactor including 
or more point mutations which affect the enzymatic perfor- a guanine nucleotide having a ribose Sugar With a mcleo- 
mance of the molecule. In other variations, an enzymatic PhiliC 2’ hydroxyl capable of forming an acid labile ester 
RNA molecule of the present invention includes one or more 50 inkxmediate With the CarbOXY cleavage Product. 
point mutations which improve the substrate specificity of The present invention also contemplates various methods 
the molecule. In alternative embodiments, an enzymatic of making and using enzymatic RNA molecules according to 
RNA molecule of the present invention includes one or more the present invention. In one embodiment, a method of 
mutations which improve enzymatic performance and sub- selecting an enzymatic RNA molecule that cleaves amide 
strate specificity. In an alternative embodiment, an enzy- 55 bonds, comprising the following consecutive steps: (a) 
matic FWA molecule capable of specifically cleaving amide obtaining a population of ribozymes; (b) admixing amide 
bonds is disclosed, wherein the enzymatic RNA molecule bond-containing substrate molecules with the population of 
includes one or more point mutations which affect the ribozymes to form an admixture; (c) maintaining the admix- 
enzymatic performance or substrate specificity of the mol- ture for a sufficient period of time and under predetermined 
ecule. 60 reaction conditions to allow the ribozymes and the substrate 
In one variation, the enzymatic performance comprises to interact and form ribozyme-product complexes; (d) iso- 
catalytic efficiency. It is also contemplated that enzymatic lating ribozYme-Prod~ctcomPlexeS that form; (e) allow- 
performance may comprise substrate binding affinity. Still ing the ribozyme-product complex to dissociate into sepa- 
other embodiments contemplate enzymatic RNA molecules rate fibOzYme and Product; and (0 Separating the *bozYmeS 
wherein enzymatic performance comprises substrate speci- 65 from the product. 
ficity. In various embodiments, that specificity is changed In other variations of the aforementioned method, the 
via altering the recognition sequence. substrate is tagged with an immobilizing agent. In one 
guanine base. 
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embodiment, the agent comprises biotin. In another embodi- otide substitutions within an enzymatic RNA molecule. In 
ment, a solid surface incorporated or tagged with avidin is another variation, the mutagenizing conditions comprise 
utilized to assist in the process of isolating ribozyme-product chemical modification, incorporation of randomized 
complexes. For example, the isolating step may further mutagenic oligodeoxynucleotides, or inaccurate copying by 
comprise exposing the ribozyme-product complex to a solid 5 a polymerase. In yet another variation, the mutagenizing 
surface having avidin linked thereto, whereby the complex conditions comprise use of site-dkected mutagenesis, poly- 
becomes attached to the solid surface. merase chain reaction (PCR), mutagenic PCR, or self- 
The present invention further contemplates methods of sustained sequence replication. 
cleaving an amide bond. In one variation, the method Another variation of the foregoing methods further com- 
comprises admixing an enzymatic RNA molecule with an 10 prises the step of amplifying the enzymatic RNA molecules 
amide bond-containing substrate, to form a reaction admix- selected from the diverse population. In one embodiment, 
ture, and maintaining the admixture under predetermined the amplifying is performed using a polymerase chain 
reaction conditions to allow the enzymatic RNA molecule to reaction, preferably a mutagenic polymerase chain reaction. 
cleave the amide bond. In an alternative embodiment, the In another embodiment, the amplifying is performed using 
enzymatic RNA molecule is able to cleave an amide bond at 15 self-sustained sequence replication. 
a preselected site. Methods of cleaving amide bonds as The present invention also discloses various  compos^- 
disclosed herein may also comprise the steps of separating tions. In one embodiment, a composition including an 
the products from the enzymatic RNA molecule; and adding enzymatic RNA molecule that cleaves -de bonds is dis- 
additional substrate to the enzymatic RNA molecule to form closed, In another variation, a composition including an 
enzymatic RNA molecule comprising a ribonucleotide poly- a new reaction admixture. 
Also contemplated herein are methods of engineering mer having a catalytic activity for hydrolyzing an amide 
enzymatic RNA molecules that cleave amide bonds. In one substrate to produce an amino cleavage product and a 
embodiment, the method comprises the following steps: (a) ribozyme amidase intermediate is disclosed. In another 
obtaining a population of ribozymes; (b) introducing genetic embodiment, a composition further comprises a cofactor 
variation into the population to produce a variant population; 25 bound to the ribonucleotide polymer, the cofactor including 
(C) selecting individuals from the variant population that a guanine nucleotide having a ribose sugar with a nucleo- 
meet predetermined selection criteria; (d) separating the philic 2’ hydroxyl capable of forming an acid labile ester 
selected individuals from the remainder of the variant POPU- intermediate with the carboxy cleavage product. 
lation; and (e) amplifying the selected individuals. Also contemplated by the within invention are composi- 
In another variation, methods of CatalYtiC~lY hydrolyzing tions comprising two or more populations of enzymatic 
an amide substrate are contemplated. In one embodiment, RNA molecules having characteristics as disclosed herein 
the method comprises the following Step A: contacting the and in the claims, In another variation, each population of 
amide substrate with a ribozyme comprising a ribonucle- enzymatic RNA molecules in the composition is capable of 
otide polymer having a catalytic activity for hydrolyzing the recognizing a different substrate. 
amide substrate and producing an amino cleavage product 
3o 
35 
BRIEF DESCRIPTION OF THE DRAWINGS 
and a ribozyme amidase intermediate, the ribozyme amidase 
intermediate including a carboxyl of the amide substrate 
bonded by an ester bond to a 2’ hydroxyl of a ribose sugar FIG. 1 illustrates the secondary structure of the wild-type 
on a 5’ terminal nucleotide of the ribonucleotide polymer. In Tetrahymena ribozyme (L-21 form; SEQ ID NO 1). Paired 
another variation, the method further comprises Step B as structural elements are designated by Pi. Joining regions 
follows, to be performed after Step A: hydrolyzing the ester between paired elements i and j, referred to as J i/j, are not 
bond of the ribozYme amidase inEmnediate to Produce a labeled. Nucleotide positions that were partially randomized 
carboxy cleavage product. in the initial population are indicated by shaded regions. The 
In another embodiment, the method further comprises 45 internal guide sequence (IGS) is shown in bold, and the 
providing the enzymatic RNA molecule in a reaction DNA substrate is shown in lowercase letters. Nucleotide 
medium at a concentration sufficient to cause cleavage of positions discussed in the text are labeled. 
about one molecule of substrate per molecule of enzymatic FIGS. 2A and 2B illustrate the general procedure for 
RNA Per minute. In yet another embodiment, the method selective amplification of catalytic RNA. In FTG. 2A, the 
further comprises providing the enzymatic RNA molecule in 5o overall procedure for RNA amplification is shown. ‘‘RT’= 
a reaction medium, wherein the enzymatic RNA molecule is reverse transcriptase; POY’=T~ polymerase; “prom”= 
present at a COIlCeIltratiOn SUffiCient to Cause Cleavage Of at promoter, and ‘‘RNA’’ represents the enzymatic RNA mol- 
least 10% Of a population Of substrate molecules in an hour. ecule, In FIG, 2B, the procedure for selective amplification 
The invention also contemplates a method of producing based on phosphoester transfer activity of a group I 
an enzymatic RNA molecule having a predetermined cata- 55 ribozyme is shown. “E” represents the enzymatic RNA 
lytic activity, comprising the following steps: (a) subjecting molecule; “S” represents substrate; “EX’ represents 
a population of enzymatic RNA molecules to mutagenizing enzyme/substrate complex; and “EF‘” represents enzyme/ 
conditions to produce a diverse population of mutant RNA product complex. 
molecules; (b) selecting an enzymatic RNA molecule having FIG. 2C illustrates the overall in vitro evolution procedure 
a predetermined activity from the diverse Population of 60 disclosed herein. I-Cleavage of the DNA substrate via 
mutant enzymatic RNA molecUles; and (C) Separating the phosphoester transfer results in ligation of the 3’ portion of 
RNA molecule from the diverse population Of mutant RNA the subs&& to the 3’ end of the ribozyme. 2-Selective 
molecules. In various embodiments, the predetermined isothermal amplification of DNA-cleaving ribozymes: first, 
activity comprises the ability to cleave amide or peptide selective Primer l a  hybridizes to the extended 3’ terminus of 
bonds. 65 active molecules and initiates cDNA synthesis in the pres- 
In one alternative method, the mutagenizing conditions ence of reverse transcriptase (RT); next, Primer 2, which 
comprise conditions that introduce defined or random nucle- contains a T7 promoter sequence, hybridizes to the cDNA 
40 
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and initiates second-strand DNA synthesis; finally, T7 RNA 
polymerase (T7 pol) produces multiple copies of the 
selected RNA, each of which can enter a new round of 
amplification. 3-Selective cDNA synthesis employing 
Primer l a  and reverse transcriptase. P P C R  amplification 
employing nonselective Primer 1 b and Primer 2, restores the 
original terminus of the ribozyme-encoding gene and intro- 
duces occasional mutations. 5-In vitro transcription to 
produce the progeny population of ribozymes. 
FIG. 3 illustrates the secondary structure of the Tetrahy- 
mena ribozyme (L-21 form) and also shows regions that 
were randomly mutagenized, as described further in 
Example 1 (boxed segments). 
FIG. 4 illustrates the cleavage of an amide bond-contain- 
ing substrate, showing that it generates a 5’ product that 
carries a terminal amine and a 3’ product that carries a 
terminal carboxyl. 
FIGS. 5A-C further illustrate the reaction shown in FIG. 
4, including the production of intermediates (FIG. 5B) and 
products (FIG. 5C), as well as the relationship of the 
substrate to the ribozyme (FIG. 5A). It is also shown in FIG. 
5C that the ribozyme-associated product is subsequently 
hydrolyzed, resulting in generation of a 5’ product carrying 
a terminal amine and a 3’ product carrying a terminal 
carboxyl. Subsequent to hydrolysis of the ribozyme-associ- 
ated product, the enzyme is free to cycle. 
NG. 6 illustrates the confirmation of successful synthesis 
of the oligonucleotide-oligopeptide “hybrid”. In lane 1, 
5labeled d(GGCCCTCT,,) is shown. In lanes 2 and 3, 
5’-labeled d(GGCCCTCT)-Arg is shown, as measured at 30 
and 60 minutes. 
FIG. 7 is a photograph of a gel illustrating cleavage of a 
hybrid oligonucleotide-oligopeptide substrate by enzymatic 
RNA molecules of the present invention. In lane 1, 5’-la- 
beled 8-mer marker is shown. In lane 2, interaction of 
ribozyme with a 5’-labeled hybrid substrate generates an 
8-mer 5’ product with a terminal -NH,. In lane 3, substrate 
alone (Le., in the absence of ribozyme) is shown. 
8 
-continued 
DETAILED DESCRIPTION 
A. Definitions 
As used herein, the term ‘‘amino acid residue” generally 
means an amino acid formed upon chemical digestion 
(hydrolysis) of a polypeptide at its peptide linkages. The 
amino acid residues described herein are preferably in the 
“L” isomeric form. However, residues in the “D’ isomeric 
form can be substituted for any L-amino acid residue, as 
long as the desired functional property is retained by the 
polypeptide. NH, refers to the free amino group present at 
the amino terminus of a polypeptide. COOH refers to the 
free carboxy group present at the carboxy terminus of a 
polypeptide. In keeping with standard polypeptide nomen- 
clature (described in J. Bid. Chem., 243:3552-59 (1969) 
and adopted at 37 C.F.R. 51.822 (b) (2)), abbreviations for 
amino acid residues are shown in the following Table of 
Correspondence: 
TABLE OF CORRESPONDENCE 
SYMBOL 
1-Letter 3-Letter AMINO ACID 
Y TYr tyrosine 
G GlY glycine 
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TABLE OF CORRESPONDENCE 
SYMBOL 
1-Letter 3-Letter AMINO ACID 
F 
M 
A 
S 
I 
L 
T 
V 
P 
K 
H 
Q 
E 
Z 
W 
R 
D 
N 
B 
C 
X 
Phe 
Met 
Ala 
Ser 
Ile 
Leu 
Thr 
Val 
pro 
LY s 
His 
Gln 
Glu 
Glx 
Trp 
’% 
ASP 
CYS 
Asn 
Asx 
Xaa 
phenylalanine 
methionine 
alanine 
serine 
isoleucine 
leucine 
threonine 
valine 
proline 
lysine 
histidine 
glutamine 
glutamic acid 
Glu andor Gln 
tryptophan 
arginine 
aspartic acid 
asparagine 
Asn and/or Asp 
cysteine 
Unknown or other 
It should be noted that all amino acid residue sequences 
represented herein by formulae have a left to right orienta- 
tion in the conventional direction of amino-terminus to 
carboxy-terminus. In addition, the phrase “amino acid resi- 
due” is broadly defined to include the amino acids listed in 
the Table of Correspondence and modified and unusual 
amino acids, such as those listed in 37 C.F.R. 51.822 (b) (4), 
and incorporated herein by reference. Furthermore, it should 
be noted that a dash at the beginning or end of an amino acid 
residue sequence indicates a peptide bond to a further 
sequence of one or more amino acid residues or to an 
amino-terminal group such as NH, or to a carboxy-terminal 
group such as COOH. 
The term “conservative substitution” as used herein is 
meant to denote that one amino acid residue has been 
replaced by another, biologically similar residue. Examples 
of conservative substitutions include the substitution of one 
hydrophobic residue such as Ile, Val, Leu or Met for another, 
or the substitution of one polar residue for another such as 
between Arg and Lys, between Glu and Asp or between Gln 
and Asn, and the like. The term “conservative substitution” 
also includes the use of a substituted amino acid in place of 
an unsubstituted parent amino acid provided that such a 
polypeptide also displays the requisite binding activity. 
In some instances, the replacement of an ionic residue by 
an oppositely charged ionic residue such as Asp by Lys has 
been termed conservative in the art in that those ionic groups 
are thought to merely provide solubility assistance. In gen- 
eral, however, since the replacements discussed herein are 
on relatively short synthetic polypeptide antigens, as com- 
pared to a whole protein, replacement of an ionic residue by 
another ionic residue of opposite charge is considered herein 
to be a “radical replacement”, as are replacements between 
nonionic and ionic residues, and bulky residues such as Phe, 
Tyr or Trp and less bulky residues such as Gly, n e  and Val. 
The term “correspond” in its various grammatical forms 
is used herein and in the claims in relation to polypeptide 
sequences to mean the polypeptide sequence described plus 
or minus up to three amino acid residues at either or both of 
the amino- and carboxy-termini and containing only con- 
servative substitutions in particular amino acid residues 
along the polypeptide sequence. 
As used herein, “polypeptide” and “peptide” are terms 
used interchangeably herein to designate a series of no more 
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than about 50 amino acid residues connected one to the other 
by peptide bonds between the alpha-amino and carboxy 
groups of adjacent residues. 
As used herein, the terms “peptide bond” and “amide 
bond” may be used interchangeably herein, and include 5 
amide linkages such as those typically found within 
polypeptides or proteins. As used herein, it is not necessary 
that an amidc bond or peptide bond link adjacent amino acid 
residues only; for example, peptide bonddamide bonds as 
described herein may be found linking adjacent nucleotides, io 
adjacent amino acids, or linking an amino acid to a nucle- 
otide. 
The term@) may also be considered to encompass link- 
ages akin to those including unactivated alkyl amides, as 
“Protein” is a term generally used herein to designate a 
series of greater than 50 amino acid residues connected one 
to the other as in a polypeptide. 
As used herein, the term “ribozyme” is used to describe 
an RNA-containing nucleic acid that is capable of function- 20 
ing as an enzyme. In the present disclosure, the term 
“ribozyme” includes endoribonucleases and endodeoxyri- 
bonucleases, as well as amide bond-cleaving nucleic acid 
enzymes of the present invention. Other terms used inter- 
changeably with ribozyme herein are “enzymatic RNA 25 
molecule” or “catalytic RNA molecule”, which should be 
understood to include ribozymes and enzymatically active 
portions thereof, whether derived from Tetrahymena or from 
other organisms or sources. 
molecules which have complementarity in a substrate-bind- 
ing region to a specified oligonucleotide target or substrate; 
it also has an enzymatic activity which is active to specifi- 
cally cleave the oligonucleotide substrate. Stated in another 
fashion, the enzymatic RNA molecule is capable of cleaving 35 
the oligonucleotide substrate intermolecularly. This comple- 
mentarity functions to allow sufficient hybridization of the 
enzymatic RNA molecule to the substrate oligonucleotide to 
allow the intermolecular cleavage of the substrate to occur. 
While one-hundred percent (100%) complementarity is pre- 40 
ferred, complementarity in the range of 75-100% is also 
useful and contemplated by the present invention. 
Enzymatic RNA molecules of the present invention may 
alternatively be described as having amide-cleaving, amide 
bond-cleaving, amidase, peptidase, or protease activity. 45 
These terms may be used interchangeably herein. 
The term “enzymatic nucleic acid” as used herein encom- 
passes enzymatic RNA or DNA molecules, enzymatic RNA- 
DNA polymers, and enzymatically active portions or deriva- 
tives thereof, although enzymatic RNA molecules are a 50 
particularly preferred class of enzymatically active mol- 
ecules according to the present invention. 
The term “endodeoxyribonuclease”, as used herein, is an 
enzyme capable of cleaving a substrate comprised predomi- 
nantly of DNA. The term “endoribonuclease”, as used 55 
herein, is an enzyme capable of cleaving a substrate com- 
prised predominantly of RNA. 
As used herein, the term “base pair” (bp) is generally used 
to describe a partnership of adenine (A) with thymine (T) or 
uracil (U), or of cytosine (C) with guanine (G), although it 60 
should be appreciated that less-common analogs of the bases 
A, T, C, and G may occasionally participate in base pairings. 
Nucleotides that normally pair up when DNA or RNA 
adopts a double stranded configuration may also be referred 
“Complementary nucleotide sequence” generally refers to 
a sequence of nucleotides in a single-stranded molecule of 
opposed to activated aryl amides. 15 
The term “enzymatic RNA molecules” also includes RNA 30 
to herein as “complementary bases”. 65 
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DNA or RNA that is sufficiently complementary to that on 
another single oligonucleotide strand to specifically hybrid- 
ize to it with consequent hydrogen bonding. 
“Nucleotide” generally refers to a monomeric unit of 
DNA or RNA consisting of a sugar moiety (pentose), a 
phosphate group, and a nitrogenous heterocyclic base. The 
base is linked to the sugar moiety via the glycosidic carbon 
(1’ carbon of the penrose) and that combination of base and 
sugar is a “nucleoside”. When the nucleoside contains a 
phosphate group bonded to the 3’ or 5’ position of the 
pentose, it is referred to as a nucleotide. A sequence of 
operatively linked nucleotides is typically referred to herein 
as a “base sequence” or “nucleotide sequence”, and their 
grammatical equivalents, and is represented herein by a 
formula whose left to right orientation is in the conventional 
direction of 5’-terminus to 3’-terminus, unless otherwise 
specified. 
“Nucleotide analog” generally refers to a purine or pyri- 
midine nucleotide that differs structurally from A, T, G, C, 
or U, but is sufficiently similar to substitute for the normal 
nucleotide in a nucleic acid molecule. As used herein, the 
term “nucleotide analog” encompasses altered bases, differ- 
ent sugars, or a combination of the two. A listing of 
exemplary analogs wherein the base has been altered is 
provided in section C hereinbelow. 
“Oligonucleotide or polynucleotide” generally refers to a 
polymer of single- or double-stranded nucleotides. As used 
herein, ‘‘oligonucleotide’’ and its grammatical equivalents 
will include the full range of nucleic acids. An oligonucle- 
otide will typically refer to a nucleic acid molecule com- 
prised of a linear strand of ribonucleotides. The exact size 
will depend on many factors, which in turn depends on the 
ultimate conditions of use, as is well known in the art. 
As used herein, the term “physiologic conditions” is 
meant to suggest reaction conditions emulating those found 
in mammalian organisms, particularly humans. While vari- 
ables such as temperature, availability of cations, and pH 
ranges may vary as described in greater detail below, “physi- 
ologic conditions” generally comprise a temperature of 
about 35’40” C., with 37” C. being particularly preferred, 
as well as a pH of about 7.e8.0, with 7.5 being particularly 
preferred, and further comprise the availability of cations, 
preferably divalent or monovalent cations, in a concentra- 
tion of about 5-15 mM, with a concentration of about 10 
mM being particularly preferred. “Physiologic conditions”, 
as used herein, may optionally include the presence of free 
Gow As noted previously, preferred conditions are 
described in greater detail below. 
B. Enzymatic Nucleic Acid Molecules 
Some genes have their coding sequences interrupted by 
stretches of non-coding DNA. These non-coding sequences 
are generally termed introns. To produce a mature transcript 
from these genes, the primary RNA transcript (precursor 
RNA) must undergo a cleavage-ligation reaction termed 
RNA splicing. This RNA splicing produces the mature 
transcript of the polypeptide coding messenger RNA 
(mRNA), ribosomal RNA, or transfer RNA (RNA). Introns 
are grouped into four categories (groups I, 11, 111, and IV) 
based on their structure and the type of splicing reaction they 
undergo. 
RNA molecules capable of cleaving other RNA molecules 
have recently been described. Such RNA-cleaving RNA 
molecules, which may also be referred to as ribozymes or 
enzymatic RNA molecules, may be chosen from group I, 11, 
111, or IV introns, with group I and I1 introns being of 
greatest interest. Other enzymatic RNA molecules of interest 
herein are those formed in ribozyme motifs known in the art 
’ 
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as "hammerhead" and "hairpin". Enzymatic RNA molecules tions involving RNA substrates (Zaug, et al., Science 231 : 
of interest herein also include hepatitis delta virus ribozymes 470 (1986); Kay, et al., Nature 327: 343 (1987); Been, et al., 
and RNaseP or RNaseP-like RNA. Science 239: 1412 (1988); Woodson, et al., Cell 57: 335 
Of particular interest to the present invention are the (1989); Doudna, et al., Nature 339: 519 (1989)). For 
group I introns. Group I introns undergo an intra-molecular 5 example, the ribozyme has been used as a sequence-specific 
RNA splicing reaction leading to cyclization that does not endoribonuclease (Zaug, et al., Id. (1986); Murphy, et al., 
require protein cofactors, Cech, Science 236: 1532-1539 PNAS USA 86: 9218 (1989)), a reaction that proceeds with 
(1987). (The disclosures of all references cited within this high catalytic efficiency (kcu/Km=lO8M-' min-') (Her- 
application are incorporated by reference herein, where schlag, et al., Biochemistry 29: 10159 (1990)). 
appropriate.) 10 The within-described examples utilize derivatives of the 
The group I introns, including the intron isolated from the self-splicing group I intron of Tetrahymena thermophila, a 
large ribosomal RNA precursor of Tetrahymena thenno- ribozyme that is able to catalyze sequence-specific cleavage 
phila, catalyze a sequence-specific phosphoester transfer of single-stranded RNA via a phosphoester transfer mecha- 
reaction involving RNA substrates. Zaug and Cech, Science nism (Zaug and Cech, Science 231: 47CL-475 (1986); Zaug 
229: 1060-1064 (1985); and Kay and Inoue, Nature 327: 15 et al., Nature 3 2 4  429-433 (1986)), although it is expressly 
343-346 (1987). This sequence-specific phosphoester trans- to be understood that the invention is not limited to these 
fer reaction leads to the removal of the group I intron from embodiments. The Tetrahymena ribozyme consists of 413 
the precursor RNA and to ligation of two exons in a process nucleotides and assumes a well-defined secondary and ter- 
known as RNA splicing. The splicing reaction catalyzed by tiary structure that is responsible for its catalytic activity 
group I introns proceeds via a two-step transesterification 20 (Burke, et al., Nucleic Acids Res. 15: 7217 (1987); Kim, et 
mechanism. The details of this reaction have been reviewed al., PNAS USA 84: 8788 (1987); Celander, et al., Science 
by Cech, Science 236: 1532-1539 (1987). 251: 401 (1991); Michel, et al., J. Mol. Biol. 216: 585 
The splicing reaction of group I introns is initiated by the (1990). (See FIG. 1 for a general diagram.) Phylogenetic 
binding of guanosine or a guanosine nucleotide to a site analysis, supported by site-directed mutagenesis and dele- 
within the group I intron structure. Attack at the 5' splice site 25 tion studies, points out a distinction between a conserved 
by the 3'-hydroxyl group of guanosine results in the covalent catalytic core (comprising about one-third of the molecule) 
linkage of guanosine to the 5' end of the intervening intron and surrounding stem-loop elements that offer structural 
sequence. This reaction generates a new 3'-hydroxyl group support but are not essential for catalytic activity. (See 
on the uridine at the 3' terminus of the 5' exon. The 5' exon Davies, et al., Nature 300: 719 (1982); Michel, et al., 
subsequently attacks the 3' splice site, yielding spliced exons 30 Biochimie 64: 867 (1982); Michel, et al., EMBO J. 2: 33 
and the full-length linear form of the group I intron. (1983); Cech, et al., Gene 73: 259 (1988); Price, et al., Nucl. 
The linear group I intron usually cyclizes following Acids Res. 13: 1871 (1985); Szostak, et al., Nature 322: 83 
splicing. Cyclization occurs via a third transesterification (1986); Joyce, et al., Nucl. Acids Res. 15: 9825 (1987); 
reaction, involving attack of the 3'-terminal guanosine at an Barfod, et al., Genes Dev. 2: 652 (1988); Joyce, et al., 
interval site near the 5' end of the intron. The group I introns 35 Nucleic Acids Res. 17: 7879 (1989); Couture, et al., J. Mol. 
also undergo a sequence-specific hydrolysis reaction at the Biol. 215: 345 (1990); Beaudry and Joyce, Biochemistry 29: 
splice site sequences as described by Inoue et al., J. Mol. 6534 (1990).) 
B i d .  189: 143-165 (1986). This activity has been used to The ribozyme contains a template region, referred to as 
cleave RNA substrates in a sequence-specific manner by the "internal guide sequence" (IGS), which lies at the 5' end 
Zaug et al., Nature 324: 429-433 (1986). 40 of the molecule and forms Watson-Crick base pairs with the 
The structure of group I introns has been reviewed by J. target RNA substrate. The 3'-OH of guanosine, including a 
Burke, Gene 73: 273-294 (1988). The structure is charac- guanosine residue that lies at the 3' end of the ribozyme, is 
terized by nine base paired regions, termed Pl-P9. (See, directed to attack a particular phosphoester bond within the 
e.g., Burke et al., Nucleic Acids Res. 15: 7217-7221 (1987).) ribozyme-bound substrate. A phosphoester transfer reaction 
The folded structure of the intron is clearly important for the 45 ensues, resulting in cleavage of the substrate at a position 
catalytic activity of the group I introns, as evidenced by the immediately downstream from the region of base pairing, 
loss of catalytic activity under conditions where the intron is and concomitant ligation of the 3' portion of the substrate to 
denatured. In addition, mutations that disrupt essential base- the 3' oxygen of the attacking guanosine. The wild-type 
paired regions of the group I introns result in a loss of Tetrahymena ribozyme can cleave a single-stranded DNA 
catalytic activity. Burke, Gene 73: 273-294 (1988). Com- 50 substrate with low efficiency under conditions of high mag- 
pensatory mutations or second-site mutations that restore nesium concentration (50 mM MgCl,) andor high tempera- 
base-pairing in these regions also restore catalytic activity. ture (50" C.) (Herschlag and Cech, Nature 344: 405409 
Williamson et al., J. Biol. Chem. 262: 14672-14682 (1987); (199Oa); Robertson and Joyce, Nature 344: 467-468 
and Burke, Gene 73: 273-294 (1988). (1990)). Under more physiologic conditions (e.g. 37" C., 10 
Several different deletions that remove a large nucleotide 55 mM MgCI,, pH 7 3 ,  however, the DNA-cleavage reaction 
segment from the group I introns (F'IG. 1) without destroy- is almost undetectable. 
ing its ability to cleave RNA have been reported. Burke, The Tetrahymena ribozyme can also act as a sequence- 
Gene 73: 273-294 (1988). However, attempts to combine specific endodeoxyribonuclease (Robertson and Joyce, Id. 
large deletions have resulted in both active and inactive (1990)), although the efficiency of DNA cleavage is low 
introns. Joyce et al., Nucleic Acid Res. 17: 7879 (1989). 60 (k,JKm=2O0M-' mi&, determined at 50" C., 10 mM 
The Tetrahymena ribozyme is a self-splicing group I MgC1,) (Herschlag, et al., Nature 344: 405 (1990)). The 
intron derived from the large ribosomal RNA (rRNA) pre- efficiency of RNA-catalyzed DNA cleavage under physi- 
cursor of Tetrahymena thermophila. Its biological function ologic conditions is even lower (k,,fKm=36 M-' min-', 
is to catalyze its own excision from precursor rRNA to determined at 37" C., 10 mM MgCl,). 
produce mature rRNA. This function has been expressed in 65 FIG. 1 illustrates the secondary structure of the Tetrahy- 
vitro (Kruger, et al., Cell 31: 147 (1982)) and has been mena thermophila pre-rRNA intron, with the recognition 
generalized to include various phosphoester transfer reac- sequence and the core structure that is the most conserved 
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region among group I introns shown in bold. The nomen- ferred variation, an enzymatic RNA molecule of the present 
clature used to denote various structural features is the invention is able to cleave amide bonds under physiologic 
standard nomenclature (see, e.g., Burke et ai., Nucleic Acids conditions. Many enzymatic RNA molecules of the Present 
Res. 15: 7217-7221 (1987). The nine conserved pairing invention are also capable of cleaving a single-stranded 
regions, Pl-P9, and the various loops are shown. The 5 RNA substrate, DNA substrates, or RNA-DNA hybrid sub- 
nucleotide sequence is numbered beginning at the 5’ termi- strates. 
An enzymatic RNA molecule of the present invention nus of the molecule. 
As illustrated in FIG. 1, the recognition site is located at may comprise modified RNA-DNA polymer, a modified RNA-DNA polymer, a modified DNA-RNA poly- 
mer or a modified RNA-modified DNA polymer. RNA nucleotide 19 to 27, the first spacer region is located at nucleotides 27 to 28 and 94 to 95, the P3[5’] region is located 10 contains nucleotides comprising a ribose sugar and adenine, 
at nucleotides 96 to 103, the second spacer region is located guanine, uracil or cytosine as the base at the 1 position. 
at nucleotides 104 to 106, the first stem loop is located at Modified RNA contains nucleotides comprising a ribose 
nucleotides 107 to 214, the second stem loop is located at sugar and adenine, thymine, guanine or cytosine and option- 
nucleotides 215 to 258, the third spacer region is located at ally uracil as the base. 
nucleotides 259 to 261 and the third stem loop is located at 15 nucleotides containing a ribose sugar and nucleotides con- 
nucleotides 262 to 3 14. taining deoxyribose sugar and adenine, thymine andlor 
To date, group I introns have been shown to cleave uracil, guanine or cytosine as the base attached to the 1’ 
substrates comprising either RNA, or an RNA-DNA poly- carbon of the sugar. A modified RNA-DNA polymer is 
mer, with cleavage in the latter occumng at the RNA-DNA comprised of modified RNA, DNA and optionally RNA (as 
“junction”. Zaug et al., Science 231: 470-475 (1986); Sug- 20 distinguished from modified RNA). Modified DNA contains 
imoto et al., Nucleic Acids Res. 17: 355-371 (1989); and nucleotides containing a deoxyribose or arabinose sugar and 
Cech, Science 236: 1532-1539 (1987). A DNA segment nucleotides containing adenine, uracil, guanine, cytosine 
containing 5 deoxycytosines was shown not to be a cleavage and possibly thymine as the base. A modified DNA-RNA 
substrate for the Tetrahymena IVS, a group I intron, in Zaug polymer contains modified DNA, RNA and optionally 
et al., Science 231: 470-475 (1986). 25 DNA. A modified RNA-modified DNA polymer contains 
Therefore, the identification, enhancement, modification modified RNA-modified DNA, and optionally RNA and 
and use of novel enzymatic RNA molecules as disclosed DNA. 
herein is a significant and useful development. The utility of An enzymatic RNA molecule of the present invention is 
molecules with peptidase or protease activity is well-appre- capable of cleaving an amide bond at a predetermined site. 
ciated. Such molecules are used in products as divergent as 30 An enzymatic RNA molecule of this invention may also be 
medical or pharmaceutical agents, food products, personal characterized by a nucleotide sequence defining a recogni- 
care products, and cleaning agents, and in various methods tion site that is contiguous or adjacent to the 5’ terminus of 
and applications-industrial, environmental, medical, and the nucleotide sequence, a first spacer region located 3’-ter- 
numerous others-that take advantage of a molecule’s abil- mind to the recognition site, a P3[5’] region located 3’-ter- 
ity to cleave bonds between amino acids. Thus, the within- 35 minal to the first spacer region, a second spacer region 
disclosed methods and compositions useful for cleaving located 3’-terminal to the P3[5’] region, a first stem loop 
amide bonds in a variety of substrates are of particular located 3’-terminal to the second spacer region, a second 
significance. stem loop located 3’-terminal to the first stem loop, a third 
The term “enzymatic nucleic acid”, as used herein, is used spacer region located 3-’ terminal to the second stem loop, 
to describe an RNA- and/or DNA-containing nucleic acid 40 and a third stem loop located 3’-terminal to the third spacer 
that is capable of functioning as an enzyme. region, the third stem loop comprising a 5’ stem portion 
The term “ribozyme” is used to describe an RNA-con- defining a P3[3’] region capable of hybridizing to the P3[5’] 
taining nucleic acid that is capable of functioning as an region. 
enzyme. As used herein, the term “ribozyme” may be used It is also to be understood that an enzymatic RNA 
interchangeably with “enzymatic RNA molecules”. The 45 molecule of the present invention may comprise enzymati- 
terms “ribozyme”, “enzymatic RNA molecule” and “cab- cally active portions of a ribozyme or may comprise a 
lytic RNA molecule” should all be understood to encompass ribozyme with one or more mutations, e.g., with one or more 
the enzymatically active molecules of the present invention, loops or spacers absent or modified, as long as such dele- 
whether those molecules are described as endoribonu- tions, additions or modifications do not adversely impact the 
cleases, endodeoxyribonucleases, peptidases, amide-cleav- 50 molecule’s ability to perform as an enzyme. 
ing molecules, or some other equivalent description. The recognition site of an enzymatic RNA molecule of the 
An enzymatic RNA molecule of the present invention present invention typically contains a sequence of at least 2 
may be engineered or “evolved” from a wild-type, RNA- to about 12 bases, preferably about 4 to about 8 bases, which 
cleaving ribozyme via methods which tend to generate either are capable of hybridizing to a complementary sequence of 
“random” or “non-random” mutations. Examples of meth- 55 bases within a “hybrid” oligonucleotide-oligopeptide sub- 
ods useful in generating enzymatic RNA molecules that strate or to a specific sequence of amino acids, thus giving 
include mutations not normally found in wild-type the enzymatic RNA molecule its high sequence specificity. 
ribozymes include PCR (polymerase chain reaction), 3SR For example, an enzymatic RNA molecule of the present 
(self-sustained sequence replication), and site-directed invention constructed with a recognition site base sequence 
mutagenesis. 60 of 3’-GGGAG-5’ would be able to recognize the base 
Preferably, enzymatic RNA molecules produced as dis- sequence 5’-CCCTC-3’ present within an oligodeoxynucle- 
closed herein are capable of cleaving an amide bond- otide sequence in a hybrid substrate and to cleave the 
containing substrate. In one preferred embodiment, the substrate molecule at a predetermined site (see, e.g., 
substrate is a polypeptide, although enzymatic RNA mol- Example 2). Similarly, an enzymatic RNA molecule with a 
ecules capable of cleaving “hybrid” oligonucleotide-oli- 65 recognition sequence of 3’-UCGCC-5’ will recognize the 
gopeptide molecules, or oligonucleotides containing one or target sequence 5’-AGCGG-3’ in an oligoribonucleotide 
more amide bonds, are also contemplated. In another pre- sequence in a hybrid substrate. 
RNA-DNA poiymer 
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This same recognition site also allows the enzymatic RNA 
molecule to cleave hybrid or polypeptide substrates with 
high sequence specificity. Modification or mutation of the 
recognition site via well-known methods allows one to alter 
the sequence specificity of an enzymatic nucleic acid mol- s 
ecule. 
For example, a preferred method is described by Cadwell 
and Joyce, in PCR Methods and Applications 2: 28-33 
(1992). (Also see Cadwell and Joyce, PCR Methods and 
Applications 3 (Suppl.): S136-Sl40 (1 994).) According to 10 
this modified PCR method, random point mutations may be 
introduced into cloned genes. The method has been used to 
mutagenize the gene encoding the ribozyme with a mutation 
rate of 0.66% M.13% (95% confidence interval) per posi- 
tion per PCR, as determined by sequence analysis, with no 15 
strong preferences observed with respect to the type of base 
substitution. This allows the introduction of random muta- 
tions at any position in the molecule. Another method is 
available which is useful in introducing defined or random 
mutations (Joyce and Inoue, Nucleic Acids Research 17: 20 
711-722 (1989)). The modified PCR method of Cadwell and 
Joyce is, nevertheless, particularly preferred for use as 
described herein. 
Enzymatic nucleic acid molecules of the present invention 
include those with altered recognition sites. In various zs 
embodiments, these altered recognition sites confer unique 
sequence specificities on the enzymatic nucleic acid mol- 
ecule including such recognition sites. 
The exact bases present in the recognition site are impor- 
tant in determining the base sequence or amino acid residue 30 
sequence that is recognized by the enzymatic RNA mol- 
ecule, as well as the site at which cleavage will take place. 
It should be appreciated, however, that other sequences and 
sites in the enzymatic RNA molecules of the present inven- 
tion may participate in the recognition-and-cleavage pro- 3s 
cess. Amino acid residue sequences and conformations of 
the substrate molecules may also affect this process. 
Cleavage of the substrate preferably occurs immediately 
3' of the substrate cleavage sequence, the substrate oligomer 
sequence that associates with the recognition site. For 40 
example, if the substrate is an oligonucleotide, this cleavage 
leaves a 3' hydroxyl group on the substrate cleavage 
sequence and a 5' phosphate on the nucleotide that was 
originally immediately 3' of the substrate cleavage sequence 
in the original substrate. If, on the other hand, the substrate 4s 
Use of an enzymatic RNA molecule of the present inven- 
tion with an external recognition site allows the target 
sequence to be altered by merely changing the external 
recognition site sequence. Use of a plurality of different 
external recognition sequences with an enzymatic RNA 
molecule of the present invention allows the substrate to be 
cleaved at each of the different residue sequences encoded 
by the external recognition sequences. 
First spacer regions typically contain a sequence of nucle- 
otides of about 3 to 7, preferably about 5, bases in length. In 
one variation, the nucleotides making up the first spacer 
have the sequence 5'-NNNNA-3' (SEQ ID NO 2), where N 
represents the presence of any nucleotide at that position. In 
another variation, the first spacer region is defined by the 
sequence 5'-AACAA-3' (SEQ ID NO 3). 
In other embodiments, the first spacer region is comprised 
of a nucleotide sequence defining two spacer stem loops. In 
one variation, the first spacer stem loop is 25 nucleotides in 
length, and the second spacer stem loop is 36 bases in length. 
In another variation, the first spacer stem loop has the base 
GUAGUCA-3' (SEQ ID NO 4), and the second spacer stem 
loop has the base sequence 5'-GUCUUUAAACCAAUA- 
As noted previously, the foregoing descriptions of loop 
and spacer regions are exemplary and are not to be construed 
as limiting the disclosed invention(s). 
A stem loop is a secondary structure formed by a nucle- 
otide sequence that has "folded over on itself'. A stem loop 
comprises a 5' nucleotide sequence portion, designated a 5' 
paring segment (P[5']) that is capable of hybridizing to a 
nucleotide sequence located 3' of the P[5'] and is designated 
the 3' pairing segment (P[3']). In a stem loop, the P[5'] and 
P[3'] are connected by a nucleotide sequence called a loop. 
The P[5'] and P[3'] hybridize and form a nucleic acid duplex. 
The nucleic acid duplex formed by the P[5'] and P[3'] does 
not have to be a perfect duplex and may contain stretches of 
nucleotides that are either unpaired or paired to a sequence 
outside the stem loop. 
In various alternative embodiments, an enzymatic RNA 
molecule of the present invention has an enhanced or 
optimized ability to cleave amino acid substrates. 
As those of skill in the art will appreciate, the rate of an 
enzyme-catalyzed reaction varies depending upon the sub- 
strate and enzyme concentrations and, in general, levels off 
sequence 5'-AGUUACCAGGCAUGCACCUG- 
GAUUGGAUCGGUUUAAAAGGC-3' (SEQ ID NO 5). 
is (or includes) an amino acid residue sequence, cleavage 
leaves a 3' amino group on the substrate cleavage sequence 
and a 5' carboxyl group on the amino acid that was originally 
immediately 3' of the substrate cleavage sequence in the 
original substrate. Cleavage can be redirected to a site of 
choice by changing the bases present in the recognition 
sequencehternal guide sequence (see Murphy et al., PNAS 
USA 86: 9218-9222 (1989)) and/or in other sites and 
at high substrate or enzyme concentrations. Taking such 
effects into account, the kinetics of an enzyme-catalyzed 
reaction may be described in the following terms, which 
define the reaction. 
The enhanced or optimized ability of an enzymatic RNA 
molecule of the present invention to cleave a dipeptide or 
polypeptide substrate may be determined in a cleavage 
reaction with varying amounts of labeled peptide substrate 
SO 
sequences of the enzymatic RNA molecule. 
nucleic acid, an external recognition site not covalently 
coupled to the rest of the enzymatic RNA molecule. External 
in the presence of enzymatic RNA molecule as described in 
The recognition site may also be provided as a separate ss Examples 1 and 2. The ability to cleave the substrate is 
generally defined by the catalytic rate (kea,) divided by the 
Michaelis constant (&I. The symbol k,, represents the 
recognition sites may direct cleavage at a specific amino 
acid or base sequence (see, e.g., Doudna et al., Nature 339: 
519-522 (1989)). If an external recognition site is used, the 
enzymatic RNA molecule used with it would probably not 
contain a recognition site but would tend to comprise a 
P3[5'] region, a second spacer region, a first stem loop, a 
second stem loop, a third spacer region and a third stem loop 
where the third stem loop comprises a 5' stem portion 
defining a P3[3'] region capable of hybridizing to said P3[5'] 
region. 
maximal velocity of an enzyme reaction when the substrate 
approaches a saturation value. K,,,, represents the substrate 
60 concentration at which the reaction rate is one-half maximal. 
Values for K,, and k, are determined in this invention by 
experiments in which the substrate concentration [SI is in 
excess over enzymatic RNA molecule concentration [E]. 
Initial rates of reaction (v,) over a range of substrate 
6s concentrations were estimated from the initial linear phase, 
generally the first 5% or less of the reaction. Typically eight 
data points ware fit by a least squares method to a theoretical 
5,595,873 
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line given by the equation: v=-K,(vJ[S])+V,,. Thus, k,,, 
and KM are determined by the initial rate of reaction, vo, and 
the substrate concentration [SI. 
In one embodiment of the present invention, an enzymatic 
RNA molecule of the present invention exhibits amide 5 
bond-cleaving activity not normally found in wild type 
ribozymes. In various alternative embodiments, an enzy- 
matic RNA molecule of the present invention has an 
enhanced or optimized ability to cleave amino acid sub- 
strates, preferably dipeptide or polypeptide substrates. One IO 
skilled in the art will appreciate that the enhanced or 
optimized ability of an enzymatic RNA molecule to cleave 
amino acid substrates may vary depending upon the selec- 
tion constraints applied during the in vitro evolution proce- 
Enzymatic RNA molecules of the present invention may 
also be characterized as displaying a K,,, value that is 
improved over the wild type. As noted above, K,,, represents 
the substrate concentration at which the reaction rate is 
one-half maximal; thus, an improved KM indicates an 20 
improvement in substrate processing. In various embodi- 
ments, enzymatic RNA molecules of the present invention 
have a KM that is statistically significant when compared 
with the KM of wild type ribozymes, the latter of which are 
One skilled in the art will understand that the enhanced or 
optimized ability of an enzymatic RNA molecule to process 
amino acid (e.g. polypeptide) substrates may vary depending 
upon the selection constraints applied during the in vitro 
evolution procedure of the invention and may include a 30 
reduction of the peptide concentration to favor enzymatic 
RNA molecules with improved substrate processing ability. 
In other embodiments, an enzymatic RNA molecule of the 
present invention has an enhanced or optimized ability to 
bind an amino acid substrate. The ability of an enzymatic 35 
RNA molecule to bind a polypeptide substrate is defined by 
the dissociation constant (K,). The K, is an equilibrium 
constant describing the dissociation of the enzymatic RNA 
molecu1e:substrate complex into its individual components. 
The K, constant as understood in the context of this 40 
invention is determined by a gel shift analysis to determine 
the percent enzymatic RNA molecule bound to the amino 
acid product, as described in the Examples. A binding curve 
is generated by plotting the percent of product bound to 
enzymatic RNA molecule over a range of enzymatic RNA 45 
molecule concentration. The K, is determined by fitting the 
data to a theoretical binding curve using the least squares 
method. Typically, the enzymatic RNA molecule concentra- 
tion E] vastly exceeds the product; therefore, the theoretical 
binding curve can be represented by the equation: % bound= 50 
[E]/([E]+K,), where K,=[E] when half of the total product 
is bound to the enzymatic RNA molecule. 
An enzymatic RNA molecule of the present invention 
preferably binds amino acid substrate with a K, which is an 
improvement over wild type ribozymes. For example, an 55 
enzymatic RNA molecule of the present invention prefer- 
ably binds peptides with a K, having a value less than 30 
pM. In preferred embodiments, enzymatic RNA molecules 
bind polypeptide with a K, having a value less than about 
10 pM. In more preferred embodiments, the K, of an amino 60 
acid-binding enzymatic RNA molecule is less than about 1 
pM. In an even more prefenred embodiment, the K, of an 
amino acid-binding enzymatic RNA molecule is less than 
about 50 nM, more preferably less than about 25 nM, and 
even more preferably less than about 10 nM. Especially 65 
preferred enzymatic RNA molecules bind peptide substrate 
with a K, of 5 nM or less, e.g., with a K, of about 0.1-5 nM. 
dure of the invention. 15 
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Onc skilled in the art will understand that the enhanced or 
optimized ability of an enzymatic RNA molecule to bind 
amino acid-containing substrates may vary depending upon 
the selection constraints applied during the in vitro evolution 
procedure of the invention and may include a reduction of 
the amino acid concentration to favor enzymatic RNA 
molecules with improved substrate binding affmity. 
In another variation, an enzymatic RNA molecule of the 
present invention has an enhanced or optimized substrate 
turnover rate. The enhanced or optimized substrate turnover 
rate may be determined in single-turnover kinetic experi- 
ments with the enzymatic RNA molecule in excess of the 
substrate as described in the following Examples. Initial 
rates (kobs) are obtained using no more than the first 5% of 
the reaction. Given that kc,)KpkobJIE], each kobs value, 
obtained at different enzymatic RNA molecule concentra- 
tions, provides an estimate of k,,jK,. Generally, eight or 
more measurements of k,,/KM are obtained. The value of 
k,,, in the presence of limited substrate indicates the sub- 
strate turnover number rate and is expressed in the number 
of catalytic cycles that are completed by the enzyme per unit 
of time under the assay conditions. One skilled in the art will 
appreciate that the enhanced or optimized substrate turnover 
rate of an enzymatic RNA molecule of the present invention 
may vary depending upon the selection constraints applied 
during the in vitro evolution procedure of the invention and 
may include a reduction of the reaction time to favor 
enzymatic RNA molecules with improved substrate turnover 
rates. 
In other embodiments, an enzymatic RNA molecule of the 
present invention is capable of functioning efficiently over a 
wide range of temperatures. In yet another variation, an 
enzymatic RNA molecule of the present invention is capable 
of functioning efficiently over a wide range of pH. 
In various alternative embodiments, an enzymatic RNA 
molecule of the present invention is capable of functioning 
efficiently in the presence or absence of Mg2+. Alternatively, 
an enzymatic RNA molecule of the present invention is 
capable of functioning efficiently in the presence or absence 
of divalent cations other than Mg2+. Other suitable divalent 
cations may be selected from the group comprised of Mn2+, 
Zn2+, or Ca”. It is anticipated that cation concentrations 
similar to those described above for Mg2+ will be useful as 
disclosed herein. 
Optionally, monovalent cations may also be present as 
“alternatives” for the use of divalent cations. For example, 
monovalent cations such as sodium (Na+) or potassium (K+) 
may be present, either as dissociated ions or in the form of 
dissociable compounds such as NaCl or KCl. In one embodi- 
ment, a monovalent cation is present in a concentration 
ranging from about C 2 0 0  mM. In other embodiments, 
monovalent cations are present in a concentration ranging 
from about 2-100 mM. Alternatively, the concentration of 
monovalent cations ranges from about 2 mM-50 mM. In 
other embodiments, the concentration ranges from about 2 
mM-25 mM, with a concentration of about 2 mM-15 mM 
being preferred. 
In various embodiments, an enzymatic RNA molecule of 
the present invention optionally includes a 3’ hydroxyl of G 
(Le. guanosine, or one of its 5’-phosphorylated forms), 
which functions as a nucleophile-Le., it “attacks” substrate 
molecules, particularly hybrid substrates, at a phosphodi- 
ester or amide bond. For example, in the L-21 ribozyme 
derived from the group I intron of Tetrahymena themophila, 
the G264-C311 base pair-which is known as the 
“G-site”-binds the G substrate. (See, e.g., Wang and Cech, 
Science 256: 526-529 (1992).) 
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Alternatively, in other embodiments, wherein an enzy- 
matic RNA molecule of the present invention lacks a 3’ 
terminal Go,, the G ,  may be supplied as a free (i.e., 
unattached) attacking group. In such embodiments, an enzy- 
matic RNA molecule is able to “attack” multiple substrates 
in sequential fashion. In either case, the term “enzymatic 
RNA molecules” as used in the present disclosure includes 
enzymatic RNA molecule including, as well as those lack- 
ing, a 3‘ Gow 
In various embodiments, an enzymatic RNA molecule of 
the present invention may combine one or more modifica- 
tions or mutations including additions, deletions, and sub- 
stitutions. In alternative embodiments, such mutations or 
modifications may be generated using methods which pro- 
duce random or specific mutations or modifications. These 
mutations may change the length of, or alter the nucleotide 
sequence of, a stem loop, the P3[5’], the P3[3’] region, a 
spacer region or the recognition sequence. One or more 
mutations within one catalytically active enzymatic RNA 
molecule may be combined with the mutation(s) within a 
second catalytically active enzymatic RNA molecule to 
produce a new enzymatic RNA molecule containing the 
mutations of both molecules. 
In other preferred embodiments, an enzymatic RNA mol- 
ecule of the present invention may have random mutations 
introduced into it using a variety of methods well known to 
those skilled in the art. For example, the method described 
by Cadwell and Joyce (PCR Methods and Applications 2: 
28-33 (1992)) is particularly preferred for use as disclosed 
herein, as it efficiently introduces random mutations into 
populations of enzymatic RNA molecules. (Also see Cad- 
well and Joyce, PCR Methods and Applications 3 (Suppl.): 
S136-S140 (1994).) According to this modified PCR 
method, random point mutations may be introduced into 
cloned genes. The method has been used to mutagenize the 
gene encoding the ribozyme with a mutation rate of 0.66% 
30.13% (95% confidence interval) per position per PCR, as 
determined by sequence analysis, with no strong preferences 
observed with respect to the type of base substitution. This 
allows the introduction of random mutations at any position 
in the molecule. 
Another method is available which is useful in introduc- 
ing defined or random mutations (see Joyce and Inoue, 
Nucleic Acids Research 17: 711-722 (1989)). This latter 
method involves excision of a template (coding) strand of a 
double-stranded DNA, reconstruction of the template strand 
with inclusion of mutagenic oligonucleotides, and subse- 
quent transcription of the partially-mismatched template. 
This allows the introduction of defined or random mutations 
at any position in the molecule by including polynucleotides 
containing known or random nucleotide sequences at 
selected positions. 
Enzymatic RNA molecules of the present invention may 
be of varying lengths and folding patterns, as appropriate, 
depending on the type and function of the molecule. For 
example, enzymatic RNA molecules derived from group I 
introns (e.g., Tetrahymena-derived ribozymes) may be about 
413 or more nucleotides in length, although a length not 
exceeding 413 nucleotides is preferred, to avoid limiting the 
therapeutic usefulness of molecules by making them too 
large or unwieldy. Tn various therapeutic applications, enzy- 
matic RNA molecules of the present invention comprise the 
enzymatically active portions of ribozymes. In various 
embodiments, enzymatic RNA molecules of the present 
invention comprise fewer than 400 nucleotides, fewer than 
300 nucleotides, fewer than 200 nucleotides, or fewer than 
100 nucleotides. 
20 
In other therapeutic applications, enzymatic RNA mol- 
ecules such as “hammerhead” ribozymes are preferably no 
more than about 50 nucleotides in length, with a length of 
3WO nucleotides being particularly preferred. Even more 
5 preferred are hammerhead ribozymes of about 31-36 nucle- 
otides in length. 
Moreover, if one intends to synthesize molecules for use 
as disclosed herein, the larger the enzymatic nucleic acid 
molecule is, the more difficult it is to synthesize. Those of 
lo skill in the art will certainly appreciate these design con- 
straints. 
Various preferred methods of modifying ribozymes and 
other enzymatic RNA molecules, ribonucleases, deoxyribo- 
15 nucleases, and amidases of the present invention are further 
described in Examples 1-3 hereinbelow. 
C. Nucleotide Analogs 
As noted above, the term “nucleotide analog” as used 
herein generally refers to a purine or pyrimidine nucleotide 
that differs structurally from A, T, G, C, or U, but is 
sufficiently similar to substitute for the normal nucleotide in 
a nucleic acid molecule. As used herein, the term “nucle- 
otide analog” encompasses altered bases, different sugars, or 
a combination of the two. Examples of nucleotide analogs 
useful according to the present invention include those listed 
in the following Table, most of which are found in the 
approved listing of modified bases at 37 CFR $1.822 (which 
is incorporated herein by reference) 
20 
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TABLE 1 
Nucleotide Analogs 
30 
Abbreviation Description 
ac4c 
cm 
cmnm5s2u 
d 
fm 
35 C M U  
40 gal¶ 
gm 
i6a 
mla  
mlf 
45 2; 
m22g 
m2a 
m2g 
m3C 
m5C 
5O m6a 
m7g 
mam5U 
d s 2 u  
-q 
mcm5s2.u 
55 mo5u 
ms2i6a 
ms2t6a 
65 fI 
s2c 
itacetylcytidine 
5-(carboxyhydroxylmethyl)uridine 
2’-0-methylcytidine 
5-carboxymethylaminomethyl-2- 
thioridine 
dihydrouridine 
2’-0-methylpseudouridine 
p, D-galactosylqueosine 
2’-0-methylguanosine 
inosine 
N6-isopentenyladenosine 
1 -methyladenosine 
1-methylpseudouridine 
1 -methylguanosine 
1-methylinosine 
2,2-dimethylguanosine 
2-methyladenosine 
2-methylguanosine 
3-methylcytidine 
5-methylcytidine 
N6-methyladenosine 
7-methylguanosine 
5-methylaminomethyluridine 
5-methoxyaminomethyl-2-~ouridine 
p, D-mannosylmethyluridine 
5-methoxycarbonylmethyluri~e 
5-methoxyuridine 
2-methylthio-N6- 
isopentenyladenosine 
methylthiopurine-6- 
y1)carbamoyl)threonine 
N-((9-P-D-ribofuranosylpurine-6- 
y1)N-methyl-carbamoy1)threonine 
uridine-5-oxyacetic acid 
methylester 
uridine-5-oxyacetic acid (v) 
wybutoxosine 
pseudouridine 
queosine 
2-thiocytidine 
N-((9-P-D-ribofurano~yl-2- 
5,595,873 
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TABLE 1 -continued 
Nucleotide Analogs 
Abbreviation Description 
s2t 
s2u 
s4u 
t 
t6a 
tm 
urn 
YW 
x 
araU 
araT 
5-methyl-2-thiouridine 
2-thiouridine 
4-thiouridine 
5-methyluridine 
N-((9-P-D-nbofuranosylpurine-6- 
yl)carbamoyl)threonine 
2’-0-methyl-5-methyluridine 
2’-O-methyluridine 
wybutosinc 
3-(3-amino-3- 
carboxypropy1)uridine. (acp3)u 
0, D-arabinosyl 
P, D-arabinosyl 
Other useful analogs include those described in published 
international application no. WO 92/20823, or analogs made 
according to the methods disclosed therein. Analogs 
described in DeMesmaeker, et al., Angew. Chem. Int. Ed. 
Engl. 33: 226-229 (1994); DeMesmaeker, et al., Synlett: 
733-736 (October. 1993); Nielsen, et al., Science 254: 
1497-1500 (1991); and Idziak, et al., Tetrahedron Letters 
34: 5417-5420 (1993) are also useful according to the 
within-disclosed invention and said disclosures are incorpo- 
rated by reference herein. 
D. Methods of Engineering Enzymatic RNA Molecules 
The present invention also contemplates methods of pro- 
ducing nucleic acid molecules having a predetermined activ- 
ity. In one preferred embodiment, the nucleic acid molecule 
is an enzymatic RNA molecule. In another variation, the 
desired activity is a catalytic activity. 
In one embodiment, the present invention contemplates 
methods of synthesizing enzymatic RNA molecules which 
may then be “engineered” to catalyze a specific or prede- 
termined reaction. Methods of preparing enzymatic RNA 
molecules are described herein; see, e.g., the Examples 
hereinbelow. In other embodiments, an enzymatic RNA 
molecule of the present invention may be engineered to bind 
small molecules or ligands, such as adenosine triphosphate 
(ATP). (See, e.g., Sassanfar, et al., Nature 364: 550-553 
(1993).) 
In another embodiment, the present invention contem- 
plates that a population of enzymatic RNA molecules may 
be subjected to mutagenizing conditions to produce a 
diverse population of mutant enzymatic RNA molecules or 
ribozymes. Thereafter, enzymatic RNA molecules having 
desired characteristics are selected and/or separated from the 
population and are subsequently amplified. 
Alternatively, mutations may be introduced in the enzy- 
matic RNA molecule by altering the length of the recogni- 
tion site (internal guide sequence) of the enzymatic RNA 
molecule. The recognition site of the enzymatic RNA mol- 
ecule associates with a complementary sequence of bases 
within a substrate nucleic acid or substrate hybrid oligo- 
nucleotide-oligopeptide sequence. Methods of altering the 
length of the recognition site are known in the art and 
include PCR, for example; useful techniques are described 
further in the Examples below. 
Alteration of the length of the recognition site of the 
enzymatic RNA molecule which retains the ability to rec- 
ognize a sequence of bases within the nucleic acid segment 
of a hybrid substrate molecule or with an amino acid residue 
sequence recognized thereby may have a desirable effect on 
the binding specificity of the enzymatic RNA molecule. For 
example, an increase in the length of the recognition site 
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may increase binding specificity between the enzymatic 
RNA molecule and the complementary base sequences of an 
oligonucleotide in a hybrid substrate, or may enhance rec- 
ognition of amino acid residue sequences in a hybrid mol- 
ecule or in a polypeptide substrate. In addition, an increase 
in the length of the recognition site may also increase the 
affinity with which it binds to substrate. In various embodi- 
ments, these altered recognition sites in the enzymatic RNA 
molecule confer increased binding specificity and afhi ty  
between the enzymatic RNA molecule and its substrate. 
It has recently been noted that certain oligonucleotides are 
able to recognize and bind molecules other than oligonucle- 
otides with complementary sequences. These oligonucle- 
otides are often given the name “aptamers”. For example, 
Ellington and Szostak describe RNA molecules that are able 
to bind a variety of organic dyes (Nature 346: 818-822 
(1990)), while Bock, et al. describe ssDNA molecules that 
bind human thrombin (Nature 355: 564-566 (1992)). Simi- 
larly, Jellinek, et al. describe RNA ligands to basic fibroblast 
growth factor (PNAS USA 90: 11227-11231 (1993)). 
Until the advent of the present invention, however, no one 
has described the existence of catalytically active RNA 
enzymes with reproducible amide-cleaving capabilities. The 
art has also been silent with respect to methods of engineer- 
ing and selecting catalytically active oligonucleotide mol- 
ecules possessing this ability, until now. 
One of skill in the art may realize that the enzymatic RNA 
molecules of this invention can be altered at any nucleotide 
sequence, such as the recognition site, by various methods 
disclosed herein, including PCR and 3SR. Additional nucle- 
otides can be added to the 5’ end of the enzymatic RNA 
molecule by including the additional nucleotides in the 
primer used to introduce the T7 promoter binding site. The 
additional nucleotides would be included in the primer 
between the T7 promoter sequence and the nucleotide 
sequences which hybridize to the enzymatic RNA molecule 
at the 5’ end. 
Enzymatic RNA molecules of the present invention may 
also be prepared or engineered in a more non-random 
fashion via use of methods such as site-directed mutagen- 
esis. For example, site-directed mutagenesis may be carried 
out essentially as described in Morinaga, et al., Biotechnol- 
ogy 2: 636 (1984), which is incorporated herein by refer- 
ence. A useful site-directed mutagenesis technique is also 
described in Example 1 below. 
In various embodiments, the population of group I nucleic 
acids is made up of at least 2 group I nucleic acids. In one 
variation, group I nucleic acids are nucleic acid molecules 
having a nucleic acid sequence defining a recognition site 
that is contiguous or adjacent to the 5’-terminus of the 
nucleotide sequence, a first spacer region located 3’-terminal 
to the recognition site, a P3[5’] region located 3’-terminal to 
the first spacer region, a second spacer region located 
3’-tenninal to the P3[5’] region, a first stem loop located 
3’-terminal to the second spacer region, a second stem loop 
located 3’-terminal to the first stem loop, a third spacer 
region located 3’-terminal to the second stem loop, and a 
third stem loop located 3’-terminal to the third spacer region, 
the third stem loop comprising a 5’ stem portion defining a 
P3[3’] region capable of hybridizing to the P3[5’] region. 
Other characteristics of enzymatic RNA molecules produced 
according to the presently-disclosed methods are described 
elsewhere herein. 
In other embodiments, mutagenizing conditions include 
conditions that introduce either defined or random nucle- 
otide substitutions within an enzymatic RNA molecule. 
Examples of typical mutagenizing conditions include con- 
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ditions disclosed in other parts of this specification and the 
methods described by Joyce et al., Nucl. Acids Res. 17: 
711-722 (1989); Joyce, Gene 82: 83-87 (1989); and 
Beaudry and Joyce, Science 257: 635-41 (1992). 
In still other embodiments, a diverse population of mutant 5 
enzymatic nucleic acid molecules of the present invention is 
one that contains at least 2 nucleic acid molecules that do not 
have the exact same nucleotide sequence. In other varia- 
tions, from such a diverse population, an enzymatic RNA 
molecule or other enzymatic nucleic acid having a prede- 10 
termined activity is then selected on the basis of its ability 
to perform the predetermined activity. In various embodi- 
ments, the predetermined activity comprises, without limi- 
tation, enhance catalytic activity, decreased KM, enhanced 
substrate binding ability, altered substrate specificity, and the 15 
like. 
Parameters which may be considered aspects of enzyme 
performance include catalytic activity or capacity, substrate 
binding ability, enzyme turnover rate, enzyme sensitivity to 
feedback mechanisms, and the like. In certain aspects, 20 
substrate specificity may be considered an aspect of enzyme 
performance, particularly in situations in which an enzyme 
is able to recognize and bind two or more competing 
substrates, each of which affects the enzymes’ performance 
Substrate specificity, as used herein, may refer to the 
specificity of an enzymatic nucleic acid molecule as 
described herein for a particular substrate, such as one 
comprising oligonucleotides only, polypeptides only, or a 
composite of both. In the case of the latter type of substrate, 30 
an enzymatic nucleic acid molecule of the present invention 
may preferentially bind to a particular region of such a 
hybrid or composite substrate. 
Substrate specificity may also include sequence specific- 
ity; i.e., an enzymatic nucleic acid molecule of the present 35 
invention may “recognize” and bind to a nucleic acid 
substrate having a particular nucleic acid sequence, or to a 
substrate having a particular amino acid residue sequence. 
For example, if the substrate recognition site of an enzy- 
matic nucleic acid molecule of the present invention will 40 
only bind to substrate molecules having a series of one or 
two arginine residues in a row, then the enzymatic nucleic 
acid molecule will tend not to recognize or bind nucleic acid 
substrate molecules lacking such a sequence. In various 
embodiments, selecting includes any means of physically 45 
separating the mutant enzymatic nucleic acids having a 
predetermined activity from the diverse population of 
mutant enzymatic nucleic acids. Often, selecting comprises 
separation by size, by the presence of a catalytic activity, or 
by hybridizing the mutant nucleic acid to another nucleic 50 
acid or to a peptide that is either in solution or attached to 
a solid matrix. 
In various embodiments, the predetermined activity is 
such that the mutant enzymatic nucleic acid having the 
predetermined activity becomes labelled in some fashion by 55 
virtue of the activity. For example, the predetermined activ- 
ity may be an enzymatic RNA molecule activity whereby the 
activity of the mutant enzymatic nucleic acid upon its 
substrate causes the mutant enzymatic nucleic acid to 
become covalently linked to it. The mutant enzymatic 60 
nucleic acid is then selected by virtue of the covalent 
linkage. 
In other embodiments, selecting a mutant enzymatic 
nucleic acid having a predetermined activity includes ampli- 
fication of the mutant enzymatic nucleic acid (see, e.g., 65 
Joyce, Gene 82: 83-87 (1989); Beaudry and Joyce, Science 
257: 635-41 (1992)). 
with respect to the other substrate(s). 25 
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E. Compositions 
The invention also contemplates compositions containing 
one or more types or populations of enzymatic RNA mol- 
ecules of the present invention; e.g., different types or 
populations may recognize and cleave different amino acid 
residue sequences. Compositions may further include a 
peptide-containing substrate. Compositions according to the 
present invention may further comprise magnesium ion or 
other divalent or monovalent cations, as discussed in section 
B above. 
Preferably, the enzymatic RNA molecule is present at a 
concentration of about 0.05 pM to about 2 pM. Typically, the 
enzymatic RNA molecule is present at a concentration ratio 
of enzymatic RNA molecule to substrate of from about 1:5 
to about 150. More preferably, the enzymatic RNA mol- 
ecule is present in the composition at a concentration of 
about 0.1 to about 1 pM. Even more preferably, com- 
positions contain the enzymatic RNA molecule at a concen- 
tration of about 0.1 pM to about 0.5 pM. Preferably, the 
substrate is present in the composition at a concentration of 
about 0.5 pM to about 1000 @VI. One skilled in the art will 
understand that there are many sources of amide bond- 
containing substrates including naturally-occuning and syn- 
thetic amino acids, polypeptides, and proteins (including 
those in denatured form), and molecules containing same. 
Magnesium ion (or another suitable monovalent or diva- 
lent cation, as described previously) may also be present in 
the composition, at a concentration of about 2-100 mM. 
More preferably, the magnesium ion is present in the com- 
position at a concentration of about 2 mM to about 50 mM. 
Preferably, magnesium ion is present at a concentration of 
about 5 mM to about 15 mM, with a concentration of about 
10 mM being particularly preferred. One skilled in the art 
will understand that the magnesium ion concentration is 
only constrained by the limits of solubility of magnesium in 
aqueous solution and a desire to have the enzymatic RNA 
molecule present in the same composition in an active 
conformation. 
The invention also contemplates compositions containing 
an enzymatic RNA molecule of the present invention, hybrid 
oligonucleotide-oligopeptide molecules, and magnesium ion 
in concentrations as described hereinabove. As noted pre- 
viously, other monovalent or divalent ions (e.g., Mn2+) may 
be used in place of magnesium. 
Also contemplated by the present invention are compo- 
sitions containing an enzymatic RNA molecule of the 
present invention, amino acid-containing substrate, and 
magnesium ion at a concentration of greater than about 2 
millimolar, wherein said substrate is greater in length than 
the recognition site present on the enzymatic RNA molecule. 
F. Methods of Using Enzymatic RNA Molecules 
The methods of using enzymatic RNA molecules as 
disclosed herein are legion. As discussed previously, mol- 
ecules capable of cleaving the bonds linking neighboring 
amino acid molecules (e.g., peptide bonds) have numerous 
uses encompassing a wide variety of applications. For 
example, enzymatic RNA molecules having the within- 
disclosed capabilities, structures, and/or functions are useful 
in pharmaceutical and medical products (e.g., for wound 
’ debridement, clot dissolution, etc.), as well as in household 
items (e.g., detergents, dental hygiene products, meat ten- 
derizers). Industrial utility of the within-disclosed com- 
pounds, compositions and methods is also contemplated and 
well within the scope of the present invention. 
G. Vectors 
The present invention also features expression vectors 
including a nucleic acid segment encoding an enzymatic 
25 
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RNA molecule of the present invention situated within the 
vector, preferably in a manner which allows expression of 
that enzymatic RNA molecule within a target cell (e.g., a 
plant or animal cell). 
Thus, in general, a vector according to the present inven- 
tion includes a bacterial, viral or eukaryotic promoter within 
a plasmid, cosmid, phagemid, virus, viroid, or phage vector. 
Other suitable vectors include double-stranded DNA 
(dsDNA), partially double-stranded DNA, dsRNA, partially 
dsRNA, or single-stranded RNA (ssRNA) or DNA (ssDNA). 
It should also be appreciated that useful vectors according to 
the present invention need not be circular. 
In one aspect of the present invention, a first enzymatic 
RNA molecule-encoding nucleotide sequence is transcrip- 
tionally linked to a promoter sequence. In another variation, 
one or more additional enzymatic RNA molecule-encoding 
nucleotide sequences are also included in the vector; said 
additional enzymatic RNA molecule-encoding sequences 
may be located on either side, or both sides, of a nucleotide 
sequence encoding the first enzymatic RNA molecule. Pref- 
erably, there are intervening nucleotides or nucleotide 
sequences between successive enzymatic RNA molecule- 
encoding sequences. 
In another variation, nucleotide sequences flanking each 
of the additional enzymatic RNA molecule-encoding 
sequences are preferably provided, which sequences may be 
recognized by the first enzymatic RNA molecule. The inter- 
vening or flanking sequences preferably comprise at least 1 
nucleotide; more preferably, intervening or flanking 
sequences are about 2-20 nucleotides in length, with 
sequences of about 5-10 nucleotides in length being par- 
ticularly preferred. 
The addition of polyadenine (poly(A)) tails may also be 
useful to protect the 3’ end of an enzymatic RNA molecule 
according to the present invention. These may be provided 
by including a poly(A) signal site in the expression vector, 
which would signal a cell to add the poly(A) tail in vivo. 
Preferably, the signal is aligned in such a fashion that it 
prevents unwanted secondary structure formation with other 
parts of the enzymatic RNA molecule. 
Alternatively, a poly(A) tail may be provided by intro- 
ducing a poly(A) sequence directly into the expression 
vector. Since the poly(A) sequence may decrease in size 
over time when expressed in vivo, the vector may need to be 
monitored over time. Care must be taken, however, in the 
addition of a poly(A) tail which binds poly(A) binding 
proteins, which may prevent the enzymatic RNA molecule 
from acting upon its target nucleotide sequence. Other 
vectors and methods of generating same are described in the 
art; see, e.g., published international application no. WO 
93123569. 
Thus, in one example, a vector may comprise a promoter 
operatively linked for expression to a nucleotide sequence 
encoding a first enzymatic RNA molecule followed, in a 
3’45’  direction, by: (1) a “flanking” nucleotide sequence 
capable of being recognized and cleaved by said first enzy- 
matic RNA molecule; (2) a nucleotide sequence encoding a 
second enzymatic RNA molecule; (3) another flanking 
nucleotide sequence capable of being recognized and 
cleaved by said first enzymatic RNA molecule; (4) a nucle- 
otide sequence encoding a third enzymatic RNA molecule; 
(4) yet another flanking nucleotide sequence capable of 
being recognized and cleaved by said first enzymatic RNA 
molecule; and so forth. 
Preferably, a vector according to the present invention 
includes a plurality of nucleic acid sequences encoding the 
second enzymatic RNA molecule, each flanked by nucleic 
acid sequences recognized by the first enzymatic RNA 
molecule. More preferably, such a plurality includes at least 
5, preferably 7, more preferably 9 or more, nucleic acid 
sequences. In other embodiments, a vector as disclosed 
5 herein includes a promoter which regulates expression of the 
nucleic acid encoding the enzymatic RNA molecules from 
the vector. 
The invention also contemplates that a promoter sequence 
is linked to a first or “releasing” enzymatic RNA molecule 
10 having an appropriate restriction endonuclease site. A 
single-stranded oligonucleotide is then provided which 
encodes the two flanking regions and a second (i.e., “thera- 
peutic”) enzymatic RNA molecule. The oligonucleotides are 
then allowed to form partial duplexes via hybridization at 
15 the flanking regions. The single-stranded sections are then 
filled in using a DNA polymerase and deoxyribonucleotide 
triphosphates (dNTPs) to form a dsDNA molecule, which 
may then be ligated to thc restriction endonuclease site to 
form the desircd vector. As noted above, the vector may be 
20 chosen from the group comprising plasmids, cosmids, 
phagemids, virus, viroids, or phage. 
Preferably, the plurality of nucleic acid sequences are 
identical and are arranged in sequential fashion such that 
each has an identical end nearest to the promoter. If desired, 
25 a poly(A) sequence adjacent to the sequence encoding the 
first or second enzymatic RNA molecule may be provided to 
increase stability of the RNA produced by the vector andor 
to enhance transport to appropriate cellular compartments. 
Further, a restriction endonuclease site adjacent to the 
30 nucleic acid encoding the first enzymatic RNA molecule 
may be provided to allow insertion of nucleic acid encoding 
the second enzymatic RNA molecule during construction of 
the vector. 
If delivery of a vector construct to a eucaryotic cell is 
35 desired, cellular splicing mechanisms within the target 
cell(s) may be utilized or integrated to cleave out the 
therapeutic second enzymatic RNA molecule(s) by encoding 
recognition sequences for the second enzymatic RNA mol- 
ecules within the flanking sequences of the expressed tran- 
40 script. Multiple copies of the releasing first enzymatic RNA 
molecule may be provided to enhance release of the second 
(i.e. therapeutic) enzymatic RNA molecule if the turnover 
rate is slower than the degradation rate of the second 
enzymatic RNA molecule. If the target cell is a bacterial cell, 
45 in vitro modifications and certain cell modifications may be 
enhanced by providing appropriate nucleotide sequences 
within the vector and are useful in the enhancement of the 
turnover rate, enzymatic stability, and cleavage activity of 
the within-disclosed enzymatic RNA molecules. 
50 A method of forming an enzymatic RNA molecule 
expression vector includes providing a vector comprising 
nucleic acid encoding a first enzymatic RNA molecule, as 
discussed above, and providing a single-stranded DNA 
molecule encoding a second enzymatic RNA molecule, also 
55 as discussed above. The single-stranded DNA is then 
allowed to anneal to form a partial duplex DNA which can 
be filled in by treatment with an appropriate enzyme, such 
as a DNA polymerase in the presence of dNTPs, to form a 
duplex DNA which can then be ligated to the vector. Large 
60 vectors resulting from use of this method can then be 
selected to insure that a high copy number of the single- 
stranded DNA encoding the second enzymatic RNA mol- 
ecule is incorporated into the vector. 
A method for producing enzymatic RNA molecules thus 
65 involves providing a vector as described above, expressing 
RNA from that vector, and allowing cleavage by the first 
enzymatic RNA molecule to releasc the second (and any 
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subsequent) enzymatic RNA molecule. Suitable restriction 
endonuclease sites may also be provided to ease the con- 
struction of such a vector in DNA vectors or in requisite 
DNA vectors of an RNA expression system. 
The second (and any additional) enzymatic RNA mol- 
ecule may be any desired type of enzymatic RNA molecule, 
such as a ribozyme, including group I and group I1 introns, 
hammerhead, hairpin, and other types of ribozymes or 
enzymatically active portions thereof. 
The first enzymatic RNA molecule is selected to cleave 
the encoded cleavage (e.g., “flanking”) sequence, and may 
also be any desired ribozyme+.g., a ribozyme derived 
from Tetrahymena-which may, for example, include an 
embedded restriction endonuclease site in the center of a 
self-recognition sequence to aid in vector construction. This 
endonuclease site is useful for construction of, and subse- 
quent analysis of, a vector as described herein. 
A vector according to the present invention is preferably 
operably linked for expression to an appropriate promoter. 
For example, a vector according to the present invention 
may comprise an enzymatic RNA molecule under the con- 
trol of a viral promoter, such as an Epstein-Barr Virus (EBV) 
promoter. A variety of viral promoters useful for this purpose 
are known in the art; see, e.g., those described in published 
PCT application no. WO 93/23569. 
In another variation, a vector according to the present 
invention includes two or more enzymatic RNA molecules. 
In one embodiment, a first enzymatic RNA molecule has 
intramolecular cleaving activity and is able to recognize and 
cleave nucleotide sequences to release other enzymatic RNA 
sequences; Le., it is able to function to “release” other 
enzymatic RNA molecules from the vector. For example, a 
vector is preferably constructed so that when the first 
enzymatic RNA molecule is expressed, that first molecule is 
able to cleave nucleotide sequences flanking additional 
nucleotide sequences encoding a second enzymatic RNA 
molecule, a third enzymatic RNA molecule, and so forth. 
Presuming said first enzymatic RNA molecule (i.e., the 
“releasing” molecule) is able to cleave oligonucleotide 
sequences intramolecularly, the additional (e.g. second, 
third, and so on) enzymatic RNA molecules (Le., the 
“released” molecules) need not possess characteristics iden- 
tical to the “releasing” molecule. Indeed, in various pre- 
ferred embodiments, the “released” (Le. second, third, etc.) 
enzymatic RNA molecule has amide bond-cleaving activity, 
while the first (“releasing”) enzymatic RNA molecule has 
nuclease activity. 
Alternatively, the first enzymatic RNA molecule may be 
encoded on a separate vector from the second enzymatic 
RNA molecule(s) and may have intermolecular cleaving 
activity. As noted herein, the first enzymatic RNA molecule 
can be a self-cleaving enzymatic RNA molecule (e.g., a 
ribozyme), and the second enzymatic RNA molecule may be 
any desired type of enzymatic RNA molecule (e.g., a 
ribozyme). When a vector is caused to express RNA from 
these nucleic acid sequences, that RNA has the ability under 
appropriate conditions to cleave each of the flanking 
regions, thereby releasing one or more copies of the second 
enzymatic RNA molecule. If desired, several different sec- 
ond enzymatic RNA molecules can be placed in the same 
cell or carrier to produce different ribozymes. 
Methods of isolating and purifying enzymatic RNA mol- 
ecules of the present invention are also contemplated. In 
addition to the methods described herein, various purifica- 
tion methods (e.g. those using HF’LC) and chromatographic 
isolation techniques are available in the art. See, e.g., the 
methods described in published international application no. 
28 
WO 93/23569, the disclosures of which are incorporated 
herein by reference. 
It should also be understood that various combinations of 
the embodiments described herein are included within the 
scope of the present invention. Other features and advan- 
tages of the present invention will be apparent from the 
descriptions hereinabove, from the Examples to follow, and 
from the claims. 
5 
10 
EXAMPLES 
The following examples illustrate, but do not limit, the 
present invention. 
15 
Example 1 
In Vitro Evolution of Enzymatic RNA Molecules 
2o A. General Principles 
In vitro selection and in vitro evolution techniques allow 
new catalysts to be isolated without a priori knowledge of 
their composition or structure. Such methods have been used 
25 to obtain RNA enzymes with novel catalytic properties. 
Ribozymes that undergo autolytic cleavage with lead cation 
have been derived from a randomized pool of tRNAPhe 
molecules (Pan and Uhlenbeck, Biochemistry 31: 
3887-3895 (1992)). Group I ribozyme variants have been 
3o isolated that can cleave DNA (Beaudry and Joyce, Science 
257: 635-641 (1992)) or that have altered metal dependence 
(Lehman and Joyce, Nature 361: 182-185 (1993)). Starting 
with a pool of random RNA sequences, molecules have been 
obtained that catalyze a polymerase-like reaction (Bartel and 
Szostak, Science 261: 1411-1418 (1993)). In the present 
example, refinement of specific catalytic properties of an 
evolved enzyme via alteration of the selection constraints 
during an in vitro evolution procedure is described. 
A method of in vitro evolution has now been developed 
40 for enzyme engineering. For example, the Tetrahymena 
ribozyme, an RNA enzyme that typically catalyzes 
sequence-specific phosphoester transfer reactions that result 
in cleavage or ligation of RNA substrates, is useful in the 
within-described in vitro evolutionary process. 
Darwinian evolution requires the repeated operation of 
three processes: (a) introduction of genetic variation; (b) 
selection of individuals on the basis of some fitness crite- 
rion; and (c) amplification of the selected individuals. Each 
of these processes can be realized in vitro (Joyce, Id. 
50 (1989)). A gene can be mutagenized by chemical modifica- 
tion, incorporation of randomized mutagenic oligodeoxy- 
nucleotides, or inaccurate copying by a polymerase. (See, 
e.g., Cadwell and Joyce, in PCR Methods and Applications 
2: 28-33 (1992); Cadwell and Joyce, PCR Methods and 
55 Applications 3 (Suppl.): S13fLS140 (1994); Chu, et al., 
virology 98: 168 (1979); Shortle, et al., Meth. Enzymol. 100: 
457 (1983); Myers, et al., Science 229: 242 (1985); Mat- 
teucci, et al., Nucleic Acids Res. 11: 3113 (1983); Wells, et 
al., Gene 34: 315 (1985); McNeil, et al., Mol. Cell. Biol. 5: 
60 3545 (1985); Hutchison, et al. , PNAS USA 83: 710 (1986); 
Derbyshire, et al., Gene 46: 145 (1986); Zakour, et al., 
Nature 295: 708 (1982); Lehtovaara, et al., Protein Eng. 2: 
63 (1988); Leung, et al., Technique 1: 11 (1989); Zhou, et al., 
Nucl. Acids Res. 19: 6052 (1991).) FIG. 3 illustrates the 
65 secondary structure of the Tetrahymena ribozyme (L-21 
form) and also shows regions that were randomly 
mutagenized, as described herein. 
35 
45 
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The gene product can be selected, for example, by its ribozymes: first, selective Primer l a  hybridizes to the 
ability to bind a ligand or to carry out a chemical reaction. extended 3’ terminus of active molecules and initiates cDNA 
(See, e.g., Joyce, Id. (1989); Robertson and Joyce, Id. synthesis in the presence of reverse transcriptase (RT); next, 
(1990); Tuerk, et al., Id. (19901.) The gene that corresponds Primer 2, which contains a T7 promoter sequence, hybrid- 
to the Selected gene product Can be amplified by areciProca1 5 izes to the cDNA and initiates second-strand DNA synthesis; 
Primer method, Such as the Polymerase chain reaction finally, T7 RNA polymerase (T7 pol) produces multiple 
(PCR). (See, e.g., Saiki, et d . ,  Science 230: 1350-54 (1985); copies of the selected RNA, each of which can enter a new 
Saiki, et al., Science 239: 487491 (1988).) round of amplification. 3Selec t ive  cDNA synthesis 
Alternatively, nucleic acid amplification may be carried employing Primer l a  and reverse transcriptase, ”PCR 
out using self-sustained sequence replication (3SR). (See, 10 amplification employing nonselective Primer 1 b and Primer 
e.g., Guatelli, et al., PNAS USA 87: 1874 (19901, the 2, restores the original terminus of the ribozyme-encoding 
disclosures of which are incorporated by reference herein.) gene and introduces occasional mutations. 5-1~ vitro 
According to the 3SR method, target nucleic acid sequences scription to produce the progeny popu~ation of ribozymes. 
may be amplified (replicated) exponentially in vitro under The foregoing 6csteps,, are further detailed in sections l.b, 
isothermal conditions by using three enzymatic activities 15 and below, where the processes of mutation, 
essential to retroviral replication: (1) reverse transcriptase, selection and amplification are described at length. In gen- 
(2) RNase H7 and (3) a DNA-dependent RNA polymerase. eral, though, selective amplification of active molecules 
means of cDNA intermediates, this reaction accumulates a consequence of the ability of T7 RNA polymeTase to 
cDNA and RNA copies of the original target. 20 generate 200 to 1200 copies of RNA transcript per copy of 
In SU-arY, a COntinuOUS Series of reverse transcription cDNA template (Chamberlin, et al., in The Enzymes, Vol. 15, 
and transcription reactions replicates an RNA target P. D. Boyer (ed.), Academic Press, New York, 1982, pp. 
sequence by means of cDNA intermediates. The crucial 87-108). 
elements of this design are (a) the oligonucleotide primers The amplification reaction is generally performed in a 
both Specify the target and contain 5’ e x t e m k ~ ~ s  encoding 25 single test tube at a constant temperature of 37” C., resulting 
the T7 RNA polymerase binding site, SO that the resultant in an increase of 103 to 106 times the original input of RNA 
CDNAs are competent transcription templates; cb) CDNA after one hour (Guatelli, et al., PNAS USA 87: 1874 (1990); 
synthesis can proceed to completion Of both strands due to Joyce, in Antisense RNA and DNA, J. A. H. Murray (ed.), 
the degradation of template RNA in the intermediate RNA- Wiley-Liss, New yo&, 1992, pp. 353-372). A useful pro- 
DNA hybrid by RNase H; and (C) the reaction Products 30 cedure for RNA amplification is described in Beaudry and 
(cDNA and RNA) can function as templates for subsequent Joyce, Id. (1992). 
steps, enabling exponential replication. b. Example 
A major obstacle to realizing Darwinian evolution in vitro The population of DNA-cleaving ribozymes obtained 
is the need to integrate mutation and amplification, both of after 9 generations of in vitro evolution (see Beaudry and 
which are genotype-related, with selection, which is pheno- 35 Joyce, Id. (1992)) was used as starting material. It should be 
type-related. In the case of RNA enzymes, for which geno- understood, however, that ribozymes generated as described 
type and phenotype are embodied in the same molecule, the in Example 3 below may also be utilized as starting material. 
task is simplified. Ribozymes (0.1 pM) and substrate (0.2 m) are incubated 
B. Procedures at 37” C. for 1 hr in a 100 pl volume containing 10 mM 
1. Amplification 40 MgCl, and 30 mM EPPS (pH 7.5). After ethanol precipita- 
a. Amplification Method tion, a portion of the reaction products (10-50%) was added 
Using a combination of two polymerase enzymes, it is to a 20 pl isothermal amplification reaction mixture, con- 
possible to amplify virtually any RNA. (See Kwoh, et al., taining 10 mM MgCl,, 80 mM KOAc, 50 mM Tris (pH 7.5), 
PNAS USA 86: 1173 (1989); Joyce, in Molecular Biology of 5 mM D’IT, 2 mM each NTP, 0.2 mh4 each dNTF’, 4 pCi 
RNA: UCLA Symposia on Molecular and Cellular Biology, 45 [cc-~’P]GTP, 12.5 U/pl MoMLV reverse transcriptase, 50 
T. R. Cech (ed.), Liss, N. Y., 1989, pp. 361-371.) RNA is Ulpl T7 RNA polymerase, and 20 pmol each of appropriate 
copied to a complementary DNA (cDNA) with reverse primers; the mixture was then incubated at 37” C. for 2 
transcriptase (RT), and the resulting cDNA is transcribed to hours. In experiments designed to optimize DNA cleavage 
RNA with T7 RNApolymerase (T7 Pol). (See FIGS. 2A-C). activity, primers 5’-TITATITATITATIT-3’ (Primer la, 
FIGS. 2A and 2B illustrate the general procedure for 50 SEQ ID NO 6) and S-CTGCAGAATTCTAATACGACT- 
selective amplification of catalytic RNA (Le., enzymatic CACTATAGGAGGGAAAAGATCAGGC-3’ (Primer 2, 
RNA molecules of the present invention). In FIG. 2A, the SEQ ID NO 7), were used. Primer l a  hybridizes to the 3’ 
overall procedure for RNA amplification is shown. “RT”= portion of the substrate that becomes attached to the 3’ end 
reverse transcriptase; “T7 pol”=T7 polymerase; “prom”= of the ribozyme. (Primer l b  has the sequence 5’-CGAG- 
promoter, and “RNA” represents the enzymatic RNA mol- 55 TACTCCAAAACTAATC-3’ (SEQ ID NO 8); primer l b  
ecule. In FIG. 2B, the procedure for selective amplification hybridizes to the 3’ portion of the ribozyme when no 
based on phosphoester transfer activity of a group I substrate or product remains attached. Primers l a  and lb, 
ribozyme is shown. “E’ represents the enzymatic RNA when used, perform similarly.) Primer 2 hybridizes to the 3’ 
molecule; “S” represents substrate; ‘‘EW represents end of the resulting cDNA and introduces the T7 promoter 
enzyme/substrate complex; and “EP’ represents enzyme/ 60 sequence. 
product complex. 2. Selection 
FIG. 2C illustrates the overall in vitro evolution procedure Amplification is performed selectively in that individual 
disclosed herein, in the context of a DNA-cleaving enzyme, RNAs in the population are required to catalyze a particular 
which is used as a convenient example. l--Cleavage of the chemical reaction in order to become eligible for amplifi- 
substrate via phosphoester transfer results in ligation of the 65 cation (Joyce, Id. (1989); Robertson and Joyce, Id. (1990); 
3’ portion of the substrate to the 3’ end of the ribozyme. Beaudry and Joyce, Id. (1992)). One exemplary selection 
2 4 e l e c t i v e  isothermal amplification of DNA-cleaving criterion was based on the ability of group I ribozymes to 
By mimicking the retroviral strategy Of RNA rep1ication by occurs during transcription (as described in step 2 above) as 
5,595,873 
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catalyze a sequence-specific phosphoester transfer reaction 
involving an oligonucleotide (or oligodeoxynucleotide) sub- 
strate. FIG. 2B illustrates the procedure for selective ampli- 
fication based on phosphoester transfer activity of a group I 
ribozyme. One exemplary procedure for selective amplifi- 
cation based on phosphoester transfer activity of a group I 
ribozyme is described in Beaudry and Joyce, Id. (1992). 
Another is essentially as follows. 
Twenty-five percent of the isothermal amplification prod- 
ucts were used to generate cDNA in a 20 pl reaction mixture 
containing 10 mM MgCI,, 50 mM Tris (pH 7.5),5 mM DTT, 
2 mM each NTP, 0.2 mM each dNTP, 0.2 U/pl AMV reverse 
transcriptase and 20 pmol Primer l a ,  incubated at 37” C. for 
1 hr. Approximately 5-10% of the resulting cDNA was 
amplified by the PCR in a 100 pl reaction mixture containing 
1.5 mM MgCl,, 50 mM KC1, 10 mM Tris (pH 8.3), 0.1% 
gelatin, 0.2 mM each dNTP, 20 pmol Primer 1, 20 pmol 
Primer 2, and 2.5 U Taq DNA polymerase, carried out for 30 
cycles of 92” C. for 1 min, 45’ C. for 1 min, and 72” C. for 
1 min, and 1 cycle of 72” C. for 10 min. Primer l b  is 
complementary to the 3’ end of the ribozyme, allowing 
regeneration of its original, active form. PCR DNA 
(-250-500 ng, 5-10% of the total) then served as template 
in an in vitro transcription reaction, carried out in a 25-50 
pl volume. Error-prone or mutagenic PCR may also be used 
to generate a higher percentage of variants. 
Similarly, when the selection criterion is the ability to 
bind one or more amino acids, the foregoing procedure is 
modified to enable the identification and isolation of 
ribozymes with amino-acid-containing substrate still 
attached thereto. For example, one or more amino acids in 
the substrate--e.g., the terminal amino acids-may be 
“tagged” for identification purposes, via art-recognized pro- 
cedures. One preferred method of “tagging” or “labeling” 
substrate amino acid(s) involves biotinylation, according to 
procedures known in the art. (See, e.g., Green, et al., 
Biochem. J. 125: 781 (1971); Lomant andFairbanks, J. Mol. 
Biol. 104: 243-261 (1976); and Mouton, et al., Arch. Bio- 
chem. Biophys. 218: 101-108 (1982).) Various reagents and 
kits for biotinylating amino acids, polypeptides, and proteins 
are commercially available (see, e.g., the biotinylation kits 
from Pierce Chemicals, Rockford, Ill.). 
Ribozymes with biotinylated amino acid-containing 
substrate (or product) attached thereto are then easily iden- 
tified with the use of a detecting means such as a solid matrix 
or solid surface containing avidin bound thereto or incor- 
porated therein. For example, a sample containing 
ribozymes admixed with amino acid-containing substrate, 
wherein said substrate is terminally labeled with biotin, may 
32 
Once the selected enzymatic RNA molecules (i.e., the 
ribozymes with attached product) are separated out, they 
may be prepared for a subsequent amplification step. Pref- 
erably, before amplification is initiated, the amino acid- 
5 containing product is allowed to dissociate from the 
ribozyme. As previously noted, adjustment of the pH of the 
solution may enhance or slow down this dissociation pro- 
cess. Once the ribozymes are “free” of attached amino 
acid-containing product, amplification may be initiated, 
IO using appropriate primers, as previously described. 
Alternatively, enzymatic RNA molecules capable of bind- 
ing a particular amino acid (or acids) may be identified and 
removed from a population sample using a column contain- 
ing one or more amino acids linked to a column matrix, or 
15 via other art-recognized methodologies. For example, if one 
is seeking to isolate arginine-binding ribozymes, one may 
take about 20 pg of random 32P-labeled ribozymes in water, 
heated at 65” C. for 5 minutes, with the salt concentration 
adjusted to the appropriate level. The RNA is then cooled to 
20 4” C. over a ten-minute period before the RNA solution in 
a 25 pL total volume is loaded onto the afEnity column. The 
column, which contains, e.g., an L-arginyl-L-cysteine dipep- 
tide linked through the sulfhydryl group to a thiopropyl 
Sepharose 6B column matrix (Pharmacia, Piscataway, N.J.), 
25 is washed at 4” C. for approximately 8-12 column volumes, 
and any remaining RNA sticking to the column is eluted 
with 50 mM L-arginine in column buffer. cDNA is then 
synthesized from the arginine-eluted RNA, amplified via 
PCR, and transcribed into RNA for the next cycle of 
30 amplification. (See, e.g., Connell et al., Biochemistry 32: 
It should also be noted that one may adjust the reaction 
parameters to diminish hydrolysis-thus increasing the per- 
sistence of the intermediate--e.g., by decreasing the pH of 
Methods of selecting individuals from the population will 
vary, depending upon the selection criteria applied. For 
example, if selection of ribozymes that are able to cleave 
DNA is desired, one may wish to prepare primers that will 
40 amplify ribozymes when the DNA-containing product is still 
attached to the ribozyme. Conversely, when the predeter- 
mined selection criterion is the identification of ribozymes 
with amide-cleaving ability, one may elect to prepare prim- 
ers that will amplify ribozymes after the amino acid-con- 
45 taining product has dissociated from the ribozyme. 
Therefore, if the predetermined selection criterion is the 
identification of amide bond-cleaving enzymatic RNA mol- 
ecules, the process may be described as follows: (1) obtain 
5497-5502 (1 993).) 
35 the admixture. 
be run across avidin tips, to “pull out” ribozymes with amino 
acids or polypeptides attached thereto. Molecules labeled 50 
with biotin may easily be detected with indirect immunof- 
luorescence techniques. In addition, a number of fluoro- 
chromes, as well as alkaline phosphatase and horseradish 
peroxidase (which produce colored precipitates) are avail- 
able directly conjugated to avidin. Streptavidin-fluoro- 55 
chrome conjugates are also useful in the identification of 
molecules labeled with biotin and are readily available from 
various commercial sources (e.g., Pierce Chem.). 
Samples collected after exposure to avidin may subse- 
quently be subjected to further procedures to separate 60 
ribozymes with amino acid-containing product attached 
thereto from amino acid-containing molecules that are not 
linked to a ribozyme. Such separations may be done using 
routine methods, e.g., via size separation or via use of a 
variety of well-known labeling agents and methods. (See, 65 
e.g., Ausubel, et al. (eds.), Current Protocols in Molecular 
Biology, John Wiley & Sons, Inc. (1994).) 
a population of ribozymes and place them in an appropriate 
receptacle; (2) add amide bond-containing substrate mol- 
ecules to the receptacle, to form an admixture of ribozyme 
and substrate; (3) maintain the admixture for a sufficient 
period of time and under predetermined reaction conditions 
to allow the ribozymes and substrate to interact, to form 
ribozyme-product complexes; (4) separate the ribozyme- 
product complexes from the admixture; (5 )  allow the 
ribozyme and product to dissociate from each other; and (6) 
purify or otherwise separate the ribozymes from the product. 
As described herein, after step (l), the population may 
optionally be exposed to mutagenizing conditions before 
continuing to step (2). Also as described herein, the selection 
and separation steps may take advantage of known proce- 
dures, e.g., the use of biotin labeling of the product and the 
use of an avidin-coupled support to select out and separate 
ribozyme-product complexes from the remainder of the 
admixture. It is also contemplated that the ribozymes iden- 
tified in step (6) may then be amplified, or may be run 
5,595, 
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through the entire stepwise process one or more subsequent 
times, e.g., with different selection criteria applied each 
time. It should also be apparent that the foregoing is exem- 
plary and is not intended to limit the scope of the invention. 
With regard to amplification, the transcribed RNA is 5 
generally isolated by polyacrylamide gel electrophoresis, 
visualized by UV shadowing, cut and eluted from gel, 
purified on duPont NENsorb (duPont de Nemours, Wilm- 
ington, Del.), and quantified spectrophotometrically, as 
described herein. The entire process is generally repeated 18 io 
times, the first 9 as described in section 1 above and the 
second 9 with the incubation time for the cleavage reaction 
reduced from 1 hr to 5 min. Occasionally, the cDNA was 
purified to improve the quality of the PCR amplification. To 
do so, cDNA was synthesized as above except in the 15 
presence of 25-50 pCi [a-32P]dATP. Labeled cDNA was 
isolated by electrophoresis in a 5% polyacrylamideBM urea 
gel, visualized by autoradiography, cut and eluted from gel, 
and purified on duPont NENsorb. 
and isoamyl alcohol and by precipitation with ethanol, and 
are used to transcribe RNA as described in section 3 below. 
The product of such a reaction is a molecule that contains the 
3’ portion of the substrate attached to the 3’ end of the 
ribozyme (EP; see FIGS. 2A and 2B). Selection occurs when 25 
an oligodeoxynucleotide primer is hybridized across the 
ligation junction and used to initiate cDNA synthesis. The 
primer does not bind to unreacted starting materials (<lo-’ 
compared to reaction products) and thus leads to selective 
3. Introduction of Variation 
Mutations are introduced in two ways. First, at the outset, 
a set of mutagenic oligodeoxynucleotides that contain ran- 
dom substitutions at a fixed frequency of occurrence is used. 
These partially randomized oligodeoxynucleotides are pro- 35 
duced on an automated DNA synthesizer with nucleoside 
3‘-phosphoramidite solutions that have been doped with a 
small percentage of each of the three incorrect monomers 
(McNeil, et al., Id. (1985); Hutchison, et at., Id. (1986)). 
Second, after each round of selective amplification, random 40 
mutations are introduced by performing the PCR under 
mutagenic conditions (Cadwell and Joyce, PCR Methods 
and Applications 2: 28-33 (1992); Cadwell and Joyce, PCR 
Methods and Applications 3 (Suppl.): S136-S140 (1994)). 
random mutations are introduced throughout the catalytic 
core of the molecule. In one example, four synthetic oli- 
godeoxynucleotides are prepared, each of which randomly 
mutagenizes 35 nucleotide positions at an error rate of 5% 
per position (not shown). The transcription conditions are 50 
essentially as follows: 2 pmol of DNA template (containing 
mutagenic oligodeoxynucleotides), 2 mh4 NTP’s, 15 mM 
MgCl,, 2 mM spermidine, 5 mM DIT, 50 mM tris-HC1 (pH 
7.3, 1500 U of T7 RNA polymerase are admixed to a 
volume of 60 pl and held at 37” C. for 2 hours. RNA is 55 
purified by electrophoresis in a 5% polyacrylamide-8M urea 
gel and subsequent column chromatography on Sephadex 
The degenerate oligodeoxynucleotides are incorporated 
into a DNA template that encodes the ribozyme, and the 60 
template is transcribed directly to produce the mutant RNAs 
(Joyce and Inouye, Nucl. Acids Res. 17: 711 (1989)). Twenty 
pmol molecules) of material is used at the beginning. 
Thus, the generation 0 population is expected to contain the 
wild-type ribozyme, all possible 1-, 2-, 3-, and 4-error 65 
mutants, and a sampling of the higher-error mutants (see 
Table 2 in Example 4 below). 
PCR products are purified by extraction with chloroform 20 
amplification of the catalytically active RNAs. 30 
To generate the initial population of ribozyme variants, 45 
G-50. 
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In general, when using PCR procedures, each primer 
works in combination with a second primer to amplify a 
target nucleic acid sequence. The choice of PCR primer pairs 
for use in PCR is governed by various considerations, as 
discussed herein. That is, the primers have a nucleotide 
sequence that is complementary to a sequence conserved in 
the gene of choice. Useful priming sequences have been 
disclosed herein (e.g., primers 1, lb, and 2). The strategy 
used for cloning the selected genes will depend, as is well 
known in the art, on the type, complexity, and purity of the 
nucleic acids making up the various genes. Other factors 
include whether or not the genes are to be amplified and/or 
mutagenizcd. 
Typically, the exemplary genes are comprised of poly- 
nucleotide strands, such as mRNA, cDNA, or the sense 
strand of genomic DNA, although antisense strands, rRNA, 
or tRNA may also be used in PCR. If the polynucleotide 
sequence is in the form of double stranded genomic DNA, 
it is usually first denatured, typically by melting, into single 
strands. A gene sequence is subjected to a PCR reaction by 
treating (contacting) the sequence with a PCR primer pair, 
each member of the pair having a preselected nucleotide 
sequence. The PCR primer pair is capable of initiating 
primer extension reactions by hybridizing to nucleotide 
sequences, preferably at least about 10 nucleotides in length 
and more preferably at least about 20 nucleotides in length, 
conserved within the gene sequence. Primer extension via 
PCR may be carried out from either end of the molecule, 
through the amide or through the carboxyester, as desired. 
The PCR reaction is performed by mixing the PCR primer 
pair, preferably a predetermined amount thereof, with the 
nucleic acids of the selected gene or DNA nucleotide 
sequence, preferably a predetermined amount thereof, in a 
PCR buffer to form a PCR reaction admixture. The admix- 
ture is maintained under polynucleotide synthesizing con- 
ditions for a time period, which is typically predetermined, 
sufficient for the formation of a PCR reaction product, 
thereby producing a plurality of different DNA homologs. 
The PCR reaction is performed using any suitable 
method. PCR amplification methods are described in detail 
in U.S. Pat. Nos. 4,683,192, 4,683,202, 4,800,159, and 
4,965,188, and at least in several texts including “PCR 
Technology: Principles and Applications for DNA Amplifi- 
cation”, H. Erlich, ed., Stockton Press, New York (1989); 
and “PCR Protocols: A Guide to Methods and Applications”, 
Innis et al., eds., Academic Press, San Diego, Calif. (1990). 
Themus aquaticus DNA polymerase I, which is useful in 
PCR, is described in U.S. Pat. No. 4,889,818. 
Restriction sites may also be incorporated into the 5’ and 
3’ primers to enable the amplification products to be sub- 
cloned into sequencing or expression vectors. It may also be 
helpful to place a 4-base spacer sequence proximal to the 
restriction site to improve the efficiency of cutting amplifi- 
cation products with enzymes. 
In the presently-described examples, PCR was performed 
under standard reaction conditions, resulting in an error rate 
of approximately 0.1% per position per generation. A 
mutagenic, modified PCR procedure that provides an error 
rate of 0.6653.13% per position (95% confidence level) has 
also been developed. (See Cadwell and Joyce, PCR Methods 
and Applications 2:28-33 (1992), and Cadwell and Joyce, 
PCR Methods and Applications 3 (Suppl.): SI364140 
(1994), the disclosures of which are incorporated herein by 
reference.) The RNAs obtained by selective amplification 
are subjected to reverse transcription, the resulting cDNAs 
are PCR amplified, and the PCR products are transcribed to 
produce a progeny distribution of mutant RNAs. 
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Integration of the PCR with the selective RNA amplifi- In practice, there is always the danger of developing a 
cation procedure is useful in three other ways. First, it “parasite” that circumvents the selection criterion and is 
increases the overall amplification by about 1 O3 times. amplified more efficiently than the most reactive species. For 
Second, it simplifies the process of subcloning individuals example, a sequence may arise which allows false hybrid- 
from the evolving population. Normally, only a small Par- 5 ization of one of the amplification primers at an internal site, 
tion of the DNA in the RNA amplification rmxture 1s fully generating a species with a nucleotide deletion that may be 
double-stranded, but with the PCR, the amount of double- amplified more efficiently than the full-length ribozyme. 
stranded DNA (dsDNA) is greatly increased. Third, it Thus, it is important to monitor the populations generated 
returns the RNA to a form that Can participate in the and remove such “parasites”, if and when they appear. 
RNA-CatalYzed PhoSPhoeSter transfer Or dde-cleavage 10 Substrate cleavage activity for the population as a whole 
reaction. After phosphoester transfer or amide cleavage, the is generally monitored via gel electrophoresis assay involv- 
ribozyme has the 3’ portion of the substrate attached to its 3’ ing cleavage of [5’-32P]-labeled substrate to yield a specific 
end, and after selective RNA amplification, the substrate product. Cleavage of the substrate (“S”) in the absence of 
sequence remains attached for a time (see FIGS. 2A and 2B). enzyme, in the presence of the wild-type Tetrahymena 
However, by Subsequent use of PCR, followed by in Vitro 15 ribozyme (L-21 form), and in the presence of the population 
transcription, the original 3’ end of the ribozymes is restored. of RNAs obtained at each generation (Gn, beginning with a 
Therefore, the entire mutation, selection and amplification value of 0 for n) is measured. 
process-i.e., the method of engineering enzymatic RNA Reaction conditions will vary depending on various 
~OleCules capable Of Cleaving an amide bond-maY Con- parameters, e.g., substrate recognition, afFmity, cleavage, 
VeniendY be described according to the following Stepwise 20 etc. In general, reaction conditions are essentially as follows: 
procedure. 0.5 pM ribozyme, 0.1 pM substrate (2.6 pCipmol), 30 mM 
EPPS (pH 7.3, and 10 mM MgCl, are admixed and main- 
tained at 37” C. for about 1 hour. Reaction products are 
separated by electrophoresis in a 20% polyacrylamide-8M 
lation that are able to meet predetermined selection 25 urea gel, Of which autoradiOFYms are made. One usually expects that any given mutation will more criteria; likely be detrimental than beneficial, although there may be 
4. Separate the identified (or selected) individuals from a number of neutral mutations. Through succes- 
the remainder of the population; sive generations, however, continued improvement of phe- 
5. Prepare appropriate primers; and 30 notype is observed to occur, and in succeeding generations, 
6. Amplify the selected individuals. the rate of improvement is expected to increase. 
The foregoing steps may be repeated as many times as RNAs from each generation are usually purified by poly- 
desired to generate numerous variant populations. In various acrylamide gel electrophoresis and Sephadex chromatogra- 
embodiments, it is contemplated that the amplified popula- phy. To provide a more formal assay of cleavage activity, 
tion produced in step six will be used as the “starting 35 [5’-32P]-labeled substrate was prepared as follows, and for- 
population” in the next “generation” beginning with step mation of both the ribozyme-coupled covalent intermediate 
one. and the RNA-catalyzed site-specific cleavage product is 
As those of skill in the art will appreciate, step 5 need not measured. (See also Inoue, et al., J. Mol. B i d .  189: 143 
be performed in the time sequence indicated. That is, prim- (1986).) 
ers may be prepared at any time; presumably, preparation of 40 Cleavage of 32P-labeled substrate is generally conducted 
primers is based on understanding of the predetermined under reaction conditions as described hereinabove prior to 
selection criteria. For example, if the predetermined selec- autoradiogram. Substrate (S), enzyme/product (EP), and 
tion criterion is the identification of ribozymes that are able product (P) are separated by electrophoresis in a 20% 
to cleave DNA, one may wish to prepare primers that will polyacrylamide-8M urea gel. Individual bands are cut from 
amplify ribozymes when the DNA-containing product is still 45 the gel and quantitated by Cerenkov counting. On the 
attached to the ribozyme. Conversely, when the selection average, five replicate experiments are performed on three 
criterion is the identification of ribozymes with amide- different days with two different preparations of substrate, 
cleaving ability, one may elect to prepare primers that will before data points are plotted (not shown). 
amplify ribozymes after the amino acid-containing product 5. Preparation and Sequencing of Subclones 
has dissociated from the ribozyme. Although evolution in natural populations is an accom- 
4. Substrate Cleavage Activity plished fact, evolution in vitro is a work in progress that 
The entire series of events, beginning with a heteroge- allows the experimenter to access any time period in evo- 
neous population of RNAs, proceeding with RNA catalysis lutionary history. Subclones are obtained from the evolving 
in the target reaction, selective amplification of catalytically population at every generation and individual ribozymes are 
active RNAs, reverse transcription of the selective amplifi- 55 then sequenced. 
cation products, mutagenic PCR, and in vitro transcription to a. Preparation of Subclones 
produce a progeny distribution of RNAs, is referred to as One useful method of preparing subclones is described in 
one “generation”. Typically, a generation is completed in Beaudry and Joyce, Science 257: 635-641 (1992). For 
one to two working days, excluding time for analytic work. example, DNAs used to transcribe the population of RNAs 
The initial population of mutant RNAs is referred to as 60 at each generation are amplified in a second PCR reaction 
“generation O”, while subsequent populations are referred to with appropriate primers, producing a 435-bp (base pair) 
as “generation l”, “generation 2”, and so forth. In principle, fragment with unique restriction sites at its ends. The 
there is no limit to the number of successive generations that fragment was digested with Eco RI and Hind 111 and ligated 
can be obtained. into a pUC18 vector that had been linearized with Eco RI 
Typically, each generation begins with 20 pmol of RNA. 65 and Hind I11 and purified in a 1.5% agarose gel. (See 
The amount of RNA is again quantified after selective Beaudry and Joyce, Id. (1992).) The resulting plasmid 
amplification and after transcription. DNAs were used to transform competent DH5a-F cells (see 
1. Obtain a population of ribozymes; 
2. Introduce genetic variation into the population; 
3. Identify individuals from the resulting “mutant” popu- 
50 
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Hanahan, in DNA Cloning: A Practical Approach, D. M. 
Glover, ed., IRL Press, Oxford, 1985, pp. 109-135), which 
were then grown on ampicillin-containing plates. Individual 
colonies were chosen at random and grown overnight in 
liquid media. DNA was prepared by the boiling lysis method 5 
( ~ ~ l ~ ~ ~ ,  et al., ~ ~ l ,  ~ i ~ ~ h ~ ~ .  114: 193 (1981)) and 
screened for the insert by restriction digestion. 
Another useful method of preparing subclones is as 
follows, Subclones were obtained using the Invitrogen TA 
at G27 was ligated into a linearized plasmid, and the 
resulting DNA was used to transform competent INVaF 
cells, which were grown on ampicillin/X-gal plates. Indi- 
vidual colonies containing the insert were identified by their Individual enzymatic RNA molecules containing single or 
white color, chosen at random, and grown Overnight in 15 multiple point mutations may be prepared via site-directed 
liquid media. Plasmid DNA was Prepared by the boiling, mutagenesis for analysis of the relative significance of a 
lysis method (Holmes C!L Quigley, Anal. Biochem. 114: particular mutation. Catalytic activity is then studied with an 
193-197 (1981)) and screened for the presence of insert by appropriate [5'-32P]-labeled oligodeoxyribonucleotide sub- 
restriction digestion. strate. Site-directed mutagenesis is carried out essentially as 
b. Sequencing 20 described in Morinaga, et al., Biotechnology 2: 636 (1984), 
As noted above, subclones may be obtained from the which may be described as follows. 
evolving population at every generation. Specific genera- Plasmid pT7L-21 (Zaug, et al., Biochemistry 27: 8924 
tions may also be chosen for detailed analysis. The nucle- (1988)) is digested with either (i) Eco RI and Hind 111 to 
otide sequence of the entire ribozyme gene is determined for remove the ribozyme coding region, or (ii) Bsa I and Xmn 
each of these subclones essentially as follows. 25 1 to remove the ampicillin-resistance gene. The resulting 
Cloned individuals are generaily sequenced by the fragments are purified in a 1% agarose gel and cross- 
dideoxy chain-termination method (Sanger, et al., PNAS hybridized in the presence of a 5'-phosphorylated synthetic 
USA 74: 5463 (1977); Beaudry and Joyce, Id. (1992); oligodeoxynucleotide that introduces the desired mutation. 
Zagursky, et al., Gene Anal. Tech. 2: 89 (1985)) with The annealing mixture typically contains 0.06 pmol of 
reciprocal primers 5'-GTAAAACGACGGCCAGT-3' (SEQ 30 pT7L-21 (AEcoRI-HindIII), 0.06 pmol pT7L-2l(ABsaI- 
ID NO 9) and 5'-CATGAmACGAATTC-3' (SEQ ID NO XmnI), 15 pmol of mutagenic oligodeoxynucleotide, 40 mM 
lo), which are compatible with the pUC plasmid. Sequenc- Tris-HC1 (pH 7.2), and 8 mM MgSO, in 1 2 4  volume, 
ing reactions utilized modified T7 DNApolymerase (Seque- which is heated to 100" C. for three minutes, then incubated 
nase, USB) and [3sS] (a-thiophosphate) dATP and were at 30" C. for 30 minutes, and 0" C. for 10 minutes. 
analyzed by electrophoresis in a 6% polyacrylamide-8M 35 The annealing product is made fully double-stranded with 
urea gel. Nucleotide sequences of individual subclones were the Klenow fragment of E. coli DNA polymerase I (Boe- 
also obtained (not shown). hringer-Mannheim, Indianapolis, Ind.) and T4 DNA ligase 
Individual ribozymes were prepared as follows: the gene (U.S. Biochemical, Cleveland, Ohio) and is then used to 
encoding the ribozyme was amplified by the PCR using transform competent DH5a-F' cells, which are grown on 
Primer l b  and Primer 2; the resulting DNA was used as a 40 ampicillin-containing plates. Colonies are screened by the 
template for in vitro transcription; the RNA products were colony hybridization method with [5'-32P]-labeled 
isolated by polyacrylamide gel electrophoresis, and were mutagenic oligodeoxynucleotide as a probe (Grunstein, et 
purified and quantified as described above. (See also Tsang al., PNAS USA 72:3961 (1975)). DNA is prepared from 
and Joyce, Biochemistry 33: 5966-5973 (1994).) positive colonies and sequenced throughout the ribozyme 
Analysis of the determined sequences indicates how 45 gene, as described above. 
genotype changes over the course of evolutionary history. RNA is subsequently prepared from the DNA template by 
From generation 0 to generation 3, variation introduced into in vitro transcription, which is performed essentially as 
the original ribozyme template by the use of mutagenic follows. Transcription conditions: 2 pmol of DNA template 
primers to produce generation 0 is discarded throughout (containing mutagenic oligodeoxynucleotides), 2 mM 
much of the catalytic core of the ribozyme. The mean 50 nucleotide triphosphates (NTPs), 15 mM MgCl,, 2 mM 
number of mutations per subclone decreased from 7.0 at spermidine, 5 mM dithiothreitol (DTT), 50 mM tris-HC1 (ph 
generation 0 to 2.7 at generation 3. By generation 3, a small 7.5), 1500 U of T7 RNA polymerase; 60 pl volume; 37" C., 
number of mutations outside of the original zone of random 2 hours. RNA is purified by electrophoresis in a 5% poly- 
mutation in the catalytic core of the ribozyme have occurred acrylamide-8M urea gel and subsequent column chromatog- 
because of ongoing mutation events. The consensus 55 raphy on Sephadex G-50. 
sequence still tends to be that of the wild type. Analysis of The foregoing procedures may be repeated as many times 
subsequent generations suggests that accumulation of muta- as desired to produce enzymatic RNA molecules having one 
tions coincides with improvement in the phenotype of the or more point mutations at one or more preselected sites. For 
population as a whole. The mean number of mutations per example, in addition to use of the within-disclosed in vitro 
subclone is also observed to increase, as a larger proportion 60 evolution methods to design and identify ribozymes capable 
of subclones adopt the common mutations and as mutations of binding amino acids in a polypeptide sequence and 
accumulate outside of the original zone of random mutation. cleaving the bond linking adjacent amino acids at a prede- 
The relation between genotype and phenotype in the termined site, one may use site-directed mutagenesis tech- 
context of an RNA-based evolving system can readily be niques as disclosed herein to modify the active site on an 
formalized once catalytic, kinetic, and comparable data are 65 enzymatic RNA molecule to accomplish the same objective. 
collected and analyzed. Genotype can be represented as a For example, one may use the within-disclosed tech- 
matrix A, the rows corresponding to individuals in the niques to modify the recognition site on a preselected 
population and the columns corresponding to functionally 
significant positions within the nucleotide sequence. An 
exemplary analysis is illustrated in Beaudry and Joyce, 
Science 257: 635-641 (1992). 
The data obtained from a relatively small number of 
individuals may not be sufficient to provide a meaningful 
solution to the relation of genotype to phenotype, even for 
those nucleotide positions that are known to be most sig- 
nificant based on their high frequency of accepted mutation. 
a guide to help decide which mutations are sufficiently 
important to warrant individual study, (See, e.g,, 
and Joyce, Id. (1992).) 
6. SiteWDirected Mutagenesis 
Cloning Kit (Invitrogen, San Diego, Calif,), The PCR DNA 10 One may then to use an appropriate weighing vector as 
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ribozyme, e.g., by altering the nucleotide sequence of said MgCl, and 30 mM EPPS (pH 7.5) before mixing with an 
site to exactly duplicate, or substantially mimic, a consensus equal volume of 0.05-1 nM (5'-32P)-labeled DNA product in 
nucleotide sequence which is able to bind one or more 10 mM MgCL 30 mM EpPS (PH 7.51, 0.05% xylene 
particular amino acids. Exemplary consensus sequences CYanOl, 3% glYcer01, and 80 BSA. The mixture is 
which may be incorporated into the recognition site of 5 allowed to equilibrate at 37" C. for 15-60 min before 
enzymatic RNA molecules according to the within-disclosed loading on a lo% polYacV1amide gel containing lo mh4 
methods are available in the art and include those described MgC1z and 30 mM EPPS (PH 7.5). The electrophoresis 
in Connell, et al., Science 264: 1137-1141 (1994); Connell, buffer contains lo mM and 30 (PH 
sample has entered the gel (-10 min), and is then moved into et al., Bjochemjstry 32: 5497-5502 (1993); and Famulok, J.  Am. them. soc. 116: 1698-1706 (199413 to name a few lo a 40 c. cold 
exmP1es. Other 
7.5). The gel is run at millimps in a 37" c. room the 
where the is increased to 30 
milliamps, This is done to prevent the temperature of the gel sequences may be identified using 
the methods described herein; for example, see section B.2 from rising above 370 c. The ribozyme~product complex 
above. and free product are visualized by autoradiography, cut from 
7. Kinetic Analysis the gel, and quantified by Cerenkov counting. 
Reduction in reaction time tends to favor selection of 15 A binding curve is generated by plotting the percentage of 
enzymatic RNA molecules with increased kc,, values. Rep- product bound to ribozyme (% bound) over a range of 
resentative ribozymes may be chosen from the evolving ribozyme concentrations. K, is determined by fitting the 
population and analyzed at each generation to determine k,, data to a theoretical binding curve using a least squares 
and K,,,, values for the individuals selected. It is to be method. Where ribozyme is in vast excess over product, the 
appreciated that the k,,, and K,,,, values of the selected 20 theoretical binding curve may be represented by the equa- 
ribozymes are not necessarily equivalent to the average tion: % bound=[E]/([E]+K,), where K,=[E] when half of 
values for the entire population, however. the total product is bound to the ribozyme. 
Cleavage reactions are generally carried out at 37" C. in The substrate need not be a nucleotide or nucleotide 
10 mM MgCl,, 30 mM EPPS (pH 7.5), and 40 pg/@ BSA, analog. The only requirement is that RNAs that react with 
using (5'-32P)-labeled substrate. BSA is added to prevent 25 the substrate become tagged in some way so that they can be 
oligonucleotides from adhering to the walls of the 500 @ distinguished from nonreactive molecules with respect to the 
Eppendorf tubes, and does not affect the course of the amplification process. For example, reactive RNAs could 
reaction. Ribozyme and substrate are preincubated sepa- become joined to a portion of the substrate that is attached 
rately for 15 min at 37" C., and then mixed to initiate the to a solid support, while nonreactive RNAs would be 
reaction. Typically, 5 aliquots of 3-10 pl each are removed 30 washed away, leaving the bound RNAs to be selectively 
from the reaction mixture at specified times and quenched amplified. These and other methodologies are further 
by addition to 1-2 volumes of an ice-cold mixture contain- described elsewhere herein. 
ing 8M urea, 50-100 mM EDTA, 0.05% xylene cyanol, 9. Extension of Directed Evolution to Develop Additional 
0.05% bromophenol blue, 10% SDS, 9 mM Tris-borate (pH Evolved Species 
8.3), and 20% sucrose. Substrate and product are separated 35 As an in vitro model of Darwinian evolution, a population 
by electrophoresis in a 20% polyacrylamide/8M urea gel, of macromolecular catalysts was directed toward the expres- 
visualized by auto-radiography, excised from gel, and quan- sion of novel catalytic function. In the Examples presented 
tified by Cerenkov counting. herein, the development of ribozymes that cleave DNA and 
K,, and k,,, values are determined in experiments with those that demonstrate amide bond-cleaving activity with 
substrate ( S )  in excess over ribozyme (E). Initial rates of 40 improved eEciency under physiologic conditions has now 
reaction (VJ, over a range of substrate concentrations, are been demonstrated. 
estimated from the initial linear phase, generally the first 5% 
or less of the reaction. Typically 8 data points were fit by a Beginning with any generation of a population of 
least squares method to a theoretical line given by the ribozymes as described herein, successive generations of in 
equation: v=K, (vJ[S])+V,,. 45 vitro evolution are carried out. Variation in the population is 
Single-turnover experiments are performed with maintained by PCR amplification, which introduces muta- 
ribozyme in excess of substrate (Herschlag & Cech, Eo-  tions at a rate of -0.1% per nucleotide position per genera- 
chemistry 29: 10159-10171 (1990b)). Initial rates (kobs) are tion. Because mutation is ongoing, evolution based on 
obtained using no more than the first 5% of the reaction. Darwinian principles can occur. Progeny ribozymes have the 
Given that k,,/KpkObJ[E], each kobs value, obtained at 50 opportunity to acquire new mutations that confer favorable 
different ribozyme concentrations, provided an estimate of attributes not possessed by the parent molecules. This phe- 
k,,/Kw Generally 8 or more measurements of k,JKM are nomenon is reflected by the steadily increasing frequency of 
obtained. accepted mutations over subsequent generations (not 
ribozyme can be optimized by appropriate manipulation of 55 b. Improvement of Substrate Binding Affinity 
the selection constraints during an in vitro evolution proce- Beginning with any generation of enzymatic RNA mol- 
dure. For example, beginning with a heterogeneous popu- ecules, the concentration of substrate is lowered--e.g., from 
lation of ribozymes, enriched for modest amide bond-cleav- 10 @I to 0.2 pM-to impose increased selection pressure 
age activity, successive generations are produced to obtain favoring individuals with enhanced substrate binding affin- 
ribozymes with amidase activity that have successively- 60 ity. In order to assess the impact of this change, K, values 
improved catalytic rates and substrate binding affinities. for the complex between ribozyme and product are deter- 
8. Determination of Binding Constants mined for the population of ribozymes at regular intervals, 
The equilibrium dissociation constant, K,, of the corn- e.g., at every third generation. 
plex between ribozyme and product (P) is determined by It is anticipated that, when the within-disclosed proce- 
gel-shift analysis in a native polyacrylamide gel (Pyle et al., 65 dures are followed, improvement in substrate binding affin- 
PNAS USA 873187-8191 (1990)). Ribozyme at twice final ity over successive generations of in vitro evolution may be 
concentration is preincubated at 37" C. for 15 min in 10 mM observed. 
a. Evolution In Vitro 
Specific catalytic properties of an amide-cleaving shown). 
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The product, rather than substrate, is employed to avoid a screen a significant number of organisms or constructs in an 
cleavage reaction during the gel-shift analysis. The binding effort to identify a suitable protease; using the methods 
affinity for the product is assumed to be similar to that of the disclosed herein, one of skill in the art may now design and 
substrate, based on previous studies showing that the wild- construct molecules with the desired Specificity and activity. 
type ribozyme binds the RNA substrate with the same 5 Additionally, as there are no essential contacts with the 
affinity as it binds the product (Pyle et al., PNAS USA 87: downstream nucleotides, it is likely that the downstream 
8187-8191 (1990); HerscHag & Cech, Biochemistry amino acids can be replaced with other amino acids, pep- 
29:10159-10171 (1990b)). tides, or polypeptides, or with other chemical substituents. 
Converting an enzymatic RNA molecule to a full-fledged 
amide bond-cleaving molecule that recognizes, binds and 
cleaves a polypeptide may be accomplished using the 
within-disclosed in vitro evolution techniques, selecting for 
ribozymes that retain amide-cleaving activity and bind a 
particular protein. (Also see Tuerk and Gold, Science 249: 
505-510 (1990); and Jellinek, et al., PNAS USA 90: 
The enzymatic RNA molecules with the ability to cleave 
evolution methods such as those described in Example 1 
20 herein. Thus, while the ribozymes disclosed herein may 
alternatively be described as having the ability to cleave a 
EXAMPLE 2 
Enzymatic RNA Molecules With Amide-Cleaving 
Activity 
Enzymatic RNAmolecules (or ribozymes) have now been 15 1227-11231 (1993).) 
developed which are capable of cleaving amide bonds-e.g., 
inactive alkyl amide bonds-via a metal-dependent hydro- 
out by protease/peptidase enzymes, which enzymes typi- 
cally consist of protein themselves. 
lytic mechanism. This is comparable to the reaction carried target amides are preferably prepared according to in 
There have been reports in the literature describing 
Of an activated 
particular phosphoester bond in the context of a ribonucle- 
ficial enzymes that promote otide, deoxyribonucleotide, or some other nucleotide-con- 
amide; for Janda, et Science 241: 1188-1192 taining substrate (e.g. an arabinonucleotide substrate), it has 
(1988) describe an antibody with amidase activity. now been observed that when the evolved ribozymes are 
this is not an insignificant development, it nonetheless 25 presented with a substrate that contains an -de in place of 
cleaved is not a peptide bond. There has also been a report 
showing that a modified Tetrahymena ribozyme has modest 
certain circumstances (Piccirilli, et at., Science 256: 
involves a protein with enzymatic activity and the bond a phosphate, they catalyze cleavage of the amide to generate 
products with free amine and free carboxyl termini, 
30 matic RNA molecules capable of cleaving amide bonds ability to accelerate hydrolysis of an aminoacyl ester under 
In Order to the progressive Of enzy- 
1420-1424 (1992)). This reaction is easily accomplished by 
a hydrolysis reaction, however, in the absence of 
between neighboring amino acids, 
ecules+.g. molecules comprising a series Of One Or more 
"hybrid" 
enzyme. Conversely, it is the amide hydrolysis reaction that 
demands a catalyst. 
In contrast, the enzymatic RNA molecules disclosed 
herein catalyze cleavage of an unactivated alkyl amide, 
which is more akin to the amide linkage within a polypep- 
exhibit amide-cleaving activity, are not themselves proteins. 4o segment of a hybrid molecule, e.g., d(GGCCmcT 
While the Present example employs Substrates containing (SEQ ID NO l l ) ,  is described essentially as follows. 
the amide linkage in the context of an oligodeoxynucleotide- The 7-mer d(GGCCCTC) (SEQ ID NO 12) was prepared 
Polypeptide "hybrid" molecule, with 8 nucleotides upstream on an automated DNA synthesizer, deprotected in the usual 
and one Or more amino acids downstream of the target way, and purified by polyacrylamide gel electrophoresis and 
amide, it is anticipated that any amide-linkage-containing 45 subsequent affinity chromatography on dupont NENsorb 
molecule recognized Or recognizable by an enzymatic RNA (duPont, Wilmington, Del.). The T, residue was provided 
molecule of the present invention may be cleaved as dis- in the form of 3'-amino'3'deoxythymdine-5'-triphosphate 
closed herein-including polypeptides and proteins. In addi- (u.s. Biochemical, Cleveland, ohia) and was coupled enzy- 
tion, since the ribozyme binds the substrate via Watson- matically to the 7-mer using te-nal deoxynucleotidyl 
Crick Pairing and tertiary contacts involving the Upsweam 50 transferase (TdT; available from U.S. Biochemical, Cleve- 
nucleotides present in hybrid molecules, thereby drawing land, Ohio or B=, Gaithersburg, Mass.), producing the 
the amide into close proximity to a bound Mg2' cofactor, it desired 8-mer product. 
is expected that sequential replacement of said upstream The 8-mer was purified by polyacrylamide gel electro- 
nucleotides with amino acids within the framework Of the in phoresis and subsequent affinity chromatography. The 8-mer 
Vitro evolutionary methods disclosed in Example 1 above 55 was found to migrate appreciably slower than the unreacted 
Will Produce a riboZYme that binds tightly to Polypeptide 7-mer (data not shown). Finally, the purified 8-mer was 
molecules. [5'-32P]-using [y-32P]ATP and T4 polynucleotide kinase, 
The present invention is also uniquely useful in facilitat- according to standard protocols. (In general, the labeling 
ing the engineering and selection of catalytically active RNA admixture comprised 2 pl 5x buffer, 1 pl &mer, 1 pl 
molecules which are able to cleave a specific amide bond at 60 CZ-~~P-ATP, 4 pl H,O, and 2 pl T4 kinase, and was main- 
a desired location; in other words, the present invention tained at 37" C. for 1 hour.) 
permits the construction of a vast array of RNA molecules, As shown in FIG. 7, this 8-mer d(GGCCCTCTNH2) (SEQ 
each having the ability to cleave a specific peptide bond ID NO 11) marker and the 8-mer 5' product of the enzymatic 
between particular, preselected amino acids. The advantages RNA molecule-catalyzed cleavage of the amide-bond-con- 
of being able to efficiently and expeditiously design 65 taining substrate have the same mobility. This effectively 
enzymes of such specificity are inestimable. The present demonstrates the amide-cleaving activity of the enzymatic 
invention is also advantageous in that it obviates the need to RNA molecules of the present invention. 
nucleotides linked to a series of one or more amino acids- 
are first synthesized as described hereinbelow. Such mol- 
35 ecules may then be used to identify useful enzymatic RNA 
molecules according to the present invention. 
A, Synthesis of Ribozymes and Substrates 
1, Synthesis of Oligonucleotides 
tide. Furthermore, the within-disclosed mOleCUkS, which The procedure for preparation of the o~igonucleotide 
NH2 
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2. Preparation of Ribozymes 
Enzymatic RNA molecules identified herein as clones 48 
and 61 were used in the within-described cleavage experi- 
ments, although it is to be appreciated that the present 
invention is not limited to use of said ribozymes. Clones 48 5 
and 61 were optimized for DNA-cleavage ability and were 
prepared as described in Example 1 (and in Beaudry and 
Joyce, Science 257: 635-641 (1992) and Tsang and Joyce, 
Biochemistry 33: 5966-5973 (1 994)). Ribozymes from 
clones 48 and 61 were selected from the 27th generation. 
Ribozymes 48 and 61 (G27 #48 and G27 #61) are 
described as follows. Ribozyme G27 #48 includes the fol- 
lowing mutations at the sites noted: 44:G+A, 51/52:insert 
AGAA, 87:A+del, 94A+U, 115:A+U, 116:G+A, 
166C+A, 17OC+U, 188:G+A, 190:U+A, 191:G+U, 15 
205:U+C, 215:G+A, 239:U-+A, 312:G+A, 35O:C+U, 
and 364:C-N. Ribozyme G27 #61 has the following muta- 
tions: 44:G+A, 51152:insert AGAA, 87:A+del, 94:A+U, 
115:A+U, 116:G+A, 166:C+A, 17O:C+U, 188:G+A, 
190:U+A, 191:G+U, 205:U+C, 215:G+A, 313:G+C, 20 
and 314:A+G. 
Ribozyme G27 #48 includes the following mutations, 
which are not present in G27#61: 239:U+A, 312G+A, 
350:C+U, and 364:CjU. Similarly, ribozyme G27 #61 
includes the following mutations, which are absent in G27 25 
#48: 313:G+C and 314A+G. 
3. Synthesis of Hybrid Molecules 
As noted above, an oligonucleotide is first prepared. Next, 
that nucleotide sequence “head” is linked, via an amide 
bond, to an amino acid residue sequence “tail” to form a 30 
hybrid substrate molecule. Preferably, an entire “series” of 
hybrid molecules is prepared for use in a continuing in vitro 
evolutionary process, whereby the first molecule in an 
exemplary series may comprise an oligonucleotide sequence 
(e.g., an 8-mer) linked to a polypeptide (e.g., a monomer or 35 
dimer) by an amide bond. For an example, a first hybrid 
molecule in such a series may comprise an oligonucleotide 
8-mer linked to a polypeptide dimer. Subsequent hybrid 
molecules in such a series preferably comprise one fewer 
nucleotide each time-e.g., the second molecule in the 40 
series comprises an oligonucleotide 7-mer linked to a 
polypeptide trimer; the third molecule comprises an oligo- 
nucleotide 6-mer linked to a polypeptide tetramer; and so on, 
until only a single nucleotide remains at the “head” of the 
hybrid molecule. Exemplary hybrid molecules in such a 45 
“series” may be used in a consecutive manner in conjunction 
with in vitro evolution methodologies as disclosed herein to 
identify useful enzymatic RNA molecules in successive 
rounds of mutation, selection, and amplification. 
mers, dimers, and so forth are described as exemplary, a 
hybrid molecule according to the present invention may 
comprise longer and more complex polypeptide sequences. 
That is, hybrid molecules of the present invention may 
include as few as one or two amino acid residues, or may 55 
include substantially longer polypeptides or proteins, pro- 
vided that the length of the polypeptide “tail” does not 
substantially interfere with the ability of enzymatic RNA 
molecules of the present invention to recognize and bind 
hybrid molecules, or otherwise interfere with cleavage of 60 
amide bonds therein. 
It should also be appreciated that the sequence of nucle- 
otides and/or amino acids may be varied as desired. For 
example, the nucleotide sequence at the “head” of the hybrid 
may be comprised of common and/or unusual or modified 65 
nucleotides (as described in 37 CFR $$1.821 et seq.), in any 
order. Similarly, while certain exemplary hybrid molecules 
10 
It is also to be understood that although peptide mono- 50 
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disclosed herein include pairs of identical amino acids in the 
“tail” sequence, it is expressly to be understood that the 
amino acid residue sequence of hybrid molecules according 
to the present invention may be varied, and may include 
unusual or modified amino acids, as well. 
Hybrid molecules according to the present invention are 
typically designed and constructed so that the nucleotide and 
amino acid sequences are linked by an amide bond. In 
general, methods such as those described by Zieboll and 
Orgel, J. Mol. Evol. 38: 561-565 (1994) and Ehler, et al., 
Biochim. et Biophys. Acta 434: 233-243 (1976) the disclo- 
sures of which are incorporated by reference herein-were 
used and adapted as follows. 
Typically, a 0.5M solution of imidazole is first prepared, 
into which the amino acid of choice is dissolved. In the 
present example, arginine (L-arginine, 98% purity; Aldrich 
Chem. Co., Milwaukee, Wis.) was dissolved into a 0.5M 
imidazole solution, until a final concentration of arginine of 
0.1M was achieved. Next, 125 pl of the arginine solution 
was placed into an Eppendorf tube. Two microliters (2 pl) of 
oligonucleotide is then placed into a separate, clean Eppen- 
dorf tube, dried (e.g. via spin-vac), and cooled (e.g., placed 
on ice). In the present example, 2 pl of radiolabeled d(GGC- 
CCTCT,) (SEQ ID NO 11)-synthesized as described in 
section 1 above-was placed into a separate, clean Eppen- 
dorf tube, dried, and placed on ice. 
Approximately 0.1 mg 1, 1 ‘-carbonyldiimidazole (“CDI”; 
Aldrich, Milwaukee, Wis.) was measured and added into 
0.1M arginine solution; CDI served to “activate” the amino 
acids. (See Ehler, et al., Id. (1976).) As soon as the CDI 
dissolved into the solution, the admixture was placed on ice 
for about 1 minute. About 20 pl of the above-noted solution 
was added to the tube containing the d(GGCCCTCT-,) 
(SEQ ID NO l l ) ,  on ice (ie., at about 0” C.). The tube 
containing this admixture was then transferred into a cold 
room and incubated. At various time points (e.g. 30 minutes, 
60 minutes), 10 pl of sample was removed, quenched with 
2x gel loading buffer, and placed on ice. Half of each sample 
(from each time point) was loaded on an 8M urea-20% 
polyacrylamide gel, and run according to standard protocols, 
as described previously. 
FIG. 6 illustrates the confirmation of successful synthesis 
of an exemplary oligonucleotide-oligopeptide “hybrid”. In 
lane 1, 5’-labeled d(GGCCCTCTNm) is shown. In lanes 2 
and 3, 5’-labeled d(GGCCCTCT)-Arg is shown, as mea- 
sured at 30 and 60 minutes. 
Two hybrid molecules synthesized as described above 
were isolated and used in cleavage reactions conducted 
essentially as described below. The first molecule, identified 
herein as “oligo-Arg”, had the sequence d(GGCCCTCT)- 
Arg (SEQ ID NO 13); the second molecule, “oligo-Arg;’, 
had the sequence d(GGCCCTCT)-ArgArg (SEQ ID NO 14). 
It is expressly to be understood, however, that the hybrid 
and polypeptide substrates cleavable by enzymatic RNA 
molecules of the present invention are not limited to those 
containing arginine residues only. Substrates lacking argin- 
ine, and/or substrates further comprising common or 
unusual/modified amino acids (preferably in L-form) are 
also contemplated by the within-disclosed invention. For 
example, amino acids listed in the Table of Correspondence 
appearing in Section A of the Detailed Description are useful 
in the hybrid and polypeptide substrates of the present 
invention, as are those described in 37 CFR $1.822. 
Hybrid oligonucleotide-oligopeptide molecules useful in 
the in vitro evolution procedures disclosed herein may also 
include uncommon amino acids, variants of “common” 
amino acids, or amino acid analogs, e.g., p-alanine, S-ad- 
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enosylmethionine, S-adenosylcysteine, S-adenosyl-ho- When a polypeptide desired for use according to the 
mocysteine, L(+)-canavanine, hydroxyproline, methion- present invention is relatively short (Le., less than about 
inemethylsulfoniumchloride, and w-nitroarginine. (See also 25-50 amino acid residues in length) direct peptide synthetic 
Zieboll and Orgel, J. Mol. Evol. 38:561-565 (1994).) techniques are generally favored, usually by employing a 
4. Amide, Polypeptide and Protein Substrates solid phase technique such as that of Merrifield (JACS 85: 
As disclosed herein, the enzymatic RNA molecules of the 2149 (1963)). Appropriate protective groups usable in the 
present invention may be engineered to cleave a bond aforementioned syntheses are described in the above texts 
between adjacent amino acids, with great selectivity and and in J. F. W. McOmie, Protective Groups in Organic 
specificity. Any amide, polypeptide or protein substrate, Chemistry, Plenum Press, New York, 1973, which is incor- 
whether naturally-occumng (i.e. “native”), synthesized, 10 porated herein by reference. 
derivatized, or conjugated, is an appropriate substrate for the A polypeptide useful as disclosed herein can also be 
enzymatic RNA molecules disclosed herein. synthesized by recombinant DNA techniques. Such recom- 
An amide substrate is a compound which includes a binant techniques are favored especially when the desired 
scissile amide bond. Preferred amide substrates include polypeptide is relatively long (greater than about 50 amino 
peptides and peptide conjugates having an amide linkage 15 acids residues in length). When recombinant DNA tech- 
between a secondary amine and a terminal peptide carboxy niques are employed to prepare an instant polypeptide, a 
group. 2-’Amino 3’-deoxynbose is a preferred secondary DNA segment encoding the desired polypeptide is incorpo- 
amine. When the ribozyme hydrolyzes an amide substrate, it rated into a preselected vector that is subsequently expressed 
produces an amino cleavage product and a ribozyme-acyl in a suitable host. The expressed polypeptide is then pref- 
intermediate, Le., a ribozyme amidase intermediate. The 20 erably purified by a routine method such as gel electrophore- 
amino cleavage product includes the secondary amine, e.g., sis, immunosorbent chromatography, and the like. 
2’-amino 3’-deoxyribose or a peptide fragment having a free Again, while initial rounds of in vitro evolution may 
amino terminus. A preferred ribozyme amidase intermediate conveniently be conducted using small polypeptides--e.g., 
includes an ester linkage between a ribozyme hydroxyl during the selection process-it should be appreciated that 
group and the terminal carboxyl group of a peptide. The 25 enzymatic RNA molecules of the present invention may be 
peptide may include one or more amino acid residues. engineered to recognize, bind and cleave polypeptides or 
Additionally, the peptide may be linear or cyclic and may proteins of a variety of lengths, conformations and bio- 
include non-natural amino acids and amino acids incapable chemical or physical characteristics, by use of the within- 
of ribosomal translation. Furthermore, the amino acid resi- disclosed techniques. 
dues may be either the D or L isomer. 30 B. Cleavage of Hybrid Molecules 
Alternative amide substrates include amide linked glyco- Six p1 of hybrid molecule prepared as described, 2 pl of 
peptides and carbohydrates containing acetylated amino 5x low-Mg2+ buffer, and 2 fi ribozyme were admixed and 
sugars, e.g., 2-acetamido-N-(L-aspart-4-oyl)-2-deoxy-P-D- incubated at 37” C. for about 8 hours, or overnight. After 
glucopyranosylamine or asparaginyl-N-acetylglucosamine. incubation, a sample comprising approximately one-half of 
Cleavage of either of these amide substrates yields an amino 35 the admixture was labeled, loaded and run on an 8M 
sugar as the amino cleavage product. Cleavage of N-acetyl urea-20% polyacrylamide gel, as before. A sample of 5’-la- 
amino sugars produces a ribozyme amide intermediate hav- beled d(GGCCCTCTNm) (SEQ ID NO 11) was also run as 
ing an acetylated deoxynucleotide. Cleavage of glycopep- a control. 
tides produces a nbozyme amide intermediate having an In FIGS. 4 and SA-C, cleavage of a hybrid substrate by a 
ester linkage between a ribozyme hydroxyl group and a 40 ribozyme of the present invention is illustrated and shown to 
peptide carboxyl group. The peptide carboxyl group may be generate an 8-mer 5’ product with a terminal -NH,. For 
a terminal carboxyl group or an aspartic acid or glutamic example, FIG. 4 illustrates the cleavage of an amide bond- 
acid residue. Amide linked glycans, including peptidogly- containing substrate, showing that it generates a 5’ product 
cans, are yet a further class of amide substrate cleavable by that carries a terminal amine and a 3’ product that carries a 
amidase active ribozymes. 45 terminal carboxyl. FIGS. SA-C further illustrate the reaction 
Although polypeptides of any length are cleavable using shown in FIG. 4, including the production of intermediates 
RNA enzymes of the present invention, one seeking to (FIG. 5B) and products (FIG. 5C), as well as the relationship 
design a specific enzymatic RNA molecule according to the of the substrate to the ribozyme (FIG. SA). It also shows that 
present invention may find it convenient to utilize shorter, the ribozyme-associated product is subsequently hydro- 
rather than longer, polypeptides in the initial stages of in 50 lyzed, resulting in generation of a 5’ product carrying a 
vitro evolution. For example, while polypeptides comprising terminal amine and a 3’ product carrying a terminal carboxyl 
12 or fewer amino acids (e.g., dimers, tetramers, 8-mers, (FIG. SC). Subsequent to hydrolysis of the ribozyme-asso- 
etc.) are discussed herein as exemplary, it is expressly to be ciated product, the enzyme is free to cycle-Le., it is free to 
understood that the invention is not so limited. cleave another amide bond. (See also Hentzen, et al., Bio- 
A polypeptide used as disclosed herein can be derived 55 chimica et Biophysica Acta 281: 228-232 (1972).) 
from an existing source (e.g. via proteolysis of a larger For purposes of illustration only, FIGS. 4 and 5 (A-C) 
polypeptide or protein) or synthesized by any of the peptide have been drawn to show the amide bond in the context of 
synthetic techniques known to those skilled in the art. A an oligonucleotide molecule. It is expressly to be understood 
summary of some of the techniques available can be found that one or both of the motifs identified in FIG. SA-C as 
in J. M. Stuard and J. D. Young, “Solid Phase Peptide 60 “DNA 1” and “DNA 2” may be replaced by the appropriate 
Synthesis”, W. H. Freeman, Co., San Francisco (1969); J. amino acid structural formulas and labels. For example, if 
Meinhofer, “Hormonal Proteins and Peptides” Vol. 2, pp. 46, the motif labeled “DNA 2” were replaced with the label 
Academic Press (New York) 1983; E. Schroder and K. “Arg” and the appropriate chemical drawing, the interme- 
Kubke, “The Peptides”, Vol. 1, Academic Press (New York), diate shown in FIG. 5B would illustrate that the arginine 
1965 for classical solution synthesis, and U.S. Pat. No. 65 moiety remains temporarily attached to the ribozyme after 
4,631,211, the disclosures of which are incorporated herein the peptide bond is cleaved and is subsequently released via 
by reference. hydrolysis (FIG. SC). 
5 
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FIG. 7 illustrates the results of an exemplary ribozyme- After incubation, a sample comprising approximately 
catalyzed cleavage of a hybrid molecule. Typical reaction one-half of the admixture is loaded and run on an appropri- 
conditions are as follows: 1 pM ribozyme, 1 pM [5'-32P]- ate gel, as described above. A sample of substrate polypep- 
labeled substrate, 10 mM MgCl,, and 30 mM EPPS, at 37" tide, in the absence of enzyme, may be run as a control; a 
C., pH 7.5, for 8 hours. sample of expected cleavage product is also preferably run 
FIG. 7 is a photograph of a gel illustrating cleavage of a as a control. Examination of the results will confirm whether 
hybrid oligonucleotide-oligopeptide substrate by enzymatic site-specific cleavage has occurred. Subsequent evaluations 
RNA molecules of the present invention. In lane 1, 5'-la- utilizing larger substrate polypeptides may be performed to 
beled 8-mer marker is shown. In lane 2, interaction of further confirm site-specific cleavage between preselected 
ribozyme with a 5'-labeled hybrid substrate generates an 10 amino acids. 
8-mer 5' product with a terminal -NH,. In lane 3, substrate 
alone (i.e., in the absence of ribozyme) is shown. 
As shown in FIG. 7, the 8-mer d(GGCCCTCT,,,) (SEQ 
ID NO 11) marker and the 8-mer 5' product of the enzymatic 
RNA molecule-catalyzed cleavage of the amide-bond-con- 15 
taining substrate have the same mobility. This effectively A. Preparation of Wild-Type Ribozyme 
demonstrates the amide-cleaving activity of the enzymatic The L-21 form of the Tetrahymena ribozyme was pre- 
RNA molecules of the present invention. pared by in vitro transcription of Hind JII-digested pl7L-21 
The reaction appears to be dependent upon the presence plasmid DNA (Zaug et al., Biochemistry 27: 8924-8931 
of Mg2+, although other divalent cations are also expected to 20 (1988)). The transcription reaction mixture contained 0.1 
be useful; for example, use of Mn2+ instead of Mg2+ also pg/pl of cut plasmid, 15 mM MgCl,, 2 mM spermidine, 50 
produced satisfactory results. In general, the reactions have mM Tris (pH 7.5), 5 mM DTT, 2 mM each NTP, 0.005 U/pl 
been run at 37" C. for eight (8) hours or overnight, but it is inorganic pyrophosphatase, and 25 U/pl T7 RNA poly- 
expected that these parameters will continue to be adjusted merase, incubated at 37" C. for 2 hr. The 23-nucleotide 3' 
as in vitro evolution techniques are applied. For example, 25 exon sequence was removed by RNA-catalyzed site-specific 
selection of enzymatic RNA molecules that carry out the hydrolysis (Inoue et al., J. Mol. Biol. 189: 143-165 (1986)): 
cleavage reaction during shorter time periods will likely be RNA was incubated in the presence of 50 mM CHES (pH 
favored. Selection of enzymatic RNA molecules that utilize 9.0) and 10 mM MgC1, at 42" C. for 1 hr. The resulting RNA 
different monovalent or divalent cations may also be a useful was isolated by electrophoresis in a 5% polyacrylamide/8M 
choice. 30 urea gel, visualized by UV shadowing, eluted from the gel 
Thus, as shown in FIG. 7, cleavage of hybrid oligonucle- overnight at room temperature in a buffer containing 200 
otide-oligopeptide substrate by enzymatic RNA molecules mM NaC1, 10 mM Tris (pH 7.5), and 0.5 mM EDTA, and 
of the present invention has been confirmed. purified by aflinity chromatography on duPont Nensorb 
It was observed that ribozyme G27 #48 cleaved the amide (Wilmington, Del.). The concentration of ribozyme was 
bond more rapidly than did G27 #61 (data not shown). It was 35 determined spectrophotometrically, based on e,,,,=3.2x106 
also noted that the cleavage reaction rate decreases as the M-' cm-' (Zaug et al., Biochemistry 27: 8924-8931 (1988)). 
temperature is raised to 45" C. and ceases altogether at 50" B. Alternative Methods of Preparing Ribozymes 
C. (not shown). Unlike experiments involving oligonucle- One alternative method of preparing wild-type and mutant 
otide cleavage, it was observed that the ribozyme might ribozymes may be described as follows. Wild-type and 
occasionally cleave one position upstream of the bond 40 mutant ribozymes were produced by first isolating the 443 
"intended" to be cleaved in the hybrid molecule, but it did base-pair Eco RI to Hind III restriction endonuclease frag- 
not cleave downstream of the amide bond. (See, e.g., Tsang ment from the plasmid PT7-21 described by Zaug et al., 
and Joyce, Biochemistry 33: 5966-5973 (1994).) This 'h i s -  Biochemistry 27: 8924 (1988) using the standard methods 
cleavage" event is illustrated in FIG. 7, in lane 2, as described in Current Protocols in Molecular Biology, 
evidenced by the band "beneath" the band representing the 45 Ausubel et al., eds. John Wiley and Sons, New York (1987). 
product generated when cleavage occurs at the desired This 443 base-pair fragment contains the T7 promoter 
(preselected) site. Such "mis-cleavage" events may be selec- described by Dunn et al., J. Mol. Biol. 166: 477-535 (1983) 
tively eliminated from the evolving population, however; and residues 22-414 of the Tetrahymena IVS and residues 
e.g., by going back the previous generation of variants and 1-25 of the 3' Tetrahymena exon described by Been et al., 
generating a different subpopulation therefrom, or by apply- 50 Cell 47: 207-216 (1986). This E o  RI and Hind II fragment 
ing selection criteria designed to eliminate ribozymes that was inserted into the M13 vector M13mp18 (which is 
cleave at locations other than the one desired. similar to the vector described by Yanisch-Perron et al., 
C. Cleavage of Polypeptide Molecules Gene 33: 103-119 (1985)), which vector had been previ- 
The following general procedure is useful for confirming ously cleaved with Eco RI Hind III, according to standard 
site-specific cleavage between preselected, adjacent amino 55 subcloning procedures such as those described in Current 
acids. For example, to confirm that an enzymatic RNA Protocols in Molecular Biology, Ausubel et al, eds. John 
molecule capable of site-specific cleavage of a bond Wiley and Sons, New York (1987). The resulting M13T7L- 
between two arginine molecules has been identified, the 21 DNA construct was used to transform E. coli host cells 
following procedure may be used. according to the transformation procedure described in 
A small polypeptide substrate (e.g., an 8-mer) is prepared 60 Molecular Cloning: A Laboratory Manual (Maniatis et al., 
as described in section A.4 above and preferably includes a eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, 
single paired Arg-Arg moiety. Six pl of the peptide substrate, N.Y. (1989)). 
2 pl of 5x low-Mg2+ buffer, and 2 pl ribozyme are admixed Single-stranded DNA was then prepared from the 
and incubated at 37" C. for about 8 hours, or overnight. M13T7L-21-transfomed cells according to the procedures 
Labeling of the polypeptide substrate will facilitate detection 65 described in Current Protocols in Molecular Biology (Id., 
of reaction products and confirm site-specific cleavage, as 1987). The accuracy of the above construction was con- 
described previously. firmed by DNA sequencing using the Klenow fragment of E. 
5 
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coli DNA polymerase I (Boehringer Mannheim Biochemi- 
cals, Indianapolis, Ind.) and the dideoxynucleotide sequenc- 
ing method (see Sanger et al., PNAS USA 74: 5463-5467 
(1 977)). 
The wild-type and mutant ribozymes were prepared 
directly from the single-stranded M13T7L-21 DNA using a 
modification of the technique previously described by Joyce 
and Inoue, Nucleic Acid Research 17: 711-722 (1989). The 
technique involves construction of a template strand that 
optionally includes one or more mutagenic oligodeoxy- 
nucleotides. The resulting partially-mismatched double- 
stranded DNA is transcribed directly using T7 RNA poly- 
merase. 
Briefly, the procedure is as follows. A five-fold molar 
excess of a terminator polynucleotide and a mutator oligo- 
nucleotide were admixed with 5 pg of single-stranded 
M13T7L-21 DNA and a solution containing 20 mM tris 
[hydroxy-methyl]aminomethanc adjusted to pH 7.5 with 
HCl(Tris-HCI), 50 mM NaCl and 2 mM MgCI,. This 
solution was maintained at 70 degrees centigrade (70" C.) 
for 5 minutes and then steadily cooled to 30" C. over 40 
minutes. Fifteen units(U) of T4 DNAligase (U.S. Biochemi- 
cals, Cleveland, Ohio) and 7.5 U of T4 DNA polymerase 
(US.  Biochemicals) were admixed into the solution, 
together with sufficient amounts of reagents to make a 
solution containing a final concentration of 20 mM Tris-HC1 
at pH 7.5,50 mM NaCl, 5 mM MgCI,, 2 mM dithiothreitol 
(DIIT), 1 mh4 adenosine triphosphate (ATP), and 0.5 mM 
each of dGTP, d", dATP and dCTP (dNTPs). The result- 
ing solution was maintained at 37" C. for 60 minutes to 
complete the synthesis of the mutant strand. The resulting 
DNA was purified by ethanol precipitation and then used to 
direct the transcription of mutant RNA. 
Transcription took place either in a 10 pl volume con- 
taining 18 g of mutant DNA, 2 pCi [a3'P] GTP and 50 U of 
T7 RNA polymerase that was prepared as previously 
described by Davanloo et al., PNAS USA 81: 2035-2039 
(1984), and the resulting product was purified according to 
a procedure originally developed by Butler & Chamberlain, 
J. Bio. Chem. 257: 5772-5779 (1982), or in a400 pl volume 
containing 10 pg of mutant DNA, 40 pCi [3H]UTP and 
2,400 U of T7 RNA polymerase. In either case, the tran- 
scription mixture also contained 40 mM Tris-HC1 at pH 7.5, 
15 mM MgCI,, 10 mM dithiothreitol, 2 mM spermidine, and 
1 mM (each) NTPs, and was incubated at 37" C. for 90 
minutes. The T7 RNA polymerase was extracted with phe- 
nol and the transcription products were purified by ethanol 
precipitation. The mutant RNA was isolated by electro- 
phoresis in a 5% polyacrylamide/8M urea gel, eluted from 
the gel, and purified by ethanol precipitation and chroma- 
tography on Sephadex G-50. 
The 3' exon sequence was removed by RNA-catalyzed 
site-specific hydrolysis as has been previously, Inoue et at., 
J.  Mol. Bid .  189: 143-165 (1986). Briefly, the RNA was 
incubated in the presence of 50 mM CHES at pH 9.0 and 10 
mM MgCl, at 42" C. for 1 hour. Wild-type and mutant 
RNAs were isolated by electrophoresis in a 5% polyacry- 
lamide/8M urea gel, eluted from the gel, and purified by 
affinity chromatography on duPont Nensorb (duPont, Wilm- 
ington, Del.). RNAs were sequenced by primer extension 
analysis using AMV reverse transcriptase (Life Technolo- 
gies, Inc., Gaithersburg, Md.) in the presence of dideoxy- 
nucleotides, using a modification of the methods described 
by Sanger et al. (PNAS USA 74: 5463-5467 (1977)), except 
for those containing the Delta P9 deletion (not shown), 
which were sequenced from the 3' end by partial RNase 
digestion, Donis-Keller et al., Nucleic Acids Res. 15: 
8783-8798 (1987). 
50 
Other methods of preparing enzymatic RNA molecules of 
the present invention are based on chemical synthesis. 
Methods useful in the chemical synthesis of RNA arc similar 
to those used to synthesize DNA. The additional 2'-OH 
5 group in RNA, however, requires a different protecting 
group strategy to deal with selective 3'-5' internucleotide 
bond formation, and with RNA susceptibility to degradation 
in the presence of bases. 
The recently-developed method of RNA synthesis utiliz- 
IO ing the t-butyldimethylsilyl group for the protection of the 2 
hydroxyl seems to be the most reliable method for chemical 
synthesis of ribozymes. The method reproducibly yields 
RNA with the correct 3'-5' internucleotide linkages, with 
average coupling yields in excess of 99%, and requires only 
15 a two-step de-protection of the polymer. 
Other useful methods are available. For example, pub- 
lished PCT application no. WO 93/23569 describes various 
methods of chemically synthesizing ribozymes. 
20 EXAMPLE 4 
Optimization of DNA Substrate Cleavage 
The wild-type enzymatic RNA molecule, which can be 
25 "forced" to cleave a single-stranded DNA substrate (albeit 
only under conditions of high temperature (50" C.) or high 
MgCl, concentration (50 mM), or both), has now been 
"evolved" to produce variants that can cleave DNA under 
physiologic conditions with improved efficiency compared 
30 to the wild-type. (Robertson and Joyce, Id. (1990); Beaudry 
and Joyce, Science 257: 635-641 (1992).) 
The catalytic efficiency of RNA-catalyzed DNA cleavage 
under physiologic conditions has recently been improved, 
thereby generating ribozymes that efficiently cleave DNA in 
35 vivo (Tsang and Joyce, Biochemistry 33: 5966-5973 
(1994)). Since it is not obvious how one should change the 
Tetrahymena ribozyme to convert it from its "native" RNA- 
cleaving phenotype to a new phenotype, directed evolution 
was selected as a means to acquire the desired phenotype. 
40 Directed evolution is now discovered to be appropriate for 
use in designing and identifying enzymatic RNA molecules 
with DNA-cleaving ability, as well as amide-bond-cleaving 
andor peptide-recognition and binding capabilities. 
As described in the foregoing examples, to generate the 
45 initial population of ribozyme variants, random mutations 
are introduced throughout the catalytic core of the molecule. 
In one example, four synthetic oligodeoxynucleotides were 
prepared, each of which randomly mutagenizes 35 nucle- 
otide positions at an error rate of 5% per position (not 
The following Table illustrates the composition of the 
initial population (generation 0). The probability P of having 
K errors in a doped oligonucleotide of length v and degen- 
55 eracy d is given by: P(k,v,d)=[v!/(~-k)!k)]d~(lkI)~-~. A total 
of 140 positions were randomly mutagenized (v=140) at a 
degeneracy of 5% per position (d4.05). The number of 
distinct k-error sequences of length v is given by: N,=[v!/ 
(v-k)!k!]3'. The expected number of copies per sequence is 
6o based on a population size of 20 p m o l ( l . 2 ~ l O ' ~  molecules). 
50 shown). 
TABLE 2 
~~ 
Probability 
Errors (a) Sequences CopieslSequence 
0 (wt) 0.1 1 9 x 109 65 
1 0.6 420 2 x 108 
51 
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TABLE 2-continued 
Probability 
Errors @) Sequences Copies/Sequence 
2 2.1 9 x 104 3 x 106 
4 9.0 1 x 109 9x102  
5 12.8 1 x 10” 15 
6 15.2 I x 10’2 0.3 
3 5.0 1 x 107 5 x 104 
I+ 55.4 
For example, in order to initiate the development of a 
population of ribozyme variants with optimized DNA-cleav- 
ing ability, the phylogenetically conserved portions of the 
molecule that are known to be essential for catalytic activity 
was first partially randomized. Superior DNA-cleaving 
ribozymes were distinguished from less active molecules 
based on the likelihood of attachment of the 3’ portion of the 
substrate to the 3’ end of the ribozyme. A DNA primer was 
hybridized across the ligation junction of successful reaction 
products, and used to initiate a selective isothermal ampli- 
fication reaction. The selectively amplified molecules then 
served as templates for cDNA synthesis; the resulting cDNA 
was amplified by the polymerase chain reaction (PCR) 
(Saiki et al, Science 230: 1350-1354 (1985); Saiki et al, 
Science 239:487-491 (1988)); and the PCR products were 
transcribed to generate a new pool of RNAs. The entire 
process, beginning with the cleavage reaction and followed 
by selective isothermal amplification, cDNA synthesis, PCR 
amplification, and in vitro transcription, constitutes one 
“generation” of the in vitro evolution procedure. 
This in vitro procedure was successfully used to generate 
over 40 successive generations, starting with a pool of l O I 3  
variants of the Tetrahymena ribozyme. After the 9th gen- 
eration (G9), individual ribozymes were isolated from the 
population and shown to catalyze the cleavage of a DNA 
substrate 100-fold more efficiently compared to the wild- 
type enzyme. This modest improvement in catalytic effi- 
ciency resulted from both an increased catalytic rate (kcal) 
and a decreased value for the Michaelis constant (KM). 
For each generation, the evolving population was pro- 
vided with 10 pM DNA substrate and allowed 1 hr to cany 
out the DNA-cleavage reaction. By G9, K,, had improved 
from 6 pM for the wild-type to about 2 @I for the evolved 
individuals (Beaudry and Joyce, Id., (1992)). Accordingly, it 
appeared that the population was no longer under stringent 
selection pressure to drive further improvement of Knn 
Individual cleavage rates, on the other hand, were on the 
order of 0.007 min-’ by G9, still slow enough to be 
constrained by the 1 hr incubation period. However, if the 
reaction rate continued to improve, then the selection con- 
straints would eventually become insufficient to favor fur- 
ther improvement of the catalytic rate. As successive gen- 
erations of ribozymes were subjected to in vitro evolution, 
using different selection constraints, substantially greater 
DNA-cleavage activity was developed in members of the 
population in each successive generation. 
In the present examples, in vitro evolution techniques 
have been applied each time with a higher level of sophis- 
tication and control. Because the outcome of an in vitro 
evolution experiment depends on the nature of the selection 
constraints, specific catalytic properties of a ribozyme, such 
as substrate binding affinity, catalytic rate, substrate speci- 
ficity, and turnover, may be improved by appropriate 
manipulation of the reaction conditions. With this in mind, 
optimization of two catalytic properties of the DNA-cleav- 
ing ribozymes, namely, substrate binding affinity and cata- 
lytic rate was achieved. It was hypothesized that ribozymes 
with the greatest aBinity for the substrate would enjoy a 
selective advantage when the substrate is presented at low 
concentrations. Under saturating conditions, ribozymes with 
the fastest first-order rate of reaction would be favored when 
the reaction time is very short. 
For example, the concentration of the DNA substrate was 
first reduced 50-fold, to favor ribozymes with improved 
substrate binding aflinity. Next, the reaction time was 
reduced 12-fold to favor ribozymes with improved catalytic 
rate. In both cases, the evolving population responded as 
expected, first improving substrate binding 25-fold, and then 
improving catalytic rate about 50-fold. The population of 
ribozymes has undergone 27 successive generations of in 
vitro evolution, resulting in, on average, 17 mutations rela- 
l5 tive to the wild-type that are responsible for the improved 
DNA-cleavage activity. 
The previously-characterized G9 population of DNA- 
cleaving ribozymes (see Beaudry and Joyce, Id. (1992)) was 
“resurrected” and 27 additional generations of in vitro 
evolution were canied out under somewhat different reac- 
tion conditions. From generations 10 through 18, the sub- 
strate concentration was reduced 50-fold, from 10 @I to 0.2 
pM. From generations 19 through 27, the lower substrate 
concentration was maintained and the reaction time was 
25 reduced 12-fold, from 1 hr to 5 min. On the basis of binding 
and kinetic studies, the population of ribozymes responded 
to each alteration of the selection constraints as predicted, 
becoming enriched with tighter substrate binders during 
generations 10-18, and then with faster catalysts during 
30 generations 19-27. Even more successive generations have 
been produced, and the in vitro evolutionary procedure 
continues. 
A. Materials 
Unlabeled nucleoside triphosphates (NTPs) and deoxy- 
35 nucleoside triphosphates (dNTPs) were purchased from 
Pharmacia (Piscataway, N.J.), and dideoxynucleoside triph- 
osphates (ddNTPs) were from U.S. Biochemical (USB, 
Cleveland, Ohio). [cx-~’P]GTP, [6-35P]ATP, and [3H]UTP 
were from ICN Radiochemicals (Costa Mesa, Calif.). Syn- 
40 thetic oligodeoxynucleotides were obtained from Operon 
Technologies (Alameda, Calif.) and purified by polyacryla- 
mide gel electrophoresis and subsequent chromatography on 
Sephadex G-25. Restriction enzymes and T4 polynucleotide 
kinase were from New England Biolabs (Beverly, Mass.), 
45 calf intestine phosphatase from Boehringer (Indianapolis, 
Ind.), AMV reverse transcriptase from Life Sciences (St. 
Petersburg, Ha.), MoMLV reverse transcriptase and Seque- 
nase 2.0 (modified T7 DNA polymerase) from U.S. Bio- 
chemical, and Taq DNA polymerase from Cetus 
50 (Emeryville, Calif.). T 7  RNA polymerase was prepared as 
previously described (Davanloo et al., PNAS USA 81: 
2035-2039 (1984)) and purified according to a procedure 
originally developed for SP6 RNA polymerase (Butler and 
Chamberlain, J. B i d .  Chem. 257:5772-5778 (1982)). 
The L-21 form of the Tetrahymena ribozyme was pre- 
pared as described in Example 3 above. 
B. In Vitro Evolution Procedure 
In vitro evolution was carried out as described previously 
(see Example 1 above). While polymerase chain reaction 
60 (PCR) or self-sustained sequence replication (3SR) methods 
are both useful, the within-described methodology most 
closely resembles the 3SR method (see, e.g., Guatelli et al., 
PNAS USA 87: 1874-1878 (1990)). The mutagenic PCR 
method of Cadwell and Joyce (Id. (1994)) is also particularly 
The population of DNA-cleaving ribozymes obtained 
after 9 generations of in vitro evolution in Example 1 above 
2o 
55 
65 preferred. 
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was used as starting material. Ribozymes (0.1 pM) and DNA 
substrate (0.2 pM) were incubated at 37" C. for 1 hr in a 100 
pl volume containing 10 mM MgCl, and 30 mM EPPS (pH 
7.5). After ethanol precipitation, a portion of the reaction 
products (10-50%) was added to a 20 pl isothermal ampli- 
fication reaction mixture, containing 10 mM MgCl,, 80 mM 
KOAc, 50 mM Tris (pH 7.5),5 mM DTI', 2 mM each NTP, 
0.2 mM each dNTP, 4 pCi [c~-~'P]GTP, 12.5 U/pl MoMLV 
reverse transcriptase, 50 U/pl T7 RNA polymerase, and 20 
pmol each of 5 ' - I 3 '  (Primer la, SEQ 
TATAGGAGGGAAAAGTI'ATCAGGC-3' (Primer 2, SEQ 
ID NO 15), which was incubated at 37" C. for 2 hr. Primer 
1 hybridizes to the 3' portion of the substrate that becomes 
attached to the 3' end of the ribozyme. (Primers l a  and lb, 
when used, perform similarly.) Primer 2 hybridizes to the 3' 
end of the resulting cDNA and introduces the T7 promoter 
sequence. 
Twenty-five percent of the isothermal amplification prod- 
ucts were used to generate cDNA in a 20 pl reaction mixture 
containing 10 mM MgCl,, 50 mM Tris (pH 7.5), 5 mM D'IT, 
2 mM each NTP, 0.2 mM each dNTP, 0.2 U/jd AMV reverse 
transcriptase and 20 pmol Primer la, incubated at 37" C. for 
1 hr. Approximately 5-10% of the resulting cDNA was 
amplified by the PCR in a 100 pl reaction mixture containing 
1.5 mM MgCl,, 50 mM KCl, 10 mM Tris (pH 8.3), 0.1% 
gelatin, 0.2 mM each dNTP, 20 pmol 5'-CGAGTACTC- 
CAAAACTAATC-3' (Primer lb, SEQ ID NO 9), 20 pmol 
Primer 2, and 2.5 U Taq DNApolymerase, carried out for 30 
cycles of 92" C. for 1 min, 45" C. for 1 min, and 72" C. for 
1 min, and 1 cycle of 72" C. for 10 min. Primer l b  is 
complementary to the 3' end of the ribozyme, allowing 
regeneration of its original, active form. PCR DNA 
(-25C-500 ng, 5-10% of the total) then served as template 
in an in vitro transcription reaction, carried out in a 25-50 
pl volume. 
The transcribed RNA was isolated by polyacrylamide gel 
electrophoresis, visualized by UV shadowing, cut and eluted 
from gel, purified on duPont Nensorb (duPont de Nemours, 
Wilmington, Del.), and quantified spectrophotometrically, as 
described above. The entire process was repeated 18 times, 
the first 9 as described above and the second 9 with the 
incubation time for the cleavage reaction reduced from 1 hr 
to 5 min. Occasionally, the cDNA was purified to improve 
the quality of the PCR amplification. To do so, cDNA was 
synthesized as above except in the presence of 25-50 pCi 
[a-3zP]dATP. Labeled cDNA was isolated by electrophoresis 
in a 5% polyacrylamidel8M urea gel, visualized by autora- 
diography, cut and eluted from gel, and purified on DuPont 
Nensorb. 
DNA substrate 5'-GGCCCTCTATITATITA-3' (SEQ ID 
NO 15) and DNA product 5'-GGCCCTCT-3' (SEQ ID NO 
16) were (5'-32P)-labeled in a 20 pl reaction mixture con- 
taining 20 pmol oligonucleotide, 10 pmol (4.5 pCi/pmol) 
[g-3zP]ATP, 5 mM MgCl,, 25 mM CHES (pH 9.0), 3 mM 
D n ,  and 1.25 U/pl T4 polynucleotide kinase, incubated at 
37" C. for 1 hr. Labeled oligonucleotide was isolated by 
electrophoresis in a 20% polyacrylamide/8M urea gel, visu- 
alized by autoradiography, eluted from the gel, and purified 
on duPont NENsorb (duPont, Wilmington, Del.). 
The RNA substrate 5'-GGCCCUCUAUUUAUUUA-3' 
(SEQ ID NO 20) was prepared by in vitro transcription using 
a partially single-stranded synthetic DNA template (Milli- 
gan et al., NucEeic Acids Res. 15: 8783-8798 (1987)), as 
described previously. The RNA transcript was dephospho- 
rylated with calf intestine phosphatase, extracted with phe- 
nol and chloroform, and then (5'-32P)-labeled and purified as 
described above. 
ID NO 21) and 5'-CTGCAGAATTCTAATACGACTCAC- 
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The G18 subclones were obtained as previously described 
(see Example 1 above). Thc G27 subclones were obtained 
using the Invitrogen TA Cloning Kit (Invitrogen, San Diego, 
Calif.). The PCR DNA at G27 was ligated into a linearized 
5 plasmid, and the resulting DNA was used to transform 
competent INVaF' cells, which were grown on ampicillin/ 
X-gal plates. Individual colonies containing the insert were 
identified by their white color, chosen at random, and grown 
overnight in liquid media. Plasmid DNA was prepared by 
10 the boiling, lysis method (Holmes & Quigley, Anal. Bio- 
chem. 114: 193-197 (1981)) and screened for the presence 
of insert by restriction digestion. Cloned individuals were 
sequenced by the dideoxy chain-termination method, as 
previously described (Sanger et al., PNAS USA 74: 
15 5463-5467 (1977); Beaudry & Joyce, Id. (1992)). Complete 
sequences of individual subclones are available upon 
request. Individual ribozymes were prepared as follows: the 
gene encoding the ribozyme was amplified by the PCR using 
Primer l b  and Primer 2; the resulting DNA was used as a 
20 template for in vitro transcription; the RNA products were 
isolated by polyacrylamide gel electrophoresis, and were 
purified and quantified as described above. 
C. Substrate Cleavage Activity 
Substrate cleavage activity for the population as a whole 
25 is generally monitored via gel electrophoresis assay involv- 
ing cleavage of [5'-32P]-labeled substrate to yield a specific 
product. Cleavage of the substrate (3") in the absence of 
enzyme, in the presence of the wild-type Tetrahymena 
ribozyme (L-21 form), and in the presence of the population 
30 of RNAs obtained at each generation (G", beginning with a 
value of 0 for n) is measured. 
Reaction conditions may be described as follows: 0.5 pM 
ribozyme, 0.1 pM substrate (2.6 pCi/pmol), 30 mM EPPS 
(pH 7.5); either 10 mM MgCl,, 37" C., 1 hour (low) or 50 
35 mM MgCl,, 2 mM spermidine, 50" C., 1 hour (high). 
Reaction products were separated by electrophoresis in a 
20% polyacrylamide-8M urea gel, of which autoradiograms 
were made. Conditions of "high" MgCl, may be considered 
useful initially, before the ribozyme has "evolved", to facili- 
It is expected that any given mutation would more likely 
be detrimental than beneficial, although there may be a 
substantial number of neutral mutations. For example, in 
examples directed to improvement of DNA cleavage activ- 
45 ity, the activity of the generation 0 population was observed 
to be less efficient than for the wild type. The generation 1 
population, having been selected for DNA cleavage activity 
under physiologic conditions, showed improved catalytic 
activity compared to generation 0 and was slightly improved 
50 over the wild type. Through successive generations, there is 
continued improvement of phenotype. By generation 7, the 
population as a whole cleaved DNA more efficiently at 37" 
C. and 10 mM MgCl, than does the wild type at the 
high-temperature, high-MgC1, condition. Through succes- 
55 sive generations, the rate of improvement has continued to 
increase. 
RNA purification and substrate cleavage were conducted 
as described in Example 1. 
DNA substrates may be prepared via the following pro- 
60 cedure. For example, an exemplary [3'-32P]-labeled DNA 
substrate was prepared with terminal deoxynucleotidyl 
transferase (TdT; available from U.S. Biochemical, Cleve- 
land, Ohio, or BRL, Gaithersburg, Md.). Reaction condi- 
tions were as follows: 4 pM d(GGCCCTCTA,(TA,),) (SEQ 
65 ID NO 17), 1 pM [c~-~'P]~ATP (3 pCi/pmol), 1 mM CoCl,, 
1 mM DTI', 50 mM potassium cacodylate (pH 7.2) and 
terminal transferase at 2.7 Ulpl, incubated at 37" C. for 30 
40 tate DNA cleavage. 
5,595,873 
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solution to the relation of genotype to phenotype, even for 
those nucleotide positions that are known to be most sig- 
nificant based on their high frequency of accepted mutation. 
The weighing vector x may thus be used as a guide to help 
decide which mutations are sufficiently important to warrant 
individual study. (See, e.g., Beaudry and Joyce, Id. (1992) .) 
E. Site-Directed Mutagenesis 
Individual enzymatic RNA molecules containing single 
mutations may be prepared by site-directed mutagenesis for 
analysis of the relative significance of a particular mutation, 
as described in Example 1.B.6. Catalytic activity is then 
studied with an appropriate [5'-32P]-labeled oligodeoxyri- 
bonucleotide substrate. 
F. Kinetic Analysis 
All cleavage reactions were carried out according to the 
procedures described in Example 1.B.7. KIM and k,, values 
were determined in experiments with substrate ( S )  in excess 
over ribozyme (E). Initial rates of reaction (vJ, over a range 
of substrate concentrations, were estimated from the initial 
linear phase, generally the first 5% or less of the reaction. 
Typically 8 data points were fit by a least squares method to 
a theoretical line given by the equation: v-KM (vJ[S])+ 
Single-turnover experiments were performed with 
ribozyme in excess of substrate (Herschlag & Cech, Bio- 
chemistry 29:10159-10171 (199Ob)). Initial rates (kob,) 
were obtained using no more than the first 5% of the 
reaction. Given that kc,~KpkobJIE], each k, value, 
obtained at different ribozyme concentrations, provided an 
estimate of k,,jK,. Generally 8 or more measurements of 
k J K M  were obtained. 
Specific catalytic properties of a DNA-cleaving ribozyme 
can be optimized by appropriate manipulation of the selec- 
tion constraints during an in evolution procedure. For 
example, beginning with a heterogeneous population of 
ribozymes, enriched for modest DNA-cleavage activity, 27 
generations were produced to obtain DNA-cleaving 
ribozymes that have a catalytic rate of 0.7 min-' and a 
substrate binding afsnity of M. These catalytic param- 
eters are improved 103-fold and 104-fold, respectively, com- 
pared to the wild-type. The greatest improvement in KD and 
KM occurred between G9 and G18 in response to alteration 
of the selection constraints to favor ribozymes with 
enhanced afsnity for the DNA substrate (not shown). Like- 
wise, based on k, values for representative individuals, the 
greatest improvement in k, occurred between G18 and 
G27, following alteration of the selection constraints to 
favor a faster rate of catalysis. 
It is important to note that some mutations may confer no 
selective advantage with respect to catalysis, but instead 
enhance the ability of the polymerase enzymes (Le., reverse 
transcriptase, T7 RNA polymerase, and Taq polymerase) to 
operate efficiently during the amplification procedure. 
Future studies, relying on site-directed mutagenesis analy- 
sis, will enable us to assess the contribution made by various 
mutations, in either the conserved core or the peripheral 
regions, to substrate binding, first-order reaction rates, and 
ribozyme folding. 
Beginning with generation 19, the reaction time was 
reduced from 1 hr to 5 min to favor selection of ribozymes 
with increased k, values. To study the effect of this change, 
two individuals isolated from the population at G9, G18 and 
G27 were chosen for formal kinetic analysis (Table 3). These 
ribozymes are representative of the population from which 
they were isolated because they contain most of the promi- 
nent mutations that occur in their respective populations. In 
addition, the total number of mutations in each of the studied 
V m a r  
minutes. The product corresponding to addition of a single 
dA residue was purified by electrophoresis in a 20% poly- 
acrylamide-8M urea gel and subsequent f in i ty  chromatog- 
raphy on NENsorb (duPont, Wilmington, Del.). The 
hydrolysis product forms either by direct cleavage of the 5 
DNA substrate or by cleavage of the ribozyme- 
d(A,(TA,),A) covalent intermediate. Together, these reac- 
tions account for less than 5% of the cleaved substrate. 
After ten generations, DNA cleavage activity for the 
population as a whole was 30 times higher than that of the 10 
wild type. Because selection is based on primer hybridiza- 
tion to the EP covalent intermediate (see FIG. 2B), there is 
selection pressure against the subsequent site-specific 
hydrolysis reaction. As a consequence, the efficiency of the 
hydrolysis reaction relative to the initial phosphoester trans- 15 
fer event drops from 4.9% for the wild type to 1.5% for the 
generation 10 population. There is selection pressure favor- 
ing accurate cleavage of the DNA at the target phosphodi- 
ester; inaccurate cleavage would result in partial mismatch 
of the primer used to initiate selective amplification. The 20 
accuracy of cleavage at first declines from 90% for the wild 
type to 45% for the generation 8 population, and then rises 
to 60% for the generation 10 population. There may be some 
individuals in the population that sacrifice accuracy for 
improved cleavage activity in order to enjoy an overall 25 
selective advantage. Of course, a preferred result is an 
individual having both high accuracy and high cleavage 
activity. 
D. Preparation and Sequencing of Subclones 
plished fact, evolution in vitro is a work in progress that 
allows the experimenter to access any time period in evo- 
lutionary history. Subclones were obtained from the evolv- 
ing population at every generation and individual ribozymes 
Subclones were prepared and sequenced as described in 
Example l., part 33, section 5. As noted therein, subclones 
may be obtained from the evolving population at every 
generation; alternatively, specific generations may also be 
Analysis of the determined sequences indicates how 
genotype changes over the course of evolutionary history. 
From generation 0 to generation 3, variation is discarded 
throughout much of the catalytic core of the ribozyme. The 
mean number of mutations per subclone decreased from 7.0 45 
at generation 0 to 2.7 at generation 3. By generation 3, a 
small number of mutations outside of the original zone of 
random mutation have occurred because of ongoing muta- 
tion events. The consensus sequence still tends to be that of 
the wild type. Analysis of subsequent generations suggests 50 
that accumulation of mutations coincides with improvement 
in the phenotype of the population as a whole. The mean 
number of mutations per subclone is also observed to 
increase, as a larger proportion of subclones adopt the 
common mutations and as mutations accumulate outside of 55 
the original zone of random mutation. 
The relation between genotype and phenotype in the 
context of an RNA-based evolving system can readily be 
formalized once catalytic, kinetic, and comparable data are 
collected and analyzed. Genotype can be represented as a 60 
matrix A, the rows corresponding to individuals in the 
population and the columns corresponding to functionally 
significant positions within the nucleotide sequence. An 
exemplary analysis is illustrated in Beaudry and Joyce, 
Science 257: 635-641 (1992). 65 
The data obtained from a relatively small number of 
individuals may not be sufficient to provide a meaningful 
Although evolution in natural populations is an accom- 30 
were then sequence. 35 
chosen for detailed analysis. 40 
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individuals coincides with the mean number of mutations 
per subclone in the corresponding population. It is empha- 
sized that the k,,, and K, values of the studied individuals 
are not equivalent to the average k,,, and K, values for the 
entire population. It is likely that the catalytic efficiencies of 
the studied ribozymes are somewhat higher than the average 
because these ribozymes possess a greater fraction of the 
dominant mutations than a typical individual in the popu- 
lation. Nevertheless, the relative differences in k,,, and K, 
values between representative pairs of individuals should be 
comparable. As expected, the improvement ink,,, is greatest 
between the G18 and G27 ribozymes (Table 3), while the 
improvement in K, is greatest between the G9 and G18 
ribozymes. 
Table 3, illustrating the catalytic parameters of DNA- 
cleaving enzymatic RNA molecules, is reproduced herein- 
below. 
TABLE 3 
Catalytic Parameters of DNA-Cleaving Ribozymes 
li.,&l 
Ribozyme Mutations (min-’) (m) min-’) 
L P  KMb (M-’ 
Wt= 0 2.4 (M.2) x 6.0 f 1.7 4.0 x 10’ 
10” 
G9 #23” 7 5.1 (N.2) x 1.8 f 0.3 2.8 x lo3 
G9 #29“ 6 7.1 (M.3) x 1.9 i 0.3 3.8 x lo3 
G18 #13‘ 12‘ 1.7 (M.1) x 0.24 i 0.04 7.1 x lo4 
G18 #66‘ 13s 1.1 (M.l) x 0.32 i 0.08 3.5 x IO4 
G27 #4gd 17” 7.0 (M.6) x 0.31 2 0.05 2.3 x lo6 
G27 #61’ 15’ 3.3 (M.7) x 0.11 k 0.06 2.9 x lo6 
10-3 
10-3 
10-2 
10” 
10-1 
10-1 
”Data obtained previously (see Example 1 above), modified slightly as a result 
of subsequent statistical analysis. 
bMeasurements were carried out as described in Materials and Methods with: 
‘0.025 pM ribozyme and 0.125, 0.25, 0.5, and 1.0 pM DNA substrate; 
d0.02 pM ribozyme and 0.1, 0.2, 0.4, and 0.8 pM DNA substrate; or 
‘0.02 @VI ribozyme and 0.05, 0.1, 0.2, and 0.4 pM DNA substrate. 
‘44:G+A, 94:A+U, 115:A+U, 116:G+A, 138:C+A, 188:G+A, 190:U+ 
A, 191:G+U, 205:U+C, 215:G+A,312:G+A, and 317:U+G. 
WI:G+A, 94:A+U, 115:A+U, 166:G+A, 138:C+A, 167:U+G, 188:G+ 
A, 19O:U+A, 191:G+U, 205:U+C, 215:G+A, 239:U+A, and 312:GjA. 
h44G+A, 51/52insertAGAA, 87:A+del, 94A+U, 115:A+U, 116G+A, 
166C+A, 17OC+U, 188:G+A, 190:U+A, 19l:G+U, 205:U+C, 
215:G+A, 239:U+A, 312G+A, 35OC+U, and 364C+U. 
‘44:G+A, 51152:insert AGAA, 87:A+del, 94A+U, 115:A+U, 116:G+A, 
166:C+A, 17O:C+U, 188:G+A, 19OU+A, 191:G+U, 205:U+C, 
215:G+A, 313:G+C, and 314:A+G. 
G. Determination of Binding Constants 
The equilibrium dissociation constant, K,, of the com- 
plex between ribozyme and DNA product (F‘) was deter- 
mined by gel-shift analysis in a native polyacrylamide gel 
(Pyle et al., PNAS USA 87: 8187-8191 (1990)). The proce- 
dure used is described in Example 1 above, in part B.8. 
A binding curve was generated by plotting the percentage 
of product bound to ribozyme (% bound) over a range of 
ribozyme concentrations. K, was determined by fitting the 
data to a theoretical binding curve using a least squares 
method. Because ribozyme was in vast excess over product, 
the theoretical binding curve could be represented by the 
equation: % bound=[E]/([E]+K,), where K,=[E] when half 
of the total product is bound to the ribozyme. 
The present successful phylogeny was continued beyond 
the tenth generation, after decreasing the concentration of 
DNA substrate in the target reaction, as further described 
herein. Through the first ten generations the substrate con- 
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centration was 10 pM, roughly matching the K, for the wild 
type. Now that the evolved individuals have attained a K, 
of about 2 @I, the substrate concentration has been reduced 
to subsaturating levels to promote further improvement in 
substrate binding. In addition, catalytic turnover in the DNA 
cleavage reaction is being improved by selecting for both 
phosphoester transfer activity, which generates the EP cova- 
lent intermediate, and subsequent RNA-catalyzed site-spe- 
cific hydrolysis activity, which frees the ribozyme to act on 
another substrate molecule. 
The selection scheme used herein may be applied to 
various substrates of the form: d(CCCTCNA,(TA,),) (SEQ 
ID NO 18), where N refers to a nucleotide analog and the 
ribozyme is selected for its ability to cleave the phosphodi- 
ester bond following the sequence CCCTCN (SEQ ID NO 
19). Examples of nucleotide analogs useful according to the 
present invention include those listed in the Table, appearing 
in section C of the Detailed Description. 
The substrate need not be a nucleotide or nucleotide 
analog. The only requirement is that RNAs that react with 
the substrate become tagged in some way so that they can be 
distinguished from nonreactive molecules with respect to the 
amplification process. For example, reactive RNAs could 
become joined to a portion of the substrate that is attached 
to a solid support, while nonreactive RNAs would be 
washed away, leaving the bound RNAs to be selectively 
amplified. These and other methodologies are further 
described below. 
H. Extension of Directed Evolution to Develop Other 
Evolved Species 
As an in vitro model of Darwinian evolution, a population 
of macromolecular catalysts was directed toward the expres- 
sion of novel catalytic function. In the present Example, the 
development of ribozymes that cleave DNA with improved 
efficiency under physiologic conditions has been demon- 
strated. 
I. Evolution In Vitro 
Beginning with the 9th generation (G9) population of 
ribozymes obtained in a previous study (Beaudry & Joyce, 
Id. (1992)), 18 additional generations of in vitro evolution 
were carried out. Variation in the population was maintained 
by PCR amplification, which introduces mutations at a rate 
of -0.1% per nucleotide position per generation. Because 
mutation is ongoing, evolution based on Darwinian prin- 
ciples can occur. Progeny ribozymes have the opportunity to 
acquire new mutations that confer favorable attributes not 
possessed by the parent molecules. This phenomenon is 
reflected by the steadily increasing frequency of accepted 
mutations over the 27 generations. 
Sequence data was obtained from 50 randomly-chosen 
subclones, isolated from the evolving population at G9, 
G18, and G27, and illustrates sites at which mutations 
occurred over the course of evolution. The mean number of 
mutations per subclone rose from 5.9 at G9, to 12.7 at G18, 
and to 16.5 at G27. Most of the mutations occurred within 
the phylogenetically conserved portions of the ribozyme that 
were randomized in the initial population (not shown). 
However, 26% of the total mutations at G18, and 38% at 
G27, occurred in peripheral regions as a result of ongoing 
mutagenesis. Most of the commonly-occurring mutations 
(>30% frequency) that occur in the G18 subclones were not 
observed at G9 (not shown), suggesting that these mutations 
arose in response to the increased selection pressure 
designed to enhance substrate binding affnity. Between Gl8  
and G27, nearly all of the most commonly-occurring muta- 
tions continued to increase in frequency (not shown). How- 
ever, two significant mutations, the NGAA insertion 
5,595,873 
59 60 
between positions 51 and 52 and the C+U change at 
position 170, first appeared during this interval, suggesting 
that these mutations arose in response to the increased 
selection pressure designed to enhance the catalytic rate. 
The changes at nucleotide positions 188,190, and 191 in 5 
the P5a region (see FIGS. 1 and 3) co-occur in 90% of 
subclones, while mutations in the J4/5 and J5/4 internal loop 
at positions 115, 116, and 205 co-occur in 68% of the 
subclones at G18. Interestingly, the J4/5 and J5/4 mutations Beginning with ~ 1 0 ,  the concentration of DNA substrate 
co-occur only if the set of P5a mutations is also present 10 employed during the RNA-catalyzed reaction was lowered 
from 10 pM to 0.2 pM to impose increased selection (c2=1 10, p <0.001), suggesting an interaction between these two regions. pressure favoring individuals with enhanced substrate bind- The 313:G+Y and 314:AjG mutations nearly always 
This change is present in nearly all of the subclones at GI8 
and G27. Of the 12 individuals that lack this mutation, 11 
carry a U+C change at position 258, which would allow a 
Watson-Crick pair to form with the wild-type G at position 
215. Thus, in 99 of 100 subclones from G18 and G27, a 
Watson-Crick base pair is expected to form between posi- 
tions 215 and 258. 
J. Improvement of DNA Binding Affinity 
occur together. These mutations co-occ~,- in 16 of 50 sub- 
clones at G9, 11 of 50 subclones at G18, and 44 of 50 15 values for the 
ing afi6nity. In Order to the impact Of this change, ‘D 
between ribozyme and DNA product 
subclones at G27. Only two G27 subclones contain the (GGCCTCT) were determined for the population Of 
mutation at position 313 but lack the mutation at position ribozymes at every third generation over the 27 generations 
314. At G9 and G18, the 313 mutation always occurs as a (not shown). 
G - N  change. At G27, however, the 313 mutation occurs A binding curve showing data obtained for the G27 
primarily as a G+C change, with the G-+U change occur- 20 population of ribozymes and illustrating the improvement in 
ring only once. The GA sequence normally present at substrate binding affinity over 27 successive generations of 
positions 313-314 is thought to form a short duplex struc- in vitro evolution was prepared (not shown). Data was fit by 
ture (P9.0) that brings the 3’-terminal guanosine residue of a least squares method to a theoretical binding curve (indi- 
the ribozyme into the catalytic core (Michel et al., Nature cated by solid line), given by the equation: y=[E]([E]+K,), 
342:391-395 (1989); Michel et al., Genes Dev. 4: 777-788 25 where y is the fraction of product (P) bound to ribozyme (E). 
(1990); Michel, et al., J. Mol. Biol. 216: 585-610 (1990)). In this case, KD=51 (k2) nM. The K D  for the population of 
The 3’-OH of this guanosine serves as the nucleophile in ribozymes at every third generation was also calculated; 
the RNA-catalyzed phosphoester reaction. Although the standard errors averaged 11 % (not shown). 
3 13-314 mutation would prevent the P9.0 duplex from The DNA product rather than substrate was employed to 
forming, the 313-314:GA+UG change confers selective 30 avoid a cleavage reaction during the gel-shift analysis. The 
advantage with respect to the DNA-cleavage reaction, as binding affinity for the product is assumed to be similar to 
demonstrated by site-directed mutagenesis studies (Beaudry that of the substrate, based on previous studies showing that 
& Joyce, Id. (1992)). The appearance of the 313-314:GAj the wild-type ribozyme binds the RNA substrate with the 
CG change, between GI8 and G27, suggests that this altered same affinity as it binds the product (Pyle et al., PNAS USA 
form of the 313-314 mutation may contribute to the 35 87:8187-8191 (1990); Herschlag & Cech, Biochemistry 29: 
The 312:G+A mutation occurs only if the Binding data for each studied population was fit to a 
3 13-314:GA-YG mutations are not present. The theoretical binding curve. As expected, the greatest improve- 
3 12:G+A change is present in 4 of 25 subclones at G3,8 of ment in binding affinity occurred between G9 and G18, 
25 subclones at G6, and 5 of 50 subclones at G9 (Beaudry 40 subsequent to tightening of the selection constraints (not 
& Joyce, Id. (1992)). There is a dramatic rise in the fre- shown). After G18, the population became saturated with 
quency of the 312:GjA mutation between G9 and G18, ribozymes having a K,of less than 0.2 pM, accounting for 
followed by an equally dramatic drop between G18 and G27 the slow but continued improvement between G18 and G27. 
(not shown). As the frequency of the 312:G+A mutation The foregoing specification, including the specific 
declines, the 313-314GAjYG mutations become more 45 embodiments and examples, is intended to be illustrative of 
abundant. the present invention and is not to be taken as limiting. 
The 215:G+A mutation, present at high frequency in all Numerous other variations and modifications can be effected 
of the studied populations, putatively allows a Watson-Crick without departing from the true spirit and scope of the 
base pair to form with the U at position 258 (see FIG. 1). present invention. 
improved catalytic rate of the DNA-cleavage reaction. 101 59-1017 1 (199Ob)). 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION 
( i i i ) NUMBER OF SEQUENCES: 20 
( 2 ) INFORMATION FOR SEQ m  NO:^: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) L E N G m  393 base pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE RNA (genomic) 
5,595,873 
61 62 
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( x i ) SEQUENCE DESCRIPTION: SEQ ID NO1:  
G G A G G G A A A A  G U U A U C A G G C  A U G C A C C U G G  U A G C U A G U C U  U U A A A C C A A U  A G A U U G C A U C  6 0  
G G U U U A A A A G  G C A A G A C C G U  C A A A U U G C G G  G A A A G G G G U C  A A C A G C C G U U  C A G U A C C A A G  1 2 0  
U C U C A G G G G A  A A C U U U G A G A  U G G C C U U G C A  A A G G G U A U G G  U A A U A A G C U G  A C G G A C A U G G  1 8 0  
U C C U A A C C A C  G C A G C C A A G U  C C U A A G U C A A  C A G A U C U U C U  G U U G A U A U G G  A U G C A G U U C A  2 4 0  
C A G A C U A A A U  G U C G G U C G G G  G A A G A U G U A U  U C U U C U C A U A  A G A U A U A G U C  G G A C C U C U C C  3 0 0  
U U A A U G G G A G  C U A G C G G A U G  A A G U G A U G C A  A C A C U G G A G C  C G C U G G G A A C  U A A U U U G U A U  3 6 0  
G C G A A A G U A U  A U U G A U U A G U  U U U G G A G U A C  U C G  3 9 3  
( 2 ) INFORMATION FOR SEQ ID N O 2  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 5 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY Iincar 
( i i ) MOLECULETYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2 
N N N N A  
( 2 ) INFORMATION FOR SEQ rn  NO^: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 5 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
A A C A A  
( 2 INFORMATION FOR SEQ m ~ 0 4 :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 27 basc pair5 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N O 4  
A G U U A C C A G G  C A U G C A C C U G  G U A G U C A  
( 2 ) INFORMATION FOR SEQ ID NO:5: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 36 basc pair5 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:% 
G U C U U U A A A C  C A A U A G A U U G  G A U C G G U U U A  A A A G G C  
5 
5 
2 1  
3 6  
( 2 INFOFOdATION FOR SEQ ID NO:6: 
( i SEQUENCE CHARACTERISTICS: 
63 
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( A ) LENGTH: 15 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ m ~ 0 . 6 :  
T T T A T T T A T T  T A T T T  
( 2 ) INFORMATION FOR SEQ m NOT 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 48 hasc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:7: 
C T G C A G A A T T  C T A A T A C G A C  T C A C T A T A G G  A G G G A A A A G T  T A T C A G G C  
( 2 ) INFORMATION FOR SEQ m NOS: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) L E N G m  20 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:8 
C G A G T A C T C C  A A A A C T A A T C  
( 2 ) INFORMATION FOR SEQ m  NO:^: 
( i ) SEQUENCE CHARACTERISTICS. 
( A ) LENGTH: 17 h a c  pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: Iincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRETION: SEQ ID N0 .9  
G T A A A A C G A C  G G C C A G T  
( 2 INFORMATION FOR SEQ m NO:IO 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:lO 
C A T G A T T A C G  A A T T C T A  
( 2 )INFORMATION FOR SEQ ID N O H :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 hasc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
1 5  
4 8  
2 0  
1 7  
1 7  
5,595,873 
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( i i ) MOLECULE TYPE DNA (genomic) 
( i x )FEATURE. 
( A ) NAMUKEY miscJcatwc 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /labcl=NH2 
I noic=”NH2 SIGNIRES THAT THE T HAS BEEN MODIFIED 
AND IS 3’- AMIN0’3’DEOX~IDINE-5’-TRIPHOSPHATE’ 
( x i ) SEQUENCE DESCRLFTION SEQ m NO:II: 
G G C C C T C ’ I  
( 2 ) INFORMATION FOR SEQ ID NO:12: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 7 basc pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:12: 
G G C C C T C  
( 2 ) IWOIMATION FOR SEQ ID NO:13: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 basc pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY lincar 
( i i ) MOLEWLE TYPE DNA (genomic) 
( i x )FEATURE: 
( A ) NAMUKEY modilicd-basc 
( B )LOCATION: 8 
( D ) OTHER INFORMATION: /modLbasdTHER 
/ labcl=ARG 
/ naa=”ARG SIGNIFIES THAT THE AMINO ACID ARGININE 
IS COVALENTLY LINKED TO ...” 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:13: 
G G C C C T C T  
( 2 ) INFORMATION FOR SEQ ID NO:14 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 basc pairs 
( B 1 TYPE nucleic acid 
( D ) TOPOLOGY lincar 
( c ) STRANDEDNESS: singlc 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( i x ) F E A m  
( A ) NAMVKEY modified-basc 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /mohbascAJTHER 
/ labcl=ARGARG 
/ noic=“ARGARG SIGNIFIES THAT THE T HAS THE AMINO 
ACID ARGININE COVALENTLY LINKED To IT AND THAT A 
SECOND ARGININE IS COVALENTLY LINKED TO THE FIRST 
( x i ) SEQUENCE DESCRIFTION: SEQ ID NO14  
G G C C C T C T  
8 
7 
8 
8 
( 2 ) INFORMATION FOR SEQ ID NO15: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 basc pairs 
5,595,873 
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( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N015: 
G G C C C T C T A T  T T A T T T A  
( 2 ) INFORMATION FOR SEQ ID N016: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:16: 
G G C C C T C T  
( 2 ) ~NFORMATION FOR SEQ m N O : I ~ :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 23 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:17: 
G G C C C T C T A A  A T A A A T A A A T  A A A  
( 2 ) INFoRMAnoN FOR SEQ m NO:W 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 21 basc pairs 
( B )TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE: DNA (genomic) 
( i x )FEATURE: 
( A ) NAMWKEY misc-lcaiwe 
( B ) LOCATION 6 
( D ) OTHER INFORMATION nabcl=N 
I nob=”N SIGNIFIES A NUCLEOTIDE ANALOG 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:18: 
C C C T C N A A A T  A A A T A A A T A A  A 
( 2 ) INFORMATION FOR SEQ ID N019:  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 6 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( i x )FEATURE: 
( A ) NAMUKEY misc-lcaiurc 
( B ) LOCATION 6 
( D ) OTHER INFORMATION: ilabcl=N 
I nolc=”N SIGNIFIES A NUCLEOTIDE ANALOG 
( x i SEQUENCE DESCRETON: SEQ ID NO:19: 
1 7  
8 
2 3  
2 1  
5,595,873 
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C C C T C N  6 
( 2 ) INFORMATTON FOR SEQ m ~ 0 : 2 0 :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 basc pairs 
( B ) TYPE: nuclcic acid 
( C ) STRANDEDhTSS: sin& 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIF’TION: SEQ ID NO20 
G G C C C U C U A U  U U A U U U A  1 7  
I claim: 
1. An enzymatic RNA molecule comprising a ribonucle- 
otide polymer having a nucleotide sequence from the group 
I intron of 7: themuphila, wherein said polymer catalyzes 
the hydrolysis of amide bonds in a substrate, and wherein 
said substrate comprises an oligonucleotide containing an 
amide, bond. 
2. The enzymatic RNA molecule of claim 1, wherein said 
polymer has a catalytic activity for hydrolyzing said sub- 
strate to produce an amino cleavage product and a ribozyme 
amidase intermediate. 
3. The enzymatic RNA molecule of claim 2, wherein: 
a. said ribonucleotide polymer has a 5’ terminal nucleotide 
with a ribose sugar having a nucleophilic 2’ hydroxyl; 
and 
b. said ribozyme amidase intermediate includes an ester 
linkage between said nucleophilic 2’ hydroxyl and a 
carboxy group of said substrate. 
4. The enzymatic RNA molecule of claim 3, wherein said 
5’ terminal nucleotide includes a guanine base. 
5. The enzymatic RNA molecule of claim 3, wherein said 
substrate includes a peptide having two or more amino acid 
residues including a carboxy terminal amino acid residue 
bearing the carboxy group of said substrate, said carboxy 
terminal amino acid residue being covalently linked by the 
ester linkage to the 2’ hydroxyl of said ribonucleotide 
polymer. 
6. The enzymatic RNA molecule of claim 2, wherein said 
ribonucleotide polymer has an effective binding affinity for 
said substrate and lacks an effective binding aflinity for said 
amino cleavage product. 
7. The enzymatic RNA molecule of claim 1, further 
comprising a cofactor bound to said ribonucleotide polymer, 
said cofactor including a guanine nucleotide having a ribose 
sugar with a nucleophilic 2’ hydroxyl capable of forming an 
acid labile ester intermediate with the carboxy cleavage 
product. 
8. The enzymatic RNA molecule of claim 1, wherein said 
nucleotide sequence comprises SEQ ID NO 1 and further 
includes one or more of the following mutations: 
44:G+A; 
87:Ajdeleted; 
94:A-C; 
116:GjA; 
166:C-A; 
170C+U; 
190:UjA; 
205:u-c; 
239:UjA; 
51152insert AGAA; 
94:A-U; 
I15:A+U; 
138:C+A; 
167:UjG; 
188:G-A; 
191:G+U; 
215:G+A; 
258:U-C; 
-continued 
312:G-A; 313:G+U; 
20 31333-C; 314:A+G; 
317:U+G; 317:U-C; 
317:U-A; 333:u+c; 
35O:C-U; and 
364:C+U. 
25 9. A ribozyme amidase intermediate comprising: 
a. a ribonucleotide polymer having a nucleotide sequence 
from the group I intron of 7: themuphila and further 
including a 5’ terminal nucleotide with a ribose sugar 
having a 2’ hydroxyl; and 
b. a substrate molecule comprising an oligonucleotide 
containing an amide bond and having one or more 
amino acid residues including a carboxy terminal 
amino acid residue, said carboxy terminal amino acid 
residue being covalently linked by an ester bond to the 
2’ hydroxyl of said ribonucleotide polymer. 
10. The ribozyme amidase intermediate of claim 9, 
wherein said ribonucleotide polymer comprises SEQ ID NO 
1 and further includes one or more of the following muta- 
tions: 
30 
35 
40 
44:G+A; 
87:Ajdeleted; 
94A-C; 
116:GjA;  
166:C+A; 
170:C+U; 
19O:U-+A; 
205:U+C; 
239:U+A; 
312:GjA;  
313:G+C; 
50 317:U+G; 
317:U+A, 
35O:C-U; and 
364:C-U. 
45 
51152insert AGAA; 
9 4 A 4 J ;  
115:A-U; 
138:C+A; 
167:U-S; 
188:G-A; 
19 1 :G+U; 
215:G-A; 
258:U+C; 
313:GjU; 
314A+G; 
317:U+C, 
333:u-c; 
55 11. A ribozyme amidase intermediate comprising: 
a. a ribonucleotide polymer having a nucleotide sequence 
from the group I intron of 7: themuphiZa; 
b. a cofactor including a guanine nucleotide having a 
ribose sugar with a 2’ hydroxyl; and 
c. a substrate molecule comprising an oligonucleotide 
containing an amide bond and having one or more 
amino acid residues including a carboxy terminal 
amino acid residue, said carboxyl terminal amino acid 
residue being covalently linked by an ester bond to the 
2’ hydroxyl of said guanine nucleotide. 
12. The ribozyme amidase intermediate of claim 11, 
wherein said ribonucleotide polymer comprises SEQ ID NO 
60 
65 
5,595,873 
71 72 
1 and further includes one or more of the following muta- 
tions: 
16. The method of claim 15, wherein said enzymatic RNA 
molecule is able to cleave an amide bond at a preselected 
44:G+A; 
87:A-deleted; 
94:A-C; 
116:G+A; 
166:C-A; 
170:C+U; 
190:U+A; 
205:U-K; 
239:U-A; 
312G-A, 
313:G-C; 
317:U-G; 
317U-A; 
35OC+U; and 
364C+U. 
5 
51l52insert AGAA; 
94A+U; 
1 1 5 : A j u .  
138:C+A, 
167:U-G; 
188:G+A; 
191 :G+U; 
258:U+C; 
3 13:G+u, 
314:A+G; 
317:U+C; 
333:u+c; 
215:G+A; 10 
15 
site. 
Of: 
17. The method of claim 15, further comprising the steps 
a. separating said products from said enzymatic RNA 
b. adding additional substrate to said enzymatic RNA 
18. A method of selecting an enzymatic RNA molecule 
that cleaves amide bonds, comprising the following con- 
secutive steps: 
a. admixing amide bond-containing oligonucleotide sub- 
strate molecules with a population of I: themophila 
group I introns (ribozymes) to form an admixture; 
b. maintaining said admixture for a sufficient period of 
time and under predetermined reaction conditions to 
allow said ribozymes and said substrate to interact and 
form ribozyme-product complexes; 
c. isolating any ribozyme-product complexes that form; 
molecule; and 
molecule to form a new reaction admixture. 
13. A method for catalytically hydrolyzing a substrate 
comprising an oligonucleotide containing an amide bond, 
contacting said substrate with a ribozyme comprising a 
ribonucleotide polymer having a nucleotide sequence 
from the group I intron of I: themophila and having a 
catalytic activity for hydrolyzing said substrate and 25 
producing an amino cleavage product and a ribozyme 
amidase intermediate, said ribozyme amidase interme- 
diate including a carboxyl of said substrate bonded by 
an ester bond to a 2'0 hydroxyl of a ribose sugar on a 
5' terminal nucleotide of the ribonucleotide polymer. 3o tagged with an 
14. A method for catalytically hydrolyzing a substrate as 
described in claim 13, the method further comprising step B 
as follows, to be performed after said Step A: 
hydrolyzing the ester bond of said ribozyme amidase 
15. A method of cleaving an amide bond, comprising: 
a. admixing an enzymatic RNA molecule according to 
claim 1 with a substrate comprising an oligonucleotide 
containing an amide bond, to form a reaction admix- 
ture; and 4o of said variant population; and 
b. maintaining said admixture under predetermined reac- 
tion conditions to allow said enzymatic RNA molecule 
to cleave said amide bond. 
the method comprising the following step A. 20 
d. allowing said ribozyme-product complex to dissociate 
e. separating said ribozymes from said product. 
19. The method of claim 18, wherein said substrate is 
20. A method of engineering enzymatic RNA molecules 
a. introducing genetic variation into a population of I: 
thennophila group I introns (ribozymes) to produce a 
b. selecting individuals from said variant population that 
c. separating said selected individuals from the remainder 
d. amplifying said selected individuals. 
into separate ribozyme and product; and 
agent. 
that cleave amide bonds, comprising the following steps: 
intermediate to produce a carboxy cleavage product. 35 variant population; 
meet predetermined selection criteria; 
* * * * *  
